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ABSTRACT 
SNARE (Soluble NSF (N-ethylmaleimide Sensitive Fusion) Attachment Protein Receptors) proteins 
have been linked to the membrane fusion mechanism since 1993 as fusion proteins and have been 
suggested to be the minimal machinery. The complexity of the fusion process means that many 
questions remain unanswered as to how SNARE proteins perform their role. The most favoured 
model (the stalk model) does not involve proteins directly and so the influence of the SNARE 
proteins on lipid properties is of interest. In this thesis, work is presented which investigates how 
these proteins may manipulate membrane properties in order to promote fusion. 
Purified proteins solutions of His6-VAMP2 (Vesicle Associated Membrane Protein 2), His6-SNAP-25 
(Synaptosomal-associated Protein 25) and a truncated form of Syntaxin 1A (His6-ΔN-Syx 1A, w.t aa 
181-288) were obtained following bacterial over-expression. Fluorescent versions of His6-VAMP2 
and His6-ΔN-Syx 1A were produced by the addition of cysteine residues to the C-terminus followed 
by labelling using Alexa Fluor® 488-C5-maleimide and Alexa Fluor® 555-C2-maleimide respectively. 
These fluorescent proteins were used to establish that the purified protein inserted into model lipid 
bilayers. 
The effect of SNARE protein incorporation on the relaxed curvature of bilayers was explored by 
examining giant unilamellar vesicles grown using electroformation. Bilayers containing either 1:300 
His6-VAMP2: DOPC or 1:1:600 His6-SNAP-25: His6-ΔN-Syx 1A: DOPC were smaller than pure DOPC 
vesicles, indicating that SNARE proteins increase the relaxed curvature of the bilayer. Analysis of 
these vesicles by micropipette aspiration suggested that VAMP2 lowered the bending rigidity of the 
membrane and a reduction in the area expansion modulus relative to the pure lipid bilayer was 
found. The t-SNARE sample also indicated a reduction in bending rigidity but the area expansion 
modulus was found to increase. These latter results are thought to be due to the formation of 
protein aggregates. 
Lipid mixing assays were conducted to investigate how changes in the properties of liposome 
bilayers affected fusion rates. It was found that the addition of DOPE to DOPC bilayers increased the 
rate of hemifusion and this was also found for cholesterol addition, suggesting both components are 
fusogens. The rate of hemifusion rose continually upon DOPE addition but reached a plateau in the 
cholesterol study shortly after 10 mol%. Despite this, the fusion rates for the cholesterol study were 
generally higher than the same mol% DOPE added. The changes in fusion rates observed have been 
explained by considering the impact of the additives on the free energy and stored curvature elastic 
stress of membranes as well as the change in the energy of formation of intermediate structures. 
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From the findings of this thesis it is proposed that the SNARE proteins are able to soften the 
membranes in which they reside. This allows the membrane to be deformed with less energy input. 
The strength of the SNARE complex and the force applied to the membranes during its formation 
increases membrane tension and reduces inter-membrane separation; promoting hemfusion. 
Following the action potential of the neuron it is proposed that a conformational change occurs in 
the synaptic SNARE complex, pulling on the hemifusion diaphragm and inducing the formation of a 
fusion pore. 
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Chapter 1.  
INTRODUCTION 
SNARE (SNAP (Soluble NSF (N-ethylmaleimide Sensitive Fusion) Attachment Proteins) Receptor) 
proteins are of central importance in membrane fusion events, in an evolutionarily conserved 
mechanism. Section 1.1 discusses the general mechanism by which all vesicle transport pathways 
operate. The SNARE proteins used in this study (Syntaxin 1A, SNAP-25b (Synaptosomal-associated 
Protein 25) and VAMP2 (Vesicle Associated Membrane Protein 2; also referred to as Synaptobrevin 
2)) are located in neurons and therefore the neurotransmission pathway is discussed in further 
detail. 
Membrane fusion requires lipid bilayers to be deformed and remodelled; SNARE proteins provide 
the energy for this to occur. Traditionally however, studies of membrane fusion have investigated 
protein roles and lipid contributions separately. In order to discuss both of these influences, general 
introductions of both are given in sections 1.2 and 1.3 respectively. Section 1.2 describes the general 
features of the SNARE super-family with explanations of the nomenclature and classifications used 
throughout this thesis. A detailed discussion of the structure of the individual SNARE proteins used, 
and the complex they form, is also included. The effect of aggregating lipid molecules into structures 
such as bilayers, and the resultant stored energy, is discussed within section 1.3. The most widely 
accepted theories of membrane fusion are discussed in section 1.4. This section brings together 
information from sections 1.2 and 1.3 to discuss the potential roles of both lipids and SNARE 
proteins at each stage of membrane fusion.  
Sections 1.5 and 1.6 introduce the concept of minimal machinery i.e. the smallest number of 
components necessary for fusion to occur. First, section 1.5 highlights the complexity and highly 
regulated nature of membrane fusion in vivo. The large number of participants (even excluding lipid 
involvement) makes it difficult to untangle individual functions. Despite this, many studies (both in 
vivo and in vitro) have been conducted with the aim of establishing what the minimal machinery is. 
While still debated, it is commonly believed that the minimal machinery consists of lipid bilayers 
which contain the appropriate SNARE proteins. Section 1.6 provides a critique of the evidence 
provided by these studies and aims to introduce the reader to the most common criticisms of 
existing studies. 
P a g e 2 
 
In recent years it has become increasingly evident that there is interplay between proteins and lipids 
in membrane fusion. While no phospholipid binding has been observed for SNARE proteins alone, 
evidence has emerged that complexes between SNAREs and regulatory proteins may be partly 
controlled by lipid moieties. Despite the lack of evidence that they form a pore, the transmembrane 
domains of SNARE proteins have also been shown to be essential for complete fusion to occur. 
Though briefly discussed throughout this chapter, protein-lipid interplay is predominantly discussed 
in section 1.7. Away from membrane fusion, there are many known examples of protein-driven 
changes in membrane environments. The general principles of this effect are described, with 
examples, in 1.7.1. Evidence for interplay in SNARE-mediated membrane fusion is discussed in 1.7.2. 
This section also includes a discussion of the controversy surrounding specific types of study used 
and the apparent link between lipid modification (including signal pathways) and the regulatory 
proteins discussed in section 1.5. Finally, section 1.8 provides the reader with concluding comments 
and outlines the rest of the thesis.  
The emerging evidence of interplay in membrane fusion events shows a need to investigate the 
lipids and proteins involved collectively. The essential involvement of SNARE proteins in fusion 
makes them a prime candidate for such a study. 
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1.1 VESICLE TRANSPORT PATHWAY 
Eukaryotic cells, unlike prokaryotes, have internal compartments. These membrane-enclosed bodies, 
known as organelles, allow for the segregation and regulation of cellular functions. Though single 
celled eukaryotic organisms exist, namely yeasts and protozoa, the majority of eukaryotes cooperate 
to form multi-cellular organisms such as mammals. This leads to specialised cells unable to survive 
independently and increased sophistication of function. 
In order for eukaryotes to work efficiently there must be continual communication between the 
organelles (intracellular communication) and additionally, in the case of multi-cellular organisms, 
neighbouring cells (intercellular communication). The vesicle transport network is the primary 
means by which intracellular communication occurs. It is also instrumental in many intercellular 
communication events such as neurotransmission. 
1.1.1 GENERAL VESICLE TRAFFICKING MECHANISM 
Despite numerous pathways within this network, the general mechanism (Figure 1.1) remains the 
same(1, 2). A vesicle, which is a small membrane body containing soluble and membrane associated 
cargo, buds from a donor organelle and fuses with the membrane of the target. First, adaptor 
proteins are recruited to the donor organelle membrane. These proteins bind to cargo receptors 
which define the soluble content of the vesicle. Adaptors also bind to coat proteins. There are three 
principal coat proteins which operate in different areas of the network. COPII between the 
endoplasmic reticulum (ER) and the Golgi complex, COPI between the Golgi complex and the ER and 
Clathrin between the Golgi complex and the plasma membrane. Despite this apparent segregation of 
coat proteins it is currently unclear whether they help to determine the path a given vesicle will 
follow. One of their functions is hypothesised to be the induction and stabilisation of high 
membrane curvature causing a vesicle to bud from the donor organelle(3, 4). During the budding stage 
other proteins are introduced including proteins vital for vesicle function; scission of the vesicle then 
follows. The coat proteins are removed before Rab GTPase proteins on the vesicle bind to receptors 
at its destination, tethering the vesicle to the target organelle(5-10). Interaction of a SNARE protein on 
the vesicle with a complimentary pair of SNARE proteins on the target membrane(11) leads to vesicle-
target fusion(1, 12-18). The docking and fusion stages of this pathway are highly regulated by a variety 
of proteins (see section 1.5). 
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1.1.2 NEUROTRANSMISSION 
Neurotransmission is an example of the use of the vesicle transport network for intercellular 
communication.  Neurons pass information to neighbouring neurons through chemical signals which 
are released as a result of exocytosis (Figure 1.2). Neurons consist of four regions: the cell body, 
axon, axon terminals and dendrites. The axon terminal of one neuron forms a synapse with the 
dendrite of a neighbour, separated by the synaptic cleft. Vesicles containing neurotransmitters 
(small molecules such as dopamine, acetylcholine and serotonin) fuse to the plasma membrane at 
the synapse. The neurotransmitters are released into the synaptic cleft where they proceed to bind 
to receptors located on the dendrite of the other neuron. 
 
Figure 1.2. Information is passed from one neuron to another through neurotransmission. Synaptic vesicles 
containing small neurotransmitter molecules originate at the trans-Golgi complex and travel to the axon 
terminals. Upon a nerve impulse (also called an action potential) the vesicle undergoes fusion. The fusion of the 
vesicle with the plasma membrane releases the content of the vesicle into the synaptic cleft (or gap). 
Neurotransmitters bind to receptors on the receiving neuron's dendrite. The vesicle can be recycled through 
direct endocytosis or incorporation into an endosome. The vesicle is able to be refilled and undergo several 
rounds of fusion. 
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The vesicles that undergo this process are called synaptic vesicles(19). They are approximately 50 nm 
in diameter, originate from the trans-Golgi complex and only fuse when triggered by an action 
potential. For these vesicles this trigger is in the form of an influx of calcium ions. Neurons must 
respond extremely quickly to an action potential and upon this stimulus, synaptic vesicles fuse and 
release neurotransmitters within 0.5 ms(20). In order for such a fast response to be possible three 
vesicles pools are located in the pre-synaptic terminal(21). First, the RRP (ready-releasable pool) 
contains approximately 1% of the total number of vesicles. Within this pool there is some evidence 
to suggest two populations of vesicles are present. The first population is of tethered vesicles and 
the second is of docked and primed vesicles. The second population is able to fuse almost 
instantaneously with the action potential. Once a vesicle has released its content it leaves the RRP 
and moves to the recycling pool, where it can be refilled. 10-15% of the total vesicles occupy this 
pool and fast exchange, recycling and trafficking is observed between it and the RRP. The third pool 
is rarely used despite containing 80-90% of the vesicle population. If stimulus is prolonged or intense 
the recycling pool can become depleted and in this situation, vesicles will transfer from the reserve 
pool to restore the population of the recycling pool. However, movement between them is slow. A 
reserve pool is necessary as axons can be up to a metre long; without it, the distance between the 
trans-Golgi complex and pre-synaptic terminal would inhibit intense/ prolonged stimulation. 
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1.2 SNARE PROTEINS 
The first SNARE proteins were discovered in the 1980s(22-25) but it was not until 1993 that Thomas 
Söllner found them to be SNAP receptors(12), therefore linking them to membrane fusion events. 
Since then many proteins have been classified as SNARE proteins. Genomics has led to the 
identification of 36 distinct mammalian SNARE proteins(26). These can be classified into four 
subfamilies; Syntaxin, SNAP-25N, SNAP-25C and VAMP, based upon homology sequencing and 
domain structure comparisons (Figure 1.3). The subfamilies have the alternative classification of Qa, 
Qb, Qc and R respectively (see section 1.2.2). SNARE proteins are proposed to have some 
involvement in the specificity of membrane fusion events as they are localised into distinct 
organelles(27-29). 
 
Figure 1.3. Adapted from Hong(26), the phylogenetic tree of the mammalian SNARE proteins is shown. The four 
branches are based upon sequence similarities within the SNARE motif. Each branch represents a SNARE 
subfamily: Qa/ Syntaxin (red), Qb/ SNAP-25N (light green), Qc/ SNAP-25C (dark green) and R/ VAMP (blue). 
Those in grey are currently unassigned to a subfamily. 
P a g e 8 
 
To be classified as a SNARE protein several criteria must be observed(30). These include the ability to 
bind to a membrane and most commonly SNARE proteins have a transmembrane domain. 31 of the 
36 mammalian SNARE proteins have a single transmembrane domain(26). The remaining SNARE 
proteins are SNAP-23, SNAP-25, SNAP-29, Syntaxin 11 and Ykt6. Of these, SNAP-25, Syntaxin 11 and 
Ykt6 have palmitoylated amino acid residues giving them lipid anchors; the remaining two have 
other forms of lipid anchor. Other criteria are that the SNARE proteins are relatively small proteins 
(typically 15-40 kDa in size) and that a large proportion of the sequence is cytosolic.   
1.2.1 NOMENCLATURE 
There are two systems of nomenclature which are used when discussing SNARE proteins. The 
earliest describes SNARE proteins as either v- or t- SNAREs based upon their location at the start of 
the membrane fusion process(31). Those SNAREs which start on the vesicle are described as v-SNAREs 
and most commonly are members of the VAMP subfamily. Conversely, the SNARE proteins located 
on the target membrane are described as t-SNAREs. The members of both the Syntaxin and SNAP-25 
subfamilies are most commonly t-SNAREs. However, within the vesicle transport network recycling 
pathways exist; v-SNARE proteins can therefore be located on target membranes and t-SNARE 
proteins in vesicles. As this can lead to confusion another nomenclature system emerged(32). Rather 
than location based, this nomenclature is based upon the sequence of the SNARE proteins. 
Throughout the SNARE super-family it has been found that some amino acid residues are conserved. 
At the centre of the SNARE complex (see section 1.2.2) this conserved residue is either an arginine 
(R) or glutamine (Q). Therefore SNARE proteins are labelled either R- or Q- SNAREs. While a few 
exceptions are known(26), R-SNARE proteins are usually found on vesicles and Q-SNAREs on target 
membranes. Therefore R-SNAREs, in most cases, can also be called v-SNAREs and Q-SNAREs called t-
SNAREs. As this thesis will not discuss recycling pathways in depth the v/t- nomenclature will be 
used from now on. 
1.2.2 UNIVERSAL STRUCTURAL FEATURES OF SNARE COMPLEXES 
Heptad repeats are present in the sequence of all SNARE proteins and form at least one amphipathic 
α-helix(18). This helix is often called the SNARE motif or core domain and this motif is found adjacent 
to the transmembrane domain (in those SNARE proteins that have such a membrane anchor). In 
SNARE proteins with lipid anchors the motif is usually found at one, or both, of the terminal 
domains. In vivo, four of these motifs form a coiled coil structure(33) known as the core SNARE 
complex. Formation of the complex buries the hydrophobic faces of each α-helix within it(34-36). It has 
been found that the amino acid residues within the heptad sequence can vary between SNARE 
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proteins. Despite this, the SNARE complexes that form have been found to be structurally highly 
similar(32, 33, 35). The SNARE proteins and the complex formed by them have been shown to have 
similarities with viral fusion proteins and the complexes that they form(15, 37).  
The SNARE complex is considered to have two states called trans and cis (Figure 1.4). The trans-
complex (also called a SNAREpin(38)) is the initial SNARE complex formed in vivo. The individual 
SNARE proteins are still localised on different membranes i.e. before full fusion has occurred. The 
cis-complex is the fully formed SNARE complex, formed after fusion. It is thought that the stability of 
the cis-complex contributes to the energy requirements of the fusion process(39, 40). 
 
Figure 1.4. The SNARE complex exists in two states, which are presented in this figure. The trans-SNARE 
complex is an intermediate structure during the fusion process, with SNARE proteins located on different 
membranes. After fusion, the complex assembles fully to form the cis-SNARE complex, its most stable state. 
These two forms are a universal feature in SNARE protein function; however, some of the structural aspects 
represented in this figure are based upon the neuronal SNARE proteins (described in section 1.2.3). 
The majority of SNARE proteins contain only one SNARE motif; formation of a SNARE complex 
therefore usually requires four SNARE proteins. There are three mammalian exceptions which are 
SNAP-23, SNAP-25 and SNAP-29 as each contains two SNARE motifs(26). These two motifs are named 
based on their position. The N-terminal motif is denoted 25N and the C-terminal motif 25C. Proteins 
belonging to the SNAP-25 subfamily are therefore split into two further subfamilies; those with 
motifs homologous to 25N and those homologous to 25C. These proteins are Q-SNAREs and the 
motifs are sometimes referred to as light chains. An alternative notation for these motifs is Qb for 
25N motif proteins and Qc for 25C proteins. The SNARE complex is made up of an R-SNARE (v-SNARE) 
motif and three Q-SNARE (t-SNARE) motifs(41, 42). The origin of each of the α-helices in the SNARE 
complex structure is usually denoted R, Qa, Qb and Qc (regardless of the nomenclature system in 
use). Qa (the heavy chain) is the helix which originates from the Syntaxin family member and R from 
the VAMP family member. 
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1.2.3 THE NEURONAL SNARE PROTEINS 
The neuronal SNARE proteins are also referred to as the synaptic SNAREs and are involved in the 
fusion of synaptic vesicles (see section 1.1.2). The neuronal SNARE complex is unusual as it is formed 
from only three SNARE proteins. A couple of isoforms of the SNARE proteins involved in this complex 
exist, those discussed here are those used in this study (which are also the most widely studied). 
These proteins are Syntaxin 1A, SNAP-25b and VAMP2 but will be referred to as Syntaxin, SNAP-25 
and VAMP from now on. 
1.2.3.1 Syntaxin 1A 
The transmembrane domain of Syntaxin is located in the C-terminal region, adjacent to which is the 
SNARE motif (Figure 1.5). The N-terminus of the protein is made up of the Habc domain which 
accounts for two thirds of the protein sequence. This domain forms three α-helices which arrange 
into an anti-parallel bundle(43, 44). Structurally this N-terminal domain is highly conserved within the 
Syntaxin subfamily and yeast homologues. The domain is connected to the SNARE motif by a flexible 
linker(45) that allows Syntaxin to form a closed conformation whereby the Habc domain binds to the 
SNARE motif. While there is evidence that the Habc domain itself could be used for regulation
(46, 47), 
the role of the four α-helix closed complex is more uncertain; though it too has been linked to 
regulation. The SNARE motif contains the conserved amino acid residue glutamine and therefore 
Syntaxin is classified as a Q-SNARE. It is also primarily located on the plasma membrane during 
exocytosis and is therefore also a t-SNARE protein. 
 
Figure 1.5. Syntaxin 1A is anchored to membranes through a transmembrane domain at its C terminus (shown 
in yellow) next to which is the SNARE motif (shown in red). The Habc domain is located towards the N-terminal 
region and consists of three α-helices (each shown in blue). An aspartic acid rich domain is also present in the 
N-terminal region. Syntaxin is a Q- and t-SNARE protein and resides primarily on the plasma membrane, where 
it functions in exocytosis. 
  
13-19 28 63 69 106 111 145 192 254 266 288
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1.2.3.2 SNAP-25 
This protein, like Syntaxin, is also classified as a Q- and t-SNARE protein. Unlike most SNARE proteins 
SNAP-25 contains two SNARE motifs. Only three SNARE proteins are required for the formation of 
the neuronal SNARE complex because SNAP-25 contributes both of these SNARE motifs to the 
SNARE complex. One of SNAP-25’s motifs is located at each terminus linked by a sequence referred 
to as the loop or linker region (Figure 1.6). Within this loop four cysteine residues (C85, C88, C90 and 
C92) are palmitoylated(48-50) to provide SNAP-25 with lipid anchors rather than a transmembrane 
domain. 
 
Figure 1.6. The Q- or t-SNARE protein SNAP-25 contains two SNARE motifs (shown here in red), one located at 
each terminus. Four palmitoylated cysteine residues provide SNAP-25 with lipid anchors (shown in green). The 
exact position of these anchors differs slightly between the two isoforms, a and b. It resides predominantly in 
the plasma membrane. 
1.2.3.3 VAMP2 
Also called Synaptobrevin, VAMP is located on the vesicle and as such is a v-SNARE protein. It also 
contains the conserved residue arginine within its SNARE motif and is therefore also classified as an 
R-SNARE.  The N-terminal region of VAMP is made up of two domains. At the extreme end is a 
proline rich region, 24 amino acid residues long and ending with dibasic residues(51). The second 
domain is highly conserved within the Synaptobrevin family. This domain appears to have two 
sequences which are highly predisposed to form α-helices. Both of these regions are thought to 
interact with regulatory proteins (see section 1.5). The C-terminus contains the transmembrane 
domain. Despite having a transmembrane domain it has been shown that VAMP is also 
palmitoylated(52). VAMP only has one cysteine residue, which is located within the transmembrane 
domain and is therefore considered to be the site of this lipid anchor. This positions the anchor 8 
residues from the membrane-cytoplasmic border and may be involved in regulation(53). Like 
Syntaxin, the SNARE motif of VAMP is located adjacent to the transmembrane domain (Figure 1.7). 
 
Figure 1.7. The transmembrane domain of VAMP2 is in the C-terminal region (shown in yellow). Adjacent to this 
membrane anchor is the SNARE motif (shown in red). VAMP2 functions mainly from synaptic vesicles in 
exocytosis, though it is present on other membranes due to recycling pathways. 
N C
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1.2.3.4 The Neuronal SNARE Complex 
The crystal structure of the core neuronal SNARE complex was determined to 2.4 Å resolution in 
1998(34). The structure was formed from the minimal fragments of Syntaxin 1A, SNAP-25b and 
VAMP2 required to form the complex. The complex was found to be a 4-helix twisted structure with 
the helices arranged parallel to each other. The overall cylindrical structure was 120 Å long with a 
circular cross section, though the radius of cross section changed appreciably over the length. The 
core SNARE complex forms 16 hydrogen bonded layers over approximately 60 residues with the 
layers orientated so that they are perpendicular to the bundle axis (Figure 1.8). The layers are 
numbered from -7 to +8 and mainly made up of side chains of hydrophobic residues. The central 
layer (labelled the zero layer) is made from the conserved amino acid residue (which gives the R/Q- 
nomenclature) in each of the SNARE proteins. As such, unlike the other layers, the zero layer is 
hydrophilic and is thought to be important in the disassembly of the complex once membrane fusion 
has occurred(54-56). 
 
Figure 1.8. Adapted from Chen(18) the backbone of the core 
neuronal SNARE complex and the 16 interacting layers are 
shown on the left. To the right, a top down view of amino acid 
residue interactions is shown (VAMP in blue, Syntaxin in red and 
SNAP-25 in green). The zero (hydrophilic) layer, seen centre 
right, shows the interaction between the conserved amino acid 
residues found throughout the SNARE super-family. 
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In vitro it has been shown that no more than one arginine can be present in the zero layer but that it 
is possible to form a complex from four Q-SNARE proteins. In vivo this layer consists of one arginine 
and three glutamines during membrane fusion(41, 42, 57). The central layer is surrounded by three 
layers (-1, -2 and +2) which show geometry and composition typical of leucine zipper protein 
complexes(34). They are made from leucine, isoleucine and valine which interact in a plane. However, 
the remaining layers deviate significantly from classic leucine zipper models(58). This is discussed 
further in the original crystallography paper(34). The 16 layers of the complex make it extremely 
stable. The complex has been found to resist denaturation when exposed to the detergent SDS(59) 
(Sodium Dodecyl Sulphate) or heated to 90°C(60). Proteases(59, 61, 62) and clostridial toxin(62, 63) were 
also shown to be ineffectual. Other SNARE protein complexes are considered to have this ladder of 
interacting residues, though the exact number may vary.  
The end of the core complex, made from the N-terminal regions of the SNARE helices, shows 
interactions between Syntaxin and SNAP-25, while the C-terminus of the complex shows interactions 
between Syntaxin and VAMP. The surface of the complex was found to have distinct patches of 
hydrophobicity and hydrophilicity as well as charged regions. These, along with the highly grooved 
contours of the surface suggest interactions of the complex with other proteins. These interactions 
could be regulatory, though the surface features may also be important in membrane fusion 
events(34). 
In July 2009 a crystal structure was published(64) for a SNARE complex including the linker and the 
transmembrane domains of Syntaxin 1A and VAMP2 (Figure 1.9). The protein crystal was grown by 
incorporating n-nonyl β-D glucopyranoside into the buffer and a resolution of 3.4 Å was achieved. 
This study showed that the linker and transmembrane domains of these proteins were helical, 
forming continuous helices from the core domain through to the C-terminus. This complex was 
found to be more stable than the core complex and successive removal of the membrane anchors 
reduced the stability. The linker regions were shown to interact through aromatic side chain 
contacts, forming a collar surrounded by basic residues. Using computer modelling, the complex was 
inserted into a lipid bilayer. This simulation suggested that the cis-SNARE complex sits as a rod, 
perpendicular to the bilayer with the linker regions of VAMP and Syntaxin buried in the upper 
monolayer. It was hypothesised that amino acid residues in the linker region interact with the polar 
headgroups of lipids in the upper monolayer. 
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Figure 1.9 Modified from the figures of the original crystallography paper(64), the solved crystal structure of the 
SNARE complex with the linker and transmembrane domains of Syntaxin 1A and VAMP2 included is shown. The 
crystal structure reveals that Syntaxin 1A and VAMP2 form continuous helices from the beginning of the SNARE 
motif through to the C-terminal domains. The structure of the complex formed by the SNARE motifs is 
consistent with the core crystal structure found in 1998 by Sutton(34). Beyond the core complex, the linker and 
transmembrane domains of Syntaxin and VAMP interact; twisting around each other. The position of the 
complex within a lipid bilayer was assessed using computer simulations and showed residues within the linker 
region interacting with the polar headgroups of the lipids. 
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1.3 LIPID MEMBRANE PROPERTIES 
Biological membranes are primarily composed of proteins and amphiphilic molecules called lipids. 
Despite the apparent role of SNARE proteins in membrane fusion, the event results in the melding of 
lipids from two, initially distinct, membrane structures. It is therefore important to consider the 
properties of lipid molecules and their possible contribution to membrane fusion events. 
1.3.1 SELF AGGREGATION AND MESOPHASES 
Lipids are amphiphiles possessing both hydrophobic and hydrophilic properties. In the presence of 
solvent, lipid molecules will self aggregate. Commonly, and in the case of cells, the solvent is water. 
The headgroup region of the lipids is hydrophilic and the aggregated structure is orientated so that 
this region shields the hydrophobic section (usually in the form of hydrocarbon chains) from the 
water.  
The way in which lipids will aggregate depends on both the temperature of the system and the 
amount of solvent present(65). The lipid molecular structure itself is also an important consideration. 
The aggregated structures formed are called mesophases. Neither solid nor liquid, the lipids within a 
mesophase are able to diffuse two dimensionally with respect to the surface. These mesophases are 
also called lyotropic liquid crystal phases. 
1.3.1.1 The Lateral Pressure Profile 
The aggregation of lipids is driven by the hydrophobic effect (the energetic cost of exposing the 
hydrocarbon chains to water). In biology, the most common aggregate structure is that of a lipid 
bilayer; within this structure lipids form two monolayers, which are coupled back to back. Within 
each monolayer forces act between individual molecules to both repel and attract them. These 
forces, which act within the plane of the lipid surface, can be represented by the lateral pressure 
profile(66-70) which shows how the lateral pressure, π(z), varies across the depth of a monolayer 
(Figure 1.10). 
The headgroup region of a lipid molecule is often charged or polar. Electrostatic repulsion therefore 
occurs when headgroups are aggregated. Steric hindrance and hydration forces can act to further 
increase the repulsive force at this depth. However, if headgroups are able to interact through 
hydrogen bonding, the lateral pressure of the headgroup region can be reduced. Within the chain 
region of the monolayer, collisions between chains can occur; providing a repulsive force. The ability 
of the chains to orientate so to avoid collisions with neighbouring chains usually increases with 
depth. This leads to a decrease in the repulsion over the length of the chain region. However, 
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introduction of chain unsaturation reduces the degrees of freedom leading to increased lateral 
pressure. Weak Van der Waal forces within the chain region provide some attractive force, though 
not sufficient to counteract the repulsive forces experienced.  At the interface between the polar 
and non-polar regions is a highly attractive force. This force acts to keep the molecules together, 
shielding the chains from water (i.e. it is driven by the hydrophobic effect). 
 
Figure 1.10. Interactions between aggregated lipid molecules lead to several forces acting within the aggregate 
structure. These forces (illustrated on the left of this figure) result in lateral pressure and torque tension. In this 
figure the lateral pressure is shown on the right, as a function of bilayer depth. Electrostatic repulsion and steric 
hindrance apply a repulsive force in the headgroup region. The flexibility of the lipid chains leads to collisions 
which introduce repulsive force within the chain region. At the interface between head and tail groups the 
hydrophobic effect drives the structure to shield the tail regions from polar solvent.  
 In order for a monolayer to reach equilibrium the lateral pressure must balance so that no net 
pressure acts (Equation 1.1). 
 ()	 
   Equation 1.1 
Integration of the moments acting at the various depths of the monolayer gives the torque tension, τ. In most cases the net torque is not zero (Equation 1.2). In these cases torque will act upon the 
monolayer and it will bend. 
     ()	 
   Equation 1.2 
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1.3.1.2 Type and Curvature 
The torque tension of a monolayer can be negative or positive. Therefore, the curvature that results 
from this non-zero torque can also be defined as negative or positive. Conventionally positive 
curvature is defined as surfaces which bend away from water and towards the chain region, and 
negative for surfaces that bend towards water (away from the chain region). Mesophases can be 
divided into two groups depending upon curvature. Those that possess surfaces of positive 
curvature are called normal phases (or type I), those with negative curvature surfaces are referred to 
as inverted (type II) mesophases. The classification of type is also used for individual lipids. Based on 
whether a single lipid component system displays positive or negative curvature the lipid molecules 
themselves can also be described as type I or II lipids. 
For a spherical mesophase, the curvature is simply the reciprocal of the spheres radius. The surface 
of a sphere has the same curvature at any point but this is not the case for other surfaces. Two 
curvatures are needed to define the curvature of a surface at any point(71). Two circles are drawn 
normal to the surface intersecting at the same point (Figure 1.11). The reciprocals of the radii give 
the curvatures. The two circles intersecting this point with the most negative (or most positive) 
curvatures are the principal curvatures c1 and c2 and are perpendicular to each other. 
 
Figure 1.11. Non spherical structures usually have more than one 
curvature component at any given point. In order to characterise the 
overall curvature of a mesophase, these components must be 
evaluated. Circles coincident to the surface at a particular point are 
drawn. Those with the minimum and maximum curvature (the 
reciprocal of the circle radius) are defined as the principal curvatures. 
 
 
 
As already stated, the principal curvatures of a spherical surface are equal. In a hexagonal 
mesophase lipids aggregate into cylinders which hexagonally pack. In this case one principal 
curvature will be negative or positive, depending on type, as it follows the elliptical cross section of 
the cylinder. The other curvature (which follows the long axis of the cylinder) will be zero. A saddle 
surface like the one shown in Figure 1.11 has one positive and one negative principal curvature. In a 
completely planar surface these curvatures are both zero. 
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1.3.2 THE ENERGY OF CONSTRAINT 
Section 1.3.1 described how aggregation of lipids usually results in curved monolayer surfaces; 
defined by the two principal curvatures. In 1973 Helfrich(66) derived the free energy model for 
membranes. Providing that the thickness is negligible compared to the surface area, the membrane 
can be collapsed to a single sheet of infinitesimal thickness. The curvature free energy of the surface 
per unit area, gc, can be expressed as, 
   (    )  Equation 1.3 
Where, κ is the bending rigidity (or splay modulus) and κG, the Gaussian (or saddle splay) modulus. 
The spontaneous curvature, c0, is related to the torque tension
(70, 72) as  . Equation 1.3 can 
be used to express the free energy of either monolayers or bilayers. However, the meaning of the 
moduli will be different. 
The principal curvatures of a sphere are equal. By exploiting this, and differentiating Equation 1.3, it 
has been shown(73) that a spherical interface is at the global energetic minimum providing     ! . The curvature of the system in this minimal energy state is the relaxed curvature, cr, and can be related to the spontaneous curvature, 
 $      Equation 1.4 
Equation 1.3 can therefore be re-expressed based upon the relaxed, rather than spontaneous, 
curvature.  
   %&  '()(*  *$)  %& '()(*  +) Equation 1.5 
As with Equation 1.3, the membrane is collapsed to a minimal sheet. In this case the sheet is situated 
at the pivotal plane; the position where the cross sectional area does not change during isothermal 
bending. In Equation 1.5, H is the mean curvature and K is the Gaussian curvature and are defined as  
 *   (  )  
 +   Equation 1.6 
The moduli of Equation 1.5, k and ,  are the bending rigidity and coupling modulus respectively. 
These moduli can be related to the moduli of the original Helfrich expression (Equation 1.3) 
providing that    ! ; 
 &    
 ,      Equation 1.7 
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In biology, as already stated, the principal lipid structure is that of bilayers. The coupling of two 
monolayers back to back means that neither monolayer can adopt its preferred curvature (unless 
the monolayers possess relaxed curvatures of the same magnitude but opposite sign). If both were 
to bend to their relaxed curvature, a vacuum within the bilayer or hydration of the chain region 
would be necessary; both cases are energetically highly unfavourable (Figure 1.12).  
 
Figure 1.12. Figures A and B show monolayers which have adopted their relaxed curvature. The monolayers of 
A both have negative relaxed curvature and B, positive. As the figures show, if each leaflet bends to its relaxed 
curvature a vacuum region would form or the chain regions would be exposed to water. Both of these 
possibilities are energetically highly unfavourable. The leaflets of the bilayer are therefore unable to adopt the 
relaxed monolayer curvature. 
For a bilayer made up of a single lipid component, both monolayers will have the same relaxed 
curvature, in both magnitude and direction. In this case the monolayers counter each other exactly 
and there is no overall desire to bend(74). The relaxed curvature of the bilayer, *$-, is therefore equal 
to zero(75). Assuming a symmetric bilayer, the bending rigidity and coupling modulus of the 
monolayers are related to their bilayer equivalents as follows; 
 &-  &  
 ,-  ,  ./*$(,  &) Equation 1.8 
Where, / is the thickness of the monolayer. 
The constraint imposed on monolayers by back to back coupling means that, relative to the relaxed 
state of each monolayer, there is an increase in the energy of the system. This additional energy is 
known as stored curvature elastic stress. 
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1.4 MEMBRANE FUSION 
Research into membrane fusion has now been conducted for over two decades. Research has taken 
many forms from genetics and structural determination of proteins to theoretical modelling and 
lipid phase diagrams. A wealth of information has been gathered and a consensus on some aspects 
of membrane fusion has been reached. However, the complexity of fusion, particularly in biology, 
leaves much to be explained and key aspects are still debated. 
1.4.1 CLOSE PROXIMITY 
It is now widely believed that while the details of fusion may differ, there are general mechanisms by 
which two disparate membranes fuse. First, the membranes must be bought into close proximity. 
Neutral lipid bilayers in equilibrium can be as close as 2 nm(76); however this is not sufficient for 
fusion to occur. In order to fuse, the repulsion between two membranes must be overcome; 
requiring energy. The fusion site itself must have an inter-membrane distance of less than 1 nm(77). 
In some pure lipid systems and cells this can be achieved by dehydrating the contact area by the 
addition of PEG (Polyethylene Glycol)(78, 79). Biological membranes contain proteins of many kinds as 
well as charged lipids. The additional steric hindrance and electrostatic repulsion increases the 
equilibrium inter-membrane distance and cellular membranes are typically 10-20 nm apart(71).  
It is widely accepted that proteins play a key role in decreasing the membrane separation prior to 
fusion events. In the case of synaptic exocytosis, Rab GTPases and Rab effectors are thought to 
initially tether the vesicle to the plasma membrane(5). It is hypothesised that SNARE proteins then 
bring the membranes closer still, providing energy to overcome repulsion. The t-SNARE proteins 
(Syntaxin and SNAP-25 for synaptic exocytosis) form an initial, intermediary complex(80, 81). With the 
vesicle tethered to the target, the N-terminus of the v-SNARE (VAMP) interacts with that of the 
intermediary complex(82). VAMP binds to a groove on the intermediary complex surface, forming the 
trans-SNARE complex. This coiled-coil SNAREpin zips from the N-terminal regions towards the C-
terminus (and therefore the transmembrane domains); bringing the membranes close together(59, 83, 
84). The stability of the SNARE complex (even as the trans-complex) is thought to be sufficient to 
overcome repulsion and a single SNAREpin may provide enough energy to merge the proximal 
leaflets (the outer monolayer of each membrane)(85). It is thought however that more than one 
complex is involved at each fusion site. Indeed, it has been suggested, that a ring of SNARE 
complexes forms around the fusion site(86, 87). The number of SNARE complexes required has still not 
been proven experimentally but at least three are thought to be required for the fusion of secretory 
granules to the plasma membrane in PC12 cells(88).  
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Figure 1.13. During the formation of the trans-SNARE complex, the SNARE proteins must bend. If the linker 
region between the transmembrane domain (shown in yellow) and the SNARE motif (red for Syntaxin and blue 
for VAMP) is rigid enough then the bending of the protein will apply a torque force to the membrane. This 
torque could force the membrane to bend locally, forming a dimple. This figure shows dimple formation on 
both membranes and therefore assumes that both Syntaxin and VAMP have sufficient rigidity. 
 When a trans-SNARE complex is fully formed the core SNARE complex lies between the two 
membranes and each SNARE protein is bent between the SNARE motif and transmembrane domain 
(Figure 1.13). The cross section of the core SNARE complex suggests that it may prevent the 
membranes coming in close enough proximity(89). The inter-membrane distance therefore needs to 
be reduced further. In both VAMP and Syntaxin the transmembrane domain and SNARE motif are 
separated by a highly basic linker region. Studies which lengthened this linker showed that fusion 
was impeded(90). The linkers have been shown to be partially embedded into the outer monolayer of 
the membrane in which the protein resides(89, 91, 92) and a polybasic region within the Syntaxin linker 
interacts with negatively charged lipids(93). Most recently, the cis-SNARE complex structure has been 
solved including the transmembrane domains and linker regions of VAMP2 and Syntaxin 1A (see 
section 1.2.3.4). This also finds that the linker regions insert into the lipid bilayer and that a 
continuous twisted helical structure forms from the SNARE motifs through to the membrane 
anchors(64). The SNARE complex is therefore unlikely to hinder close membrane proximity as much as 
was once thought. In addition, as the SNAREpin complex forms the proteins are forced to bend. 
Modelling of the Syntaxin linker suggests that this region is rigid enough that this bending applies a 
torque force to the membrane causing the plasma membrane to dimple towards the vesicle(94). As 
VAMP contains a similar linker it is possible that the vesicle membrane is also bent (towards the 
plasma membrane) as the SNARE complex forms. This dimple formation would further decrease 
membrane separation. 
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Dimpling has also been suggested for viral fusion with the HA2 ectodomain of the influenza virus 
hemaglutinin (HA) causing dimpling of the viral membrane towards the target(95). The same is 
proposed for the fusion of paramyxovirus, except that it is the target not viral membrane which 
bends(96). Evidence from inflating cells has shown the importance of dimpling in the fusion 
process(71), however, the role of dimpling may not be to simply bring contact sites close enough 
together. Bending the membrane would cause the lipids of the outer monolayer to stretch and the 
lipids of the inner leaflet to compress. Bending the membrane in this way is likely to increase the 
stored curvature elastic stress of the bilayer (section 1.3.2). This is due to the lipid molecules 
stretching and compressing as well as bending further away from the preferred global curvature. 
Dimpling of the membranes towards each other gives the proximal leaflet of each membrane a 
positive curvature. Evidence has shown that the presence of lipids with a preferred positive 
curvature (e.g. lysophospholipids) inhibit the progression to the next stage of membrane fusion(97). 
The inhibition of fusion at this stage could be partly due to the stabilisation of the dimple. If dimpling 
functioned to bring membranes into close proximity and also increase the energy of the system, 
then dimples which are highly stressed will drive the system to remodel in order to lower free 
energy. A dimple containing positive lipids in the outer leaflet would not be as unstable as one 
without these lipids and therefore may not have a sufficient driving force. 
1.4.2 MEMBRANE CONTACT 
1.4.2.1 Proteinaceous Pore 
Once close proximity has been established, there are two pathways which have been suggested for 
membrane fusion. The first of these is that proteins form a fusion pore, allowing content mixing 
before lipid interaction(98, 99). However, formation of a proteinaceous pore would not explain how 
protein free systems fuse and would therefore imply separate mechanisms for pure lipid and 
biological systems. In both in vivo and in vitro experiments it has been shown that many of the same 
factors affect both types of system, such as the addition of specific lipid types(71). This would suggest 
that the mechanism is either the same or closely related. Evidence from both systems has also 
shown that lipid mixing is observed before content mixing(100-103). This indicates that membranes 
merge, at least partially, before pore formation. However, it is still a possibility that the pores are 
too small to be measured by current methods and that pore formation somehow allows lipid 
exchange(71).  
Evidence for proteinaceous pores comes mainly from studies of the V0 subunit of vacuolar H
+-
ATPase(99). This subunit has been shown to complex with other V0 subunits and lipids to form a 
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hexameric transmembrane complex (made up of two hexamers). Triggering by calcium ions causes 
conformational changes in the complex. It has been suggested that a proteolipid channel radially 
expands opening a fusion pore(104). Lipids would then migrate around the channel allowing lipid 
mixing. This hypothesis rests mainly on evidence for calcium dependent expansion and the 
formation of transmembrane complexes. Chernomordik(71) comments that while a pore of this 
nature would account for early fusion events, it is not clear how the proteolipid channel would allow 
the merger of the two membranes. If fusion was to occur via a proteinaceous pore before lipid 
mixing, the channel would have to act as a point of lipid exchange. One hypothesis is that a fusion 
pore is formed in each of the membranes. The edge of each pore would be partially lined with lipid 
and as the two pores combine the lipids would form a continuous structure(71). The proteolipid 
channel would also need to allow the fusion pore to expand. The expansion of a fusion pore of this 
nature would require the separation of the V0 subunits. There is currently no proposal for how these 
subunits would be driven to laterally separate. In considering these mechanisms, Chernomordik also 
casts doubt that such a structure could provide enough energy for full fusion to occur. 
1.4.2.2 Lipid Stalk 
The stalk model is the second proposed pathway and no direct involvement of proteins is required in 
the initial membrane-membrane contact. It is also hypothesised that intermediary structures are 
adopted before pore formation. As such, the stalk model is applicable to both pure lipid and 
biological systems. This model is now perhaps the most widely accepted(105, 106) and originated from 
theoretical modelling and examination of protein-free lipid systems.  
Membranes undergo thermal fluctuations and electroporation studies have found that the 
maximum energy available from these fluctuations (assuming a one second timescale) is ≈40 kBT
(107, 
108). At small inter-membrane distances it has been suggested that these fluctuations allow 
protrusions from the outer monolayer of each membrane to interact. This would then lead to the 
formation of a stalk; linking the two membranes(109). Initial studies of this hypothesis assumed a 
spherical area of interaction but the energy calculations based on this showed the energy barrier to 
be unfeasibly high(110, 111). Several years later the stalk structure was re-modelled in various ways 
including tilting lipid molecules and minimising the contact area(108, 112).  This revised stalk model 
(Figure 1.14) was found to be energetically possible. Assuming a stalk width of 25 nm, the energy of 
the revised stalk model for DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) was found to be 45 kBT. 
For DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), which has a larger negative relaxed 
curvature than DOPC, the stalk energy was calculated to be -30 kBT. This is consistent with studies 
that show pure DOPE systems can spontaneously fuse(71). The dramatic difference in stalk energy 
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depending on the lipid studied highlights the importance of the lipid properties discussed in section 
1.3. The structure of the stalk is such that lipids which have negative relaxed curvature (such as 
DOPE) can more favourably adopt the curvature required. Studies have shown that while type II 
lipids in the proximal leaflets promote the transition to the next stage of fusion (hemifusion, see 
section 1.4.3), lipids of positive curvature inhibit it(79, 97, 113). As well as dimple stabilisation (section 
1.4.1) positive curvature would affect the energy of the stalk structure, making it unfeasibly high and 
therefore stalk formation unfavourable. 
Figure 1.14. Taken from Kozlovsky and Kozlov(108) this 
figure shows the optimised tilt model structure of a lipid 
stalk. The structure was determined using a continuous 
approach elastic model. The stalk represents the minimal 
contact between two lipid bilayers and is thought to be a 
transient structure forming before the merging of the 
proximal leaflets into a hemifusion diaphragm. 
Eukaryotic cells require functions to be spatially separated. The transport of content between 
organelles must also be tightly controlled. The complex lipid environment of biological membranes 
could allow the energy of a stalk structure to be equal to, or below, the energy provided by thermal 
fluctuations. In this situation, membranes in close enough proximity (much less than the equilibrium 
separation of biological membranes) could fuse spontaneously. As discussed in section 1.4.1, this 
could be directed by the actions of proteins. Alternatively, the energy of the stalk could be above the 
energy provided by thermal fluctuations. If the amount of additional energy required was not too 
high, membrane fusion could be perturbed until protein machinery introduced the remaining 
energy. This second possibility would allow even greater control of the membrane fusion process 
allowing proteins to bring membranes close together but only trigger fusion when it was required. It 
is known that vesicles in neurotransmission dock to the target membrane and fusion only occurs 
when triggered by an action potential (see section 1.1.2). It can be envisaged for example, that the 
formation of SNARE trans-complexes not only brings two membranes close enough together but 
also provides some of the energy needed, perhaps to form a stalk. The energy provided from the 
formation of one neuronal cis-SNARE complex is ≈35 kBT
(114). While the energy released from the 
formation of a trans-SNARE complex would be lower it may still be sufficient, particularly if more 
than one SNAREpin was involved at each fusion site. 
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1.4.3 FROM HEMIFUSION TO FULL FUSION 
1.4.3.1 Hemifusion 
Many studies have suggested that lipid mixing occurs before content mixing(100-103) and 
developments have been able to show that it originates from the proximal but not distal leaflets of 
the membranes. These findings can be explained by the stalk model (section 1.4.2.2). The stalk is 
formed from only a minimal contact between the proximal leaflets which is believed to then expand 
into a hemifusion diaphragm(115). The diaphragm is a single bilayer made up of the inner monolayer 
of each participating membrane. Its formation would cause the lipids of the proximal leaflet to mix 
while still keeping the content of each membrane distinct. As discussed in sections 1.4.1 and 1.4.2.2, 
it has been shown that the hemifusion intermediate is inhibited by the addition of type I lipids to the 
proximal leaflets(116-120) and there are several possible reasons for this. First, the stalk energy may be 
too high for a lipid composition containing a high proportion of this lipid type. Second, dimple 
formation would be stabilised by such lipids, giving no fusion driving force. Third, the hemifusion 
diaphragm is a structure where the newly merged proximal leaflets must adopt negative curvature. 
Therefore, the energy required to form a hemifusion diaphragm from proximal monolayers 
containing large amounts of type I lipids is likely to be prohibitively high. Consistent with the latter, it 
is has been shown that type II lipids in the outer monolayers promote hemifusion(71, 119, 121). 
1.4.3.2 Fusion Pore Formation 
The fusion of the distal leaflets allows content mixing to occur. The initial fusion structure is known 
as the fusion pore and is thought to expand out until the vesicle incorporates into the target 
membrane. In section 1.4.2.1 it was seen that while some evidence supports a proteinaceous pore 
forming after close contact, substantial evidence suggests the formation of a hemifusion diaphragm. 
It is still possible that a proteinaceous pore does form in vivo, forming after the hemifusion 
diaphragm(71). As well as the evidence from vacuolar H+-ATPase already discussed, evidence for such 
a pore has come from mutagenesis studies of Syntaxin(122). Mutagenesis of the transmembrane 
domain showed changes in the conductance of the fusion pore. This dependence on the protein 
sequence was suggested as evidence for a fusion pore containing Syntaxin. Further evidence for such 
a pore was provided by AFM (Atomic Force Microscopy) studies where SNARE proteins on opposing 
bilayers were shown to cooperate to form a circular arrangement which was 
conductive(123).However, studies of the sequences of proteins involved in fusion, such as viral 
proteins, have suggested that they cannot form the types of structure associated with known 
channel forming proteins(104, 124).  
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As well as the influence seen on stalk energy and hemifusion, lipid composition has been found to 
affect fusion pore formation(119, 125-128). This leads to a conclusion that the pore either contains both 
proteins and lipids or that the pore is lipidic. While hemifusion was inhibited by type I and promoted 
by type II lipids, the type I lipids added to the distal leaflets promote fusion pore formation. The 
affect of the lipid properties, and the capability of protein-free systems to fuse, has led to the view 
that a lipid-lined pore is most likely. 
Modelling(113) of the hemifusion diaphragm shows the formation of a fusion pore is also promoted by 
lateral tension. Studies(129) of vesicles (40 nm in diameter) showed that in order for pores to form on 
a time-scale of seconds, a lateral tension of at least 10 mN/m was required. These studies also 
showed that for a set time-scale and lateral tension, the probability of pore formation increased as 
the area of the diaphragm was increased. The rim of the hemifusion diaphragm is believed to have a 
very large lateral tension(130) (≈20 mN/m). The rim is therefore considered the most likely location of 
fusion pore formation. A recent simulation(131) of the fusion of two protein-free vesicles also showed 
that membrane tension was an important factor. In this study it was observed that vesicle fusion 
only occurred if the membrane was stretched such that the relative area stretch was above 5%. 
Varying the stretch area revealed that the larger the stretch area, the shorter the time before pore 
formation. If we consider the stretch area to be analogous to the hemifusion diaphragm then this 
simulation agrees with the model previously discussed. The pore in this simulation was also shown 
to expand at ≈5 cm s-1, in good agreement with experimental evidence(132). The study also 
hypothesised that fusion is the primary pathway for the relief of membrane tension.  
While proteins may not be a structural element of fusion pores, they could still have an important 
role in their formation. Proteins could increase the area of the hemifusion diaphragm and/or 
increase the lateral tension. It is likely that the membrane embedded areas of a protein would have 
greater influence than those areas that are not. The mutation studies of Syntaxin (discussed at the 
beginning of this subsection) altered the transmembrane domain. While the results were 
interpreted as an indication of the formation of proteinaceous fusion pores, it could have in fact 
altered Syntaxin’s ability to affect the hemifusion diaphragm. If Syntaxin was to act on the 
diaphragm to increase its area or to increase the lateral tension then it would promote fusion pore 
formation. The mutagenesis studies could also be explained if such mutants were unable to interact 
with other proteins, which together act upon the diaphragm. The importance of transmembrane 
domains in fusion has been highlighted by studies of both viral fusion proteins and SNARE proteins 
where this domain was replaced by lipid anchors. The lipid anchors used spanned only the outer 
leaflet and in these circumstances only hemi-fused states could be achieved. These studies have 
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been conducted both in vitro and in vivo (reviewed in 2007(133)). They suggest that while these 
proteins are still able to bring membranes close enough together and aid proximal leaflet merging, 
the replacement of transmembrane domains prevents distal lipid mixing. The AFM study, which 
revealed a circular array of Syntaxins, could indicate that SNARE proteins form a ring of SNARE 
complexes through homotypic interactions, perhaps at the rim of the hemifusion diaphragm. The 
torque applied to the membrane by a ring of SNARE complexes, due to complex formation; (see 
discussion of dimpling in section 1.4.1) could stress the diaphragm sufficiently to induce pore 
formation. Rather than a proteinaceous pore, mutagenesis of the transmembrane domains could 
prevent the formation of a ring of SNARE complexes; reducing the induction of membrane tension 
and consequently inhibiting fusion. 
As well as dimpling, the transmembrane domains could increase the lateral tension of the 
surrounding lipid bilayer due, in part, to hydrophobic mismatch. This results from a discrepancy 
between the length of the hydrophobic region of the protein anchor and thickness of the lipid 
bilayer. Lipid molecules would need to stretch and compress to accommodate the protein region; 
increasing the stress of the bilayer. This could further promote fusion pore formation. This would be 
particularly important in an area already under high tension, such as the diaphragm rim. It has been 
shown, by the use of synthetic peptides in in vitro studies(134) (of the same sequence as the 
transmembrane regions of VAMP and Syntaxin), that membrane fusion can be promoted by these 
regions alone. 
1.4.4 THE FUSION ROLE OF SNARE PROTEINS, A SECTION SUMMARY 
The previous subsections have suggested roles that the SNARE proteins could play in the facilitation 
of membrane fusion (Figure 1.15). SNARE proteins form complexes which span two membranes. 
Close contact can be seen in two different stages. The initial contact where a vesicle tethers to the 
target membrane is not close enough for fusion to occur. SNARE complex formation would pull the 
two bilayers together and the complex is thought to be stable enough to overcome the repulsion 
between the membranes at such short inter-membrane distances. The SNARE proteins may further 
facilitate this close contact through dimpling the membranes as the complex forms. Dimpling the 
membranes would increase the stored energy of the membranes driving the fusion mechanism 
forward. Hemifusion results from the fusion of the outer monolayers, most likely via a transient stalk 
structure. The transmembrane domains of the SNARE proteins may help the diaphragm to expand 
and/or apply additional tension; pulling open a pore as the SNARE complex folds. Whether the 
SNARE proteins are enough on their own to induce fusion however is discussed in section 1.6. 
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1.5 THE COMPLEXITY OF MEMBRANE FUSION IN VIVO 
During the discussion of membrane fusion in section 1.4, possible roles for the SNARE proteins were 
proposed. While decades of study have placed SNARE proteins firmly in a centrally important role, 
their exact contribution has yet to be established. They may undertake one, some, or all of these 
roles and the difficulty in deciphering their role arises from the myriad other components involved in 
the in vivo fusion process. There are clear indications that lipids also play a role in fast and efficient 
fusion (this evidence has come from in vitro models or lipid doping of cells). In vivo, membranes are 
made up of a complex mixture of lipids containing hundreds or possibly thousands of different types 
and the leaflets are also asymmetric. For fusion there is then also an asymmetry in the lipid 
composition of the membranes undergoing this process. In the case of synaptic fusion there is 
further complication as it is a regulated exocytosis event and therefore fusion only occurs once a 
signal has been received (in this case a calcium influx). This increases the number of proteins 
required in the mechanism further. Evidence also points to two types of fusion process being 
employed(135). The first, known as full fusion sees a fusion pore open fully and the vesicle 
incorporated into the plasma membrane. The second is a brief opening of a pore allowing some 
content to be released before the pore closes and the vesicle undocks. In this kiss-and-run process a 
vesicle can fuse in future fusion cycles without the need to be refilled first. SNARE proteins are 
therefore not the only proteins involved in the fusion process. From in vivo studies it is difficult to 
unravel the role of each protein as most show at least some interdependency and fusion is mostly a 
cyclic process. The additional proteins include Synaptotagmin and NSF (N-ethylmaleimide Sensitive 
Factor) which have been identified as key components of fusion. As with the SNARE proteins the role 
of these proteins is still under investigation. A brief description of these proteins and their proposed 
role is given in this section but most are thought of as regulatory or chaperone proteins. 
1.5.1 RAB PROTEINS 
When GDP-bound (the inactive state) these small GTPases are cytosolic but when GTP bound (the 
active state) they become bound to the membrane. They are compartment specific and over 60 
isoforms have been found to be expressed in mammals(136). These proteins are involved in tethering 
vesicles to target membranes through the recruitment of tether effectors. Rabs have also been 
shown to interact with SNARE proteins in some cases and this is believed to increase fusion 
specificity and fidelity(137, 138). Rab proteins can recruit many different effectors for jobs such as cargo 
sorting and vesicle tethering. It is believed that the Rab proteins are instrumental in allowing fusion 
to proceed efficiently, creating the ideal local environment.  
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1.5.2 SYNAPTOPHYSIN 
Synaptophysin is a membrane protein anchored by four transmembrane domains(139). This protein 
resides on synaptic vesicles with both its N and C terminal regions facing the cytoplasm. It has been 
found to bind to VAMP(135, 139-142) and may have a role in targeting VAMP which has been newly 
synthesised(143). The complex has also been shown to be dependent on cholesterol as it only forms 
when a high concentration of cholesterol is present(144). The Synaptophysin-VAMP complex makes 
VAMP unavailable to bind to the intermediary t-SNARE complex and Synaptophysin is therefore 
believed to act as a regulatory protein(135, 141, 142). Synaptophysin knock-out mice did not show 
significant changes in levels of neurotransmission(145). It is thought that this could either be an 
indication that the role of Synaptophysin is minor or just reflects the ability of homologues (such as 
Synaptoporin) to substitute in its absence(26, 146).  
There is some evidence that Synaptophysin can form channels in membranes(147). Purified 
Synaptophysin was reconstituted into lipid bilayers and voltage-sensitive channel activity measured. 
This recorded an average conductance of 150 ps. Within this study cross-linking and sedimentation 
experiments also revealed that Synaptophysin forms hexameric homo-oligomers. Based on these 
findings it was suggested that Synaptophysin is a structural component of a fusion pore.  If true then 
multiple Synaptophysin-VAMP complexes would need to come into close contact. This would allow 
Synaptophysin to form the hexameric complex once it dissociated from VAMP. However, this would 
also mean that the protein density at the fusion site would be extremely high. Each VAMP would 
require the two t-SNAREs to be present in its vicinity on the other membrane and other regulatory 
proteins (discussed within this section) would also be present. Due to the highly regulated nature of 
membrane fusion, particularly of neurotransmission, it is unlikely that the close contact of multiple 
Synaptophysin-VAMP complexes would be sufficient to dissociate them. Therefore, additional 
protein machinery would be necessary but no candidates for such a role have so far been identified. 
Additional machinery would also be required to direct the coming together of multiple 
Synaptophysin-VAMP complexes. The affinity of the Synaptophysin proteins would have to become 
greater for other Synaptophysin proteins than VAMP, in order to promote the formation of the 
Synaptophysin homo-complex over the Synaptophysin-VAMP complex. No studies have shown such 
an affinity. Together these arguments cast doubt on the involvement of Synaptophysin in a 
proteinaceous pore structure 
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1.5.3 SM PROTEINS 
The SM proteins (the Sec1/Munc18 proteins) are thought to regulate membrane fusion through 
interactions with Syntaxin. There are seven members of the SM protein family currently known in 
vertebrates(81). Munc18-1 (the SM protein linked with regulated exocytosis and therefore 
neurotransmission(26)) has been shown to form a tight 1:1 complex with the closed conformation of 
Syntaxin(148, 149). In this complex, unlike in the SNARE complex, the linker region of Syntaxin is 
structured and suggests a stabilisation of the closed Syntaxin conformation. This prevents formation 
of the t-SNARE intermediary complex. The mutation of Munc18 to prevent Syntaxin binding showed 
that secretion in neuroendocrine cells was stimulated(150). Munc18 knockout mice had only 30% the 
normal Syntaxin levels and died immediately after birth. Despite this, SNARE complexes were still 
able to form and Syntaxin was targeted correctly. However, a build up of undocked vesicles was 
seen(151). This and recent studies(152) showing direct binding of SM proteins with Rab tethering 
complexes suggests that SM proteins are involved in the tethering of vesicles to the target 
membrane. Further evidence suggests that SM proteins increase the specificity of membrane fusion. 
Liposomes containing Syntaxin 1 and SNAP-25 were able to bind to five different v-SNAREs in an in 
vitro study. Addition of Munc18-1 allowed fusion only between the t-SNAREs and VAMP2 or 
VAMP8(153, 154). 
1.5.4 MUNC13 
This 200 kDa protein is thought to catalyze Syntaxin’s change in conformation from the closed to 
open state through its interaction with the open confirmation (though there is currently no 
conclusive biophysical proof)(81). Munc13 is believed to play an important role in priming vesicles, 
taking them from the tethered vesicle population to the release-ready population(17). Inactivation of 
Munc13 in several organisms led to the abolishment of both spontaneous and triggered fusion(155). 
Munc13-1 has been shown to contain a C1 calcium binding site which binds to DAG 
(Diacylglycerol)(156). Munc13 binds to the Habc domain of Syntaxin both individually
(157) and as part of 
the intermediary t-SNARE complex(158). The Syntaxin binding site of Munc13 and Munc18 overlap(136) 
suggesting they may have a mutually exclusive relationship. While Munc18 is not able to bind to the 
open conformation of Syntaxin, mutation of the linker region of Syntaxin (which prevents the closed 
confirmation from forming) also negates the need for Munc13(159). Other proteins bind to Munc13 
including Rab3 and its tether effector RIM1(160). Munc13 may be able to bind to these two proteins at 
the same time as Syntaxin(135). It is therefore proposed that an interaction cascade between the 
tethering proteins and Munc13 controls the switch of Syntaxin from its closed, inactive state and its 
open, active state(26). 
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1.5.5 TOMOSYN 
Tomosyn is a soluble protein which is believed to act as a placeholder. As it contains an R-SNARE 
motif, it is able to form a complex with the t-SNAREs Syntaxin and SNAP-25(161, 162). This complex is 
comparable in many ways to the neuronal SNARE complex though the surface residues differ(81). 
Tomosyn occupies the same area of the complex that VAMP would. Tomosyn is therefore able to 
compete with VAMP, negatively regulating exocytosis. It has also been shown to dissociate Munc18 
from Syntaxin(161) and therefore may be part of the machinery progressing Syntaxin from the closed 
to open conformation. Tomosyn appears to bind to the t-SNARE complex in a kinase dependent 
manner i.e. it is controlled through phosphorylation(163, 164). 
Another protein similar to Tomosyn is Amisyn. This protein also forms a complex but it binds to 
Syntaxin specifically. Like the Tomosyn complex the Amisyn containing complex is non-fusogenic and 
so this protein also negatively regulates exocytosis(165). 
1.5.6 NSF AND SNAP 
Identified by Glick and Rothman in 1987(166) n-ethylmaleimide sensitive factor was one of the first 
proteins shown to be important in vesicle fusion(167, 168). When NSF is alkylated by N-ethylmaleimide 
it is inactivated and it was found that vesicles were able to dock to the target membrane but fusion 
did not occur. It was for this reason that NSF was at first thought to be a fusion protein itself. NSF 
was shown to move between the cytosol and membrane and is widely distributed along the 
transport pathways(51) but it is incapable of binding to membranes on its own(169). NSF has since been 
recognised as essential for the fusion process due to its involvement in the recycling pathways, 
rather than as a fusion protein itself.  
In 1990 α-SNAP (Soluble NSF-attachment Protein) was found to bind to both NSF and 
membranes(170). It was also observed that NSF bound to α-SNAP only when it was bound to a 
membrane(170, 171). NSF does not bind directly to α-SNAP, requiring the presence of Syntaxin(81). In 
addition, three SNAP molecules bind to the periphery of the SNARE complex (though only in its cis 
form)(172). Through this the N-terminal domain of NSF is able to interact with the SNARE complex. 
The NSF-α-SNAP-SNARE complex is sometimes referred to as the 20S complex. The 20S complex is 
believed to be involved in SNARE recycling. Once membrane fusion is complete the extremely stable 
cis-SNARE complex is formed and in order for recycling to occur it must disassemble into its 
monomeric parts. As an ATPase, NSF provides the energy required to do this through the hydrolysis 
of ATP (Adenosine Triphosphate). The ATP hydrolysis also disassembles the 20S complex(31, 173). As a 
hydrophilic protein, it is hypothesised that NSF interacts with the zero layer of the SNARE complex 
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(see section 1.2.3.4). A rotational force is appied to the complex, untwisting the coiled coil 
structure(54, 56). Mutation of the conserved glutamine of Syntaxin (which contributes to this layer) 
results in only partial disassembly of the cis-SNARE complex(174). ATP hydrolysis also results in a 
conformational change of Syntaxin, causing α-SNAP and VAMP to be released from the complex(175).  
Regulation of this process is believed to come from various sources. Phosphorylation of Ser237 in 
NSF appears to affect its binding affinity for the α-SNAP-SNARE complex. Mutation of this residue to 
mimic phosphorylation (S237E) showed no binding of NSF to the complex, whereas another 
mutation (S237A; which does not mimic it) did still result in the formation of the 20S complex(176). 
The function of NSF, and therefore exocytosis as a whole, is also regulated by nitrosylation(177, 178). 
Further regulation is provided by β-SNAP (a protein highly homologous to α-SNAP) which is 
selectively expressed in neurons and is thought to regulate α-SNAP(179, 180). Another homologue (γ-
SNAP) does not bind to SNARE proteins but does bind to NSF and it is possible that this homologue 
acts as a recycling inhibitor by reducing the availability of NSF for formation of the 20S complex(181). 
1.5.7 COMPLEXIN 
Complexin (also known as Synaphin) appears to be essential for calcium dependent synaptic vesicle 
release, despite having no apparent calcium binding site(81). Lack of Complexin increases the amount 
of spontaneous fusion but significantly reduces calcium dependent fusion(182, 183). It is believed that 
Complexin may have a dual role, both stimulating and inhibiting fusion(136). This 15 kDa soluble 
protein co-localises with Syntaxin and SNAP-25(26) and binds to SNARE complexes with high affinity in 
an anti-parallel manner(184). It binds to the surface groove between VAMP and Syntaxin and is 
thought to stabilise intermediates such as the t-SNARE complex. It has been found that Complexin 
cannot bind to the Tomosyn-t-SNARE complex(185). Evidence suggests that Complexin works together 
with another protein (Synaptotagmin; discussed in section 1.5.8) to act as a clamp, preventing the 
formation of the cis-SNARE complex(184, 186). Calcium triggering in the presence of Synaptotagmin 
could release Complexin allowing fusion to occur(136). Complexin has also been shown to facilitate 
interactions between the transmembrane domains of VAMP and Syntaxin(187) and this may aid the 
transition of the SNARE complex from its trans to cis conformation. 
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1.5.8 SYNAPTOTAGMIN 
Sixteen Synaptotagmin (Syt) proteins have been identified in vertebrates(136) with SytI predominantly 
expressed in neuronal cells(188). It is a small glycoprotein (65 kDa) which resides on synaptic 
vesicles(189, 190) and is anchored to the membrane by a single transmembrane domain. It has two 
calcium binding sites C2A and C2B(191) with SytI showing low affinity binding(192, 193), but is known to 
interact with calcium channels where ion concentrations are highest(136, 194). Syt is essential for 
calcium triggered release and SytI knockout mice showed defective synchronous release but also 
increased spontaneous (asynchronous) release(195). This suggests a role for Syt as a calcium sensitive 
regulator but also a negative regulator of spontaneous fusion(26). Syt is able to interact with Syntaxin, 
SNAP-25, the t-SNARE intermediary complex and the SNAREpin complex(25, 31, 196-200). It is believed 
that this interaction controls the development of the SNARE complex, holding a vesicle in a fusion-
ready state(81) and allowing the full SNARE-complex to form only with the action potential.  
The two fusion pathways of kiss-and-run or full fusion require different fusion pores. Kiss-and-run 
requires only small pores which are transient while full fusion requires pores to exist over longer 
time scales and to expand so that the vesicle and plasma membranes fully merge. Over-expression 
of SytI has been shown to increase pore opening and dilation times(201-203) and is therefore believed 
to be involved in determining the type of fusion event (204). 
Syt also binds to acidic lipids, such as phosphatidylserine (PS), and also to PIP2 (phosphatidylinositol 
4, 5-bisphosphate)(190, 205-209); but only in the presence of calcium. PS is present in high concentrations 
in synaptic vesicles (12 mol% of total lipid composition(189)), which also contain 1.5-2 mol% 
phosphatidylinositol lipids. PiP2 is in high abundance in microdomains within the plasma 
membrane(210) and has been found to be an essential component of secretory vesicle fusion(209). 
When bound to the SNARE complex the calcium and phospholipid binding sites of Syt are orientated 
away from the complex(81). The interaction of Syt with acidic lipids leads to the insertion of four 
hydrophobic loops to a third of the depth of a single monolayer(211). This would cause the bilayer to 
want to adopt a positive curvature (due to the area difference between the two monolayers 
caused), promoting fusion pore formation (discussed in section 1.4.3). Induction of positive 
curvature would be unfavourable for PS and PIP2 as they are type II lipids. Insertion of Syt may 
therefore increase the stored curvature elastic stress of the system, driving fusion forward.  High 
concentrations of PS (30%) also interfere with the Syt-SNARE complex(212). Upon calcium release it is 
proposed that the C2A and C2B domains cooperatively bind calcium, Syt then penetrates the 
membranes through interaction with lipids and the Syt-SNARE complex dissociates allowing the 
SNARE complex to fully fold. 
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1.6 MINIMAL FUSION MACHINERY 
The myriad factors that affect membrane fusion make pinpointing exact roles for the different 
components difficult in vivo. Assays employing liposomes containing purified protein allow the 
nature of the proteoliposomes to be controlled. The first SNARE protein-containing assay of this type 
was developed by Rothman and colleagues in 1998(38) and the removal of proteins and simplification 
of the lipid environment has provided much useful data since. In particular this method has been 
used in the determination of the minimal requirements for fusion, at least in terms of proteins. In 
the Rothman assay it was shown by lipid mixing that liposomes containing co-expressed Syntaxin 
and SNAP-25 were capable of fusing with liposomes containing VAMP. As lipid mixing cannot 
confirm full fusion, the assay was later repeated using 33P labelled DNA (Deoxyribonucleic Acid) 
duplex formation as this reports content mixing(213). The ability of the SNARE proteins to induce 
fusion was seen as evidence that they are the minimal machinery for fusion. This proposal has led to 
much debate(214) and criticism of the results from this type of assay(215).  
Many in vitro assays of this type use high SNARE protein densities in order for fusion events to occur. 
This is particularly seen with regards to VAMP where the liposomes used have often contained as 
many as 750 copies of the protein in an SUV(38, 216) (Small Unilamellar Vesicle; typically 50nm 
diameter). This gives a protein: lipid ratio of approximately 1:33 (based upon the area of a PC 
(Phosphatidylcholine)  headgroup of 63 Å2 (217)). Physiologically, studies have shown 70 copies of 
VAMP are present in synaptic vesicles (also approximately 50nm diameter)(189) which is a protein: 
lipid ratio closer to 1:350. However, VAMP accounts for approximately only 9% of the total protein 
contained in a synaptic vesicle(189). High protein densities, particularly of Syntaxin, have been shown 
to cause vesicle leakage. It is therefore thought that the results seen where such densities have been 
used may be due, more to the disruption of the lipid bilayer than the functional role of SNARE 
proteins. The fusion of proteoliposomes is still viewed by some as a leaky process whereas 
physiologically this is not a leaky event(215). It is therefore questioned whether SNARE proteins are 
sufficient for fusion to occur in a physiologically relevant way. 
Perhaps the most widely expressed criticism is of the time scales needed for fusion events to occur. 
In these assays, fusion events are often infrequent and take several minutes.  The fastest in vitro 
assay measured fusion rates of 25 ms(218). The fusion of VAMP proteoliposomes with a planar lipid 
bilayer containing the t-SNAREs Syntaxin and SNAP-25 was monitored using fluorescent lipid probes. 
Docking and full fusion were distinguished by monitoring the diffusion of the probe into the planar 
lipid bilayer. This assay showed that for fusion to occur both v- and t- SNAREs had to be present. 
Another assay, by Bowen(219), monitored fusion of SNARE containing membranes using single 
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molecule detection of content mixing and showed fusion rates of approximately 100ms. While these 
rates are a significant improvement on earlier assays they are still more than 40 times slower than 
physiological rates. However, it should be taken into account that these assays are simplified models 
and therefore do not contain regulatory proteins or complex lipid mixtures. Regulatory proteins, as 
discussed in section 1.5, usually leave vesicles in a fusion ready state with complexes that are 
already partially assembled. Physiological rates of fusion are therefore measured from a different 
starting point from the fusion observed in the in vitro assays. As a result it is perhaps overly 
simplistic to compare the fusion rates so directly. In a SNARE proteoliposome no Munc13, for 
example, is present (unless purposely added) to keep Syntaxin in its open confirmation or Tomosyn 
to stabilise the t-SNARE intermediary complex. The significance of this lack of additional, facilitating 
proteins is highlighted from studies showing that removal of the Habc domain of the protein Sso1p 
(which belongs to the Syntaxin subfamily) greatly increases the number and speed of fusion events 
in these in vitro assays(220). Removal of this domain prevents the protein adopting a closed 
confirmation. The need for Munc13 in this situation is therefore removed and Sso1p is made 
available to form a SNARE complex.  
It is still unclear whether SNARE proteins are sufficient for full fusion or whether on their own they 
are capable of only docking and fusing vesicles to a hemifused state. Results from in vitro assays are 
conflicting. Some suggest full fusion can be seen(216, 221), while other studies, using PEG to bring 
SNARE vesicles together, suggest SNAREs are insufficient(222). Studies of yeast SNARE proteins in a 
simple lipid model of only two or three lipid components suggested that the vesicles could only 
reach hemifusion(223). Some studies of vacuole fusion, in which SNARE proteins are in their native 
environment, have also shown SNARE proteins incapable of passing hemifusion(224). However, 
studies of cells with inverted (or ‘flipped’) SNAREs (engineered SNARE proteins which are embedded 
in the outermost cell membrane but stick out into the extracellular space) have shown both full and 
hemi-fusion occurring(225).  
Evidence has been gathered from in vitro studies that fusion is able to occur in the absence of SNAP-
25(81). This would suggest that VAMP and Syntaxin are sufficient for membrane fusion and would cast 
doubt on the role of the SNARE complex. This is not to suggest that they would be sufficient 
physiologically but only in simple, model systems. In these assays high protein densities were 
required and therefore, as already discussed, this result may only reflect membrane disruption. In 
vivo studies show that changes to SNAP-25 affect neurotransmission. SNAP-25 knock-out mice died 
before birth and while brain structure was considered normal, other morphological deformities were 
seen(226, 227). In vivo assays, which used neurotoxins that cleave SNAP-25, showed a reduction in 
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calcium sensitive fusion though spontaneous fusion was unaffected(228, 229). SNAP-25 has been shown 
to have some interaction with Synaptotagmin and it is likely that SNAP-25 must be present for a 
fusion event triggered by calcium to occur(230).  
VAMP 2 knock-out mice died immediately after birth(231). A slight decrease in spontaneous fusion 
was seen while the calcium dependent fusion events were reduced 100 fold. A further study(232) 
showed that VAMP deletion affected fast recycling of synaptic vesicles as its absence delays the 
replenishing time of vesicle pools. The synaptic vesicles of these VAMP knock-out mice also had 
altered size and shape. Compared to wild-type vesicles the mutant vesicles were heterogeneous in 
size, 30% larger on average and were more elongated (20% wild type vesicle had an asymmetric 
ratio of >1.2 compared to over 50% of mutant vesicles). A role for SNARE proteins in coat assembly 
(see section 1.1.1) has been suggested for several years(233). VAMP deletion shows the same affect 
on vesicle shape as mutation studies on Clathrin adaptor proteins(234, 235). As will be discussed in 
section 1.7.1, the coat protein complexes are considered to be instrumental in the induction of local 
membrane curvature. These in vivo studies suggest that VAMP may not be essential for fusion 
events to occur but that it is important for endocytosis and recycling. 
In considering whether SNARE proteins are the minimal machinery required for fusion it is important 
to define the system being examined. Not all fusion event pathways are as highly regulated as 
neurotransmission. In these cases, given the evidence from in vitro assays, SNARE proteins may be 
sufficient for fusion with additional proteins providing other input such as tethering and specificity. 
The neuronal SNARE proteins are a special case within the SNARE super-family. SNAP-25 is one of 
the few SNAREs to have a lipid anchor rather than a transmembrane domain and the SNARE complex 
only requires three individual proteins to form due to the dual contribution of SNAP-25. As in vivo 
synaptic fusion requires a calcium trigger, it can be argued that the minimal machinery must include 
all the proteins necessary for membranes to fuse in response to a calcium influx. In in vitro assays 
containing just the SNARE proteins some studies suggest that addition of calcium was not necessary 
for fusion to occur(218, 219). This is thought to be because SNARE proteins do not bind to calcium and 
the assay lacked Synaptotagmin, a protein essential for calcium sensitive fusion. Some assays have 
shown an increase in fusion with the addition of Synaptotagmin and calcium to the assays(236). 
Mutations of Synaptotagmin to reduce its affinity to SNARE proteins were shown to decrease lipid 
mixing(237). However other assays that have been conducted have shown that Synaptotagmin 
incorporation showed no affect on fusion rates whether calcium was present or not(219).  
The differing opinions on the definition of what a minimal machine is can lead to confusion when 
comparing the views of different research groups. Some consider the SNARE proteins to be merely 
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the motor for fusion, while other proteins are needed to correctly direct the energy provided by 
SNARE complex formation. Recent evidence suggests that the stabilisation energy of SNARE complex 
formation is ≈35 kBT, which is one of the highest protein folding energies recorded
(114). However, 
Sudhof(215) comments that SNAREs may be by themselves “powerful but hapless”. The most 
conventional definition is that the minimal machinery and therefore the fusion proteins must be 
“critical for fusion in a biologically relevant context and [is] sufficient to promote the merger of both 
the outer and inner leaflets of membranes in model systems”. From this definition it is largely 
accepted that SNARE proteins constitute the minimal fusion machinery(238). 
Clearly the determination of the minimal machinery of fusion does require further study. Most 
importantly, future studies need to be conducted to determine unambiguously whether SNAREs are 
capable of inducing full fusion or only hemifusion. It may be that the minimal machinery will not be 
the same for all SNARE systems, especially in the case of the neuronal SNAREs(230). In vitro and in vivo 
studies often give conflicting data. In vitro assays may currently be too simplistic to reliably 
determine the minimal machinery. In vitro assays exploring this question are still predominantly 
focussed upon protein needs and do not fully consider the contribution of the lipid environment. 
Equally, in vivo data may be misleading due to the cyclic nature of fusion pathways and protein 
redundancy may lead to homologue proteins replacing mutated or knocked-out proteins allowing 
functions to occur, at least in part. 
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1.7 PROTEIN-LIPID INTERPLAY 
Much of the doubt that SNARE proteins are the minimal fusion machinery has centred on in vitro 
studies. In these studies fusion was seen to be leaky and/or slow. Leaky vesicles are seen particularly 
at high protein concentration and as such, suggest that the SNARE proteins may influence the lipid 
bilayer in which they are contained. Membrane fusion in vivo is usually described in a proteocentric 
manner, despite the stalk model involving lipid remodelling(53). Proteins are responsible for bringing 
membranes into close proximity, providing energy, stabilising intermediates and regulating the 
process. This gives the impression that lipids are passive elements. However, as has been mentioned 
throughout the introductory sections, lipids have been shown to affect fusion rates and 
components.  
Biological membranes contain hundreds of lipids with different properties. Each of these 
components will contribute to the energy of the membrane; the membrane will therefore occupy 
the state giving the lowest global energy. Most importantly, bilayers in vivo are asymmetric and 
undergo dynamic changes in composition. The dynamic change in lipid composition is partly due to 
cellular functions that metabolise lipids. These changes in lipid species would alter the energy of the 
membrane. While a global property, if compositional change was fast enough the energy of the 
membrane would not dissipate into the entire membrane before a particular process occurred. This 
would result, at least fleetingly, in a local energy difference. 
1.7.1 GENERAL MECHANISMS OF INTERPLAY 
Protein-lipid interplay is an accepted concept in several areas of molecular biology including the 
budding of a vesicle from a donor compartment. There are thought to be two main mechanisms 
(Figure 1.16) by which proteins exploit lipid properties causing local changes in membrane curvature 
(this has been discussed at length by Zimmerberg and Kozlov(239)). First, some proteins and protein 
complexes are able to bind to membrane surfaces imposing curvature upon it. This method, known 
as the scaffold mechanism, requires the protein moiety to be sufficiently rigid for imposition of its 
curvature and to have enough binding affinity to interact with the polar lipid headgroups. The 
energy to bend a membrane must also be lower than the energy required for the protein to bind to 
the membrane. Second, proteins inserting areas of their sequence into one membrane leaflet would 
cause a local membrane deformation. This would induce a local membrane stress and/or cause a 
redistribution of lipid molecules (on a time averaged basis) causing a change in the local lipid 
composition. This is called the local curvature method. 
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Dynamin and BAR (Bin, Amphiphysin, Rvs) domain containing proteins such as Endophilin(240) act as 
scaffold proteins to promote the formation of cylindrical membrane shapes(71). The BAR domain has 
a concave face containing 12 hydrophobic amino acid residues(241) which show a strong interaction 
with lipid headgroups(242). Upon binding to this face membranes are shown to adopt the curvature of 
this banana shaped domain. Other proteins thought to follow the scaffold mechanism include the 
coat proteins Clathrin, COPI and COPII(243) mentioned in section 1.1.1. Local curvature induction is 
seen from proteins such as Epsin(244, 245), Amphiphysin(241) (which contains a BAR domain) and SarI(246). 
All work through the insertion of an amphipathic helical domain into a single membrane leaflet. Sar1 
is a core protein of the COPII coat assembly. This small GTPase is thought to insert its N-terminal α-
helix into a monolayer, thereby deforming the membrane. 
 
Figure 1.16. Proteins are capable of altering the local environment of lipid molecules by inducing curvature. The 
direct scaffold mechanism sees protein domains, such as BAR domains, bind directly to the membrane. Proteins 
which bind to the membrane via accessory proteins induce curvature by the indirect scaffolding mechanism. 
Proteins can also insert into the membrane. Insertion of an amphipathic helix into one leaflet induces curvature 
caused by area mismatch between the two monolayers. 
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In vesicle budding, Epsin and Clathrin are thought to cooperate to deform a local patch of 
membrane(239, 244). Epsin induces curvature locally which is then stabilised by Clathrin. Upon 
polymerisation of Clathrin to form a caged complex, PIP2 may be hydrolysed
(239). Epsin has a strong 
binding affinity to PiP2
(245) and is thought to bud vesicles from membrane patches rich in this lipid. 
Upon PIP2 hydrolysis Epsin dissociates from the vesicle. At this point the spontaneous curvature of 
the membrane changes but the vesicle is unable to compensate for this change through the flow of 
lipids from/to the donor compartment. It is believed that this triggers coat disassembly. During the 
budding of a vesicle from the donor membrane, a neck is formed; this neck is then sealed, causing 
fission. Dynamin, Amphiphysin and Endophilin have all been shown to be important in this process 
and believed to induce and stabilise the formation of this neck(239-241). 
1.7.2 SNARE-MEDIATED FUSION 
1.7.2.1 Controversy 
It is first important to note that the majority of evidence linking SNARE proteins to lipid properties 
comes from methods thought to investigate lipid rafts. There are two main methods of investigation 
and both are considered highly controversial. The idea of lipid rafts comes from the concept that 
membranes are not passive structures in which proteins diffuse but laterally highly organized(247).  
The first method is known as DRM (Detergent Resistant Membrane removal) and uses detergent 
extraction of membrane components. It was considered that patches high in cholesterol and 
sphingolipids exist in vivo. These patches are thought to be so tightly packed that they would resist 
dissolution in detergent preparations. It was therefore thought that membrane patches retrieved by 
this method would be a reflection of physiological membrane patches. Proteins associated with 
these extractions would show a high affinity for these patches in vivo. The data that has been 
obtained from this method often shows large variations and conflict. This is partly due to differences 
in the extraction process, ranging from the use of different detergent: protein ratios to whether or 
not detergent was used in the size separation gradient. A consensus has since been reached that 
these membrane patches are not physiologically relevant and therefore while the method may 
prove useful, interpretation of data must be treated with extreme care(53, 247, 248). 
The second method is the depletion of cholesterol, usually in vivo. Findings from in vitro studies that 
cholesterol and sphingolipids segregate into liquid-ordered phases(249) were thought to be evidence 
that these phases existed physiologically. This is now regarded as untrue(247). Nonetheless, while not 
in the form of a liquid-ordered phase, it is still believed patches containing high concentrations of 
cholesterol and sphingolipids do exist. The effect of disrupting these patches has therefore been 
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investigated. This method uses various agents to deplete cholesterol including inhibiting the 
sphingolipid metabolism process in cells or by addition of β-cyclodextrin(248). Cholesterol is an 
important molecule in many cellular processes and therefore changes seen in fusion pathways as a 
result of its depletion may not be directly related. It is not currently understood what affect 
cholesterol depletion has on cytoskeletal processes, for example. As with DRM, it is therefore 
unclear how results from studies employing this method should be interpreted. An alternative 
method would be to deplete the sphingolipids as they are considered less universally important, but 
this is not currently possible(247). 
It is also worth noting here that the definition of a lipid raft was not universal and caused problems 
in comparing studies from disparate research groups. In the Keystone Symposium on Lipid Rafts and 
Cell Function a robust definition was decided upon. Lipid rafts have been renamed membrane rafts 
to reflect protein involvement. Membrane rafts are “10-100nm in size and are heterogeneous 
structures displaying highly dynamic sterol and sphingolipid enriched domains that have functions in 
compartmentalising cellular functions”(247). Unlike lipid rafts, membrane rafts are not considered 
static entities and as such molecules are able to diffuse in and out of the domain. The composition of 
a membrane raft must therefore be considered on a time averaged basis. 
1.7.2.2 Clusters 
Within this subsection the results observed are mainly from studies which employed DRM and/or 
cholesterol depletion methodology. It is therefore unclear how physiologically relevant the finding 
are. Nonetheless they may prove to be a useful insight into protein-protein and protein-lipid 
interactions and for this reason they are still included.  
Experiments suggest that Syntaxin forms clusters 170-256nm in diameter(250). STED (Stimulated 
Emission Depletion) microscopy analysis of these clusters suggests that these are in fact clusters of 
clusters and that each individual cluster may be less than 100nm in diameter(251). Depletion in 
cholesterol within the plasma membrane is shown to severely affect the integrity of these 
clusters(250, 252). Syntaxin clusters are thought to be located at the plasmalemmal fusion site (for 
neurotransmission this would be the plasma membrane at the axon terminals) and it is proposed 
that vesicles fuse at this site due to interactions with these clusters(210, 250, 252). Mutation studies of 
Syntaxin suggest that these clusters are formed at least in part by Syntaxin-Syntaxin interactions, 
mainly through the transmembrane domains(251, 253). Studies from DRM show that Syntaxin 
association with cholesterol enriched domains is seen to be anywhere from 0 to 50%(250, 252, 254, 255). 
The use of photo-activated cholesterol and the resultant cross-linking of Syntaxin with cholesterol 
suggests a close proximity of the two entities(250). These findings have led some to consider these 
 P a g e 43 
 
Syntaxin clusters as membrane rafts, though the large variation in values cast doubt. The use of the 
so-called raft markers ThyI(250) and flotilin(252), which are thought to segregate into cholesterol rich 
domains, showed no overlap with Syntaxin clusters. It has also been shown in vitro that GUVs (Giant 
Unilamellar Vesicles) which contained liquid-ordered and liquid-disordered phases showed Syntaxin 
has a preference for the disordered phase(256, 257). 
1.7.2.3 Palmitates 
As described in section 1.2.3, SNAP-25 has four cysteine residues which are palmitoylated; providing 
SNAP-25 with a lipid anchor. There is some evidence however that the palmitates do not act merely 
as anchors.  
The first consideration is that despite containing transmembrane domains, many SNARE proteins 
including VAMP2 and other proteins such as SytI contain palmitoylated cysteine residues(49, 52). It is 
possible that these additional lipid tails help the proteins to sort properly. In addition to this it has 
been found that palmitoylation of VAMP2 only occurs in adult rats not embryos, suggesting up-
regulation during development. The SNARE protein TlgI was shown in vivo to mis-sort and undergo 
degradation when mutated to be palmitate deficient(258). This suggests that in addition to sorting, 
palmitates are important for SNARE maintenance. Studies using the DRM and cholesterol methods 
found that SNAP-25 associated with detergent resistant patches unless they were cholesterol 
depleted(252). However, as already discussed these findings are controversial and conflicting studies 
have been published. 
SNAP-25 has two isoforms; 25a and 25b. The difference between these is the position of the 
palmitoylated cysteine residues(259, 260). Both proteins are expressed in the neurons of humans but 
changes in the levels of expression of each are seen during development. In embryos SNAP-25a is 
expressed at higher levels, upon birth the levels change and 25b is more highly expressed(259). It has 
been shown that disruption of this, so that 25a expression remains high, leads to premature 
death(261). It is believed that SNAP-25b is required for fast, inducible fusion which is more greatly 
needed post birth(259, 262) and a difference in exocytosis rates is seen between the two isoforms 
(SNAP-25b produces higher rates than 25a)(263). In vivo studies showed that where neurotoxins had 
been used to abolish fusion, the system could not be rescued by addition of cysteine mutated SNAP-
25, but could by wild type SNAP-25(264). This suggests that the lipid anchor is somehow important in 
fusion events. 
Analysis of the position of the palmitate anchors during fusion reveals that they lie next to 
transmembrane regions (Figure 1.17). VAMP2 contains both a transmembrane domain and 
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palmitoylated cysteine as does SytI, both of which reside on the synaptic vesicle. In the plasma 
membrane, the arrangement of the t-SNARE complex shows that the palmitate groups of SNAP-25 
lie in a comparable position with respect to the transmembrane domain of Syntaxin(265). Whether 
this has a functional relevance to the fusion mechanism is unclear. One suggestion is that the lipid 
anchors (and possibly their interaction with transmembrane domains) are needed to properly 
transfer the energy provided by SNARE formation into the lipid bilayer, allowing remodelling(265). It is 
also possible that the ring of SNARE complexes hypothesised to form does so through interactions of 
the transmembrane domains and the lipid anchors. 
 
Figure 1.17. The protein VAMP2 contains palmitoylated amino acid residues despite the presence of a 
transmembrane domain. The lipid modification lies next to the transmembrane domain and may be important 
for sorting and in the fusion mechanism. The palmitate groups of SNAP-25 lie next to the transmembrane 
domain of Syntaxin 1 when the t-SNARE intermediary complex is formed. Figure modified from Davletov(265). 
1.7.2.4 Enzymatic Lipid Modification 
There is mounting evidence that some lipids may have a regulatory role in membrane fusion events 
in vivo. Already mentioned has been the dependency of the Synaptophysin-VAMP complex upon 
cholesterol levels (section 1.5.2) and examples of phospholipid binding, particularly the binding of 
Synaptotagmins to PS and PiP2 (section 1.5.8). Studies investigating the affects of phospholipases 
and kinases suggest that fatty acid production and phosphorylation are also important events in 
fusion.  
Phosphatidylinositols 
Phosphatidylinositol 4, 5-bisphosphate or PIP2 as it is better known, is implicated in both the docking 
and fusion of synaptic vesicles. It is highly concentrated at the plasmalemmal fusion site of the 
presynaptic terminals(210) and it interacts with many proteins associated with neurotransmission, 
suggesting an involvement in localizing synaptic vesicle fusion at this site(53). For example, PIP2 binds 
SNARE Zippering
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in a calcium dependent manner to Synaptotagmin(209, 266) and Munc13(206, 209, 267) which (as discussed 
in sections 1.5.8 and 1.5.4 respectively) are essential regulatory proteins. Studies on chromaffin cells 
have shown a direct relationship between the amount of PIP2 and the size of the ready-releasable 
vesicle pool(268) and it has been shown to inhibit fusion in model systems(269) in the absence of CAPS 
(Calcium Activated Protein in Secretion). It is also known that kinases and phosphatases (which 
together control the extent of phosphorylation of inositol lipids) regulate vesicle trafficking(270-272). 
The DAG and PIP3 which are generated by these processes are known to be important signal 
molecules. Dephosporylation of PIP2 to PI may promote hemifusion if present in the proximal leaflets 
of merging membranes as PI has been shown to have type II lipid behaviour(273). 
Diacylglycerol 
Diacylglycerol binds to Munc13 through the C1 domain(156, 274). This has been found to be an essential 
step in neurotransmission(156). It is thought that its action may be involved in Munc13-Rab 
associations regulating or directing Rab effectors and other recruiter proteins to the fusion site(265). 
In Drosophila melanogaster, inhibition of a protein which has strong similarities with DAG lipase 
results in a large decrease in neurotransmission(275, 276). PLC (Phospholipase C) generates DAG from 
PIP2. The headgroup portion is able to leave the membrane while DAG remains within the 
membrane. DAG is known to recruit the enzymes PKC (Protein Kinase C) and DAG lipase(265). DAG 
lipase breaks DAG into arachidonic acid and monoacylated glycerol(277). Arachidonic acid has been 
shown to influence neurotransmission; this will be discussed in the following paragraph. Inhibition of 
PLC and, by inference the fall in levels of DAG, is known to block exocytosis of synaptic vesicles(278, 
279).  
Fatty Acids 
Phospholipase A2, C and D (PLA2, PLC and PLD respectively) have all been thought to be involved in 
fusion for many years(280). This is partly because lysophospholipids have been shown to affect fusion 
rates both in in vivo and in vitro experiments. PLC followed by DAG lipase, as already discussed in the 
previous paragraph, produces arachidonic acid from PIP2 which is known to bind to fusion regulator 
proteins. Arachidonic acid is also produced by PLA2 from the breakdown of PC lipids along with 
lysoPC. Lysophospholipids, as discussed in section 1.4, are type I lipids and therefore implicated in 
the promotion of membrane dimple formation and fusion pores but inhibit the intermediary 
hemifusion structure. It has been shown that when membrane depolarization or neurotransmission 
occurs unsaturated fatty acids are released into the cytosol indicating a link between lipid 
metabolism and the fusion event(281-283). It is unclear what the exact role of lipid metabolism may be, 
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but evidence from studies of snake venom (which contains PLA2) suggests that these events act 
upstream of SNARE complex assembly(280, 284, 285).  
There are many studies linking arachidonic acid with membrane fusion. External addition of this fatty 
acid enhances neurotransmission and it is able to rescue systems mutated to prevent the 
biosynthesis of Polyunsaturated fatty acids (PUFAs) in C. Elegans(286-288). A fatty acid molecule, such 
as arachidonic acid, in combination with a PC lipid molecule can be considered a type II lipid(70) and 
as such could promote hemifusion. It would therefore be expected that external addition would 
facilitate fusion, at least to this stage. In vitro studies have also shown that arachidonic acid binds to 
the Syntaxin-Munc18 complex(289). Studies of human diets rich in PUFAs such as omega 3 and 6(290) 
have shown that a few genes are down-regulated including the gene that controls Munc18 
expression. It was thought that association of arachidonic acid with the Syntaxin-Munc18 complex 
promotes a change from the closed to open Syntaxin conformation. Later studies have shown 
however that Munc18 and Syntaxin remain bound even during t-SNARE complex formation(291). It is 
now thought possible that arachidonic acid loosens the closed complex of Syntaxin enough that it is 
available to bind to SNAP-25. It is perhaps conceivable that once SNAP-25 is bound, Syntaxin it is not 
able to bind non-specifically and therefore, only once the SNAREpin complex is formed, does 
Munc13 catalyze the full opening of Syntaxin and removal of Munc18.  
Further studies are needed to determine the exact relationship between all of these components.  
Lipids have been shown to be capable of inhibiting or promoting fusion without interaction with 
proteins. Lipid metabolism may change the lipid composition of the fusion site to take advantage of 
this. However, the presence of lipid binding sites in proteins linked to membrane fusion, suggest 
additional lipid roles.  
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1.8 CONCLUDING REMARKS AND PROJECT AIMS 
While there are still many questions about the affect of protein-protein interactions on membrane 
fusion, it has become clear that protein-lipid interactions must also be considered. Both 
experimental and simulation studies suggest that SNARE proteins may have several affects on 
membranes to increase the stored energy, including the stretching and compression of lipid 
molecules. By increasing the stored curvature elastic stress of membranes, fusion may be driven 
forward. In this regard, evidence that the absence of the transmembrane regions of SNARE proteins 
prevents a progression beyond a hemi-fused state is particularly important. Transmembrane 
domains, as they span both monolayers, are not considered to affect local membrane curvature, 
however they can result in a hydrophobic mismatch with the surrounding lipids. They may also apply 
a moment of force (the bending force proposed to be applied during SNARE complex formation) 
which would be expected to alter local curvature. A ring of SNAREpins encircling a hemifusion 
diaphragm would apply such a force in all directions and may lead to both an increase in the 
diaphragm area and its lateral tension; promoting fusion pore formation.  
It is important to investigate the SNARE-lipid relationship as findings show that high protein densities 
lead to the formation of leaky vesicles in vitro. It is not clear whether SNARE proteins form clusters in 
vivo. If they do then while the copy number of a protein may be low over the whole surface (of the 
synaptic vesicle for example), it may in fact concentrate into one small area making the local 
concentration higher. A local bilayer disruption (which could be represented by leaky vesicles) may 
be relevant to the fusion mechanism. 
In order to investigate the relationship between SNARE proteins and lipids it was necessary to 
develop an in vitro assay that was capable of measuring the affect of various factors on membrane 
properties. It was the aim of this project to develop such an assay in house and use it to measure the 
affects of SNARE proteins upon membrane properties. 
• Chapter 2 discusses the purification of the neuronal SNARE proteins and their reconstitution 
into artificial liposomes. The use of this technique has allowed protein density and lipid 
composition to be controlled. 
• Chapter 3 investigates the effect SNARE protein insertion has upon the size and curvature of 
GUVs (which are analogous in size to the outer membrane of cells) and therefore the implied 
affects these proteins have on the curvature free energy of the bilayer. 
• Chapter 4 presents data obtained from micropipette aspiration and compares the 
membrane properties of a pure lipid model with SNARE proteoliposomes. 
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• Chapter 5 shows the general effect that the alteration of membrane properties has on 
liposome fusion rates and relates these findings to changes in these properties due to SNARE 
protein insertion. A hypothesis for how these results may impact on the membrane fusion 
mechanism in vivo is discussed. At the end of this chapter an overall conclusion is provided, 
with suggestions for future work. 
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Chapter 2.  
PURIFICATION OF NEURONAL SNARE PROTEINS 
This chapter describes the methods used to optimise the purity and solubility of the neuronal SNARE 
proteins; qualities essential in order for the proteins to be used in in vitro assays. The methods of 
SNARE protein purification vary widely between research groups and as such various methods have 
been employed during this study. Each method was investigated in order to ascertain which would 
result in the best protein solutions for use in in vitro assays. Contaminating proteins were of 
particular concern as these could compromise the results obtained.  
High quality purified protein solutions of full length His6-VAMP2 (2 ml, 46.1 µM) and His6-SNAP-25b 
(1.5 ml, 43.6 µM) have been obtained (section 2.1). It was necessary to produce a truncated form of 
Syntaxin 1A in order to obtain a protein solution which could be used in the in vitro assays. This 
truncated form (His6-∆N-Syx) lacks the Habc regulatory domain and consists of the amino acid 
residues 181-288 of wild type Syntaxin. A 1.5 ml sample of 74.0 µM concentration was obtained. 
Cloning was carried out to produce modified His6-VAMP2 and His6-∆N-Syx (section 2.2.1.1). In this 
work additional cysteine residues were added to the C-terminal region of each protein. In one 
cloning step, it was possible to add two cysteine residues to His6-∆N-Syx but only one to His6-VAMP2. 
These new proteins, His6-VAMP2-Cys and His6-∆N-Syx-CysCys were also purified and high quality 
protein solutions obtained. Following the purification of His6-VAMP2-Cys and His6-∆N-Syx-CysCys, 
fluorescent labelling of these proteins was carried out (section 2.2.1.2). The labels chosen were the 
small molecule dyes Alexa Fluor® 488-C5-maleimide and Alexa Fluor® 555-C2-maleimide. As these are 
thiol reactive dyes they only labelled His6-VAMP2-Cys and His6-∆N-Syx-CysCys at the C-terminal 
cysteine residues, which had been added by cloning. These fluorescent probes can act as FRET 
(Förster (or Fluorescence) Resonance Energy Transfer) partners and the production of these proteins 
allows future development of this project through the use of this property. His6-VAMP2-488 was 
obtained at 30.6 µM with a protein: dye molar ratio of 1:1.2 while the concentration of His6-∆N-Syx-
555 was 35.3 µM with a ratio of 1:3.  
Liposomes were produced with SNARE protein incorporated (section 2.3). Analysis of these 
proteoliposomes by western blot confirmed protein insertion, while HPLC (High Pressure Liquid 
Chromatography) showed complete detergent extraction. It was also determined that SNAP-25 
incorporation was as a direct result of its ability to bind to ∆N-Syx.  
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2.1 PURIFICATION OF THE NEURONAL SNARE PROTEINS 
The initial constructs for full length His6-VAMP2, His6-SNAP-25, GST-Syntaxin 1A and the co-
expression system His6-SNAP-25/GST-Syntaxin 1A used in this project were generously provided by 
Dr G. Schiavo of Cancer Research UK. A truncated version of the Syntaxin 1A (ΔN-Syx) protein was 
cloned and purified in the course of this project; this is discussed in section 2.1.4.2. A schematic of 
the constructs is shown in Figure 2.1. 
 
Figure 2.1. The protein constructs for the SNARE proteins used in this project are shown. The expression 
systems for the His6-VAMP2, His6-SNAP-25b and GST-Syntaxin 1A constructs were supplied by Dr. G. Schiavo. 
The final construct, shown at the bottom of the figure consists of the C-terminal portion of Syntaxin 1A with the 
N-terminal GST tag replaced by a His6 tag and was cloned from the GST-Syntaxin 1A construct. 
All of the expression vectors were transformed into Rosetta™ cells. Rosetta™ cells are an engineered 
BL21 strain of E. coli developed to improve the expression of eukaryotic protein.  Expression trials 
were conducted to establish the best colonies and growth media in terms of levels of expression and 
proteins solubility. Part of this work was conducted in the fulfilment of an MRes degree(292). 
It should be noted that the lipid anchors of SNAP-25 and VAMP2 would be added as a post-synthetic 
modification in vivo. As a result of expression in E. coli, these anchors are not present in the purified 
protein solutions obtained in this study. VAMP2 is still able to associate with membranes as it 
contains a transmembrane region. SNAP-25 however does not have another form of membrane 
attachment. In this study SNAP-25 is added only in the presence of Syntaxin 1A (which has a 
transmembrane domain). Association of SNAP-25 to membranes is therefore only seen as a result of 
complex formation with Syntaxin. 
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While a detailed description of the materials and methods used throughout this chapter can be 
found in section 2.4, a general overview of the purification procedure followed can be seen in Figure 
2.2. 
 
Figure 2.2. This figure aims to provide the reader with an overview of the stages followed during the 
purification of the neuronal SNARE proteins. Detailed protocols for each step can be found in the materials and 
methods section of this chapter. 
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2.1.1 PURIFICATION OF VAMP2 
VAMP2 is the smallest of the neuronal SNARE proteins and runs on SDS PAGE to ≈18 kDa. The 
expression vector pET-16b inserts an N-terminal His6 tag to the VAMP2 sequence, this was used for 
purification. The initial purification methodology employed FPLC using an affinity column followed 
by size exclusion (also known as gel filtration) with the buffers HiTrap 1a, 1b and NaHEPES 
respectively. This protocol resulted in all detectable VAMP2 protein eluting in the void volume of the 
gel filtration column. As the column used has a globular protein exclusion limit of 1300 kDa, the 
presence of VAMP2 in the void volume indicated it had formed large aggregates. 
In an attempt to reduce any aggregation caused by non-specific binding, the cell lysate was 
incubated with K-elution buffer prior to purification. The presence of ATP in this buffer provided 
energy for E. coli proteins to correctly fold. The purification protocol described above was then 
repeated, with a greater quantity of soluble protein detected. SDS PAGE analysis identified an 18 
kDa band in later (lower molecular weight) gel filtration fractions. This band was confirmed to be 
VAMP2 through western blot analysis. However, in addition to this band many other protein bands 
were detected. The western blot revealed that these bands, largely, did not contain VAMP2. 
VAMP2 is believed to be largely unfolded in vivo unless bound to other proteins such as 
Synaptophysin or other SNARE proteins. Approximately 60% of the protein sequence is cytosolic and 
VAMP2 contains only one membrane-spanning domain (which has been modelled as an α-helix(34)). 
These domains usually refold spontaneously in the presence of a membrane environment or 
detergent. For these reasons it was considered possible to denature the cell lysate proteins without 
detrimentally affecting future work. The purification protocol was therefore repeated with the 
addition of 4 M urea to each of the purification buffers (renamed in section 2.4.1 as Urea HiTrap 1a, 
b and Urea NaHEPES for clarity). The amount of soluble protein was vastly increased and the cell 
lysate was diluted two-fold in Urea HiTrap buffer 1a to reduce viscosity. SDS PAGE analysis of the gel 
filtration fractions revealed a much cleaner purification (Figure 2.3).  
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Figure 2.3. In this figure the size exclusion profile of VAMP2 in Urea NaHEPES is shown (A) with the 
corresponding SDS PAGE gel (B). The amount of VAMP2 is small in comparison to other proteins eluted. 
However, the analysis clearly shows an 18 kDa band in the presence of only one other visible band and that 
these proteins are well separated from other protein bands detected. 
The later fractions contained only two detectable bands; at 18 and 36 kDa respectively. Western blot 
ascertained that both of these fractions contained VAMP2. It is believed that these bands represent 
VAMP2 monomer and dimer (Figure 2.4). Western blot analysis is often more sensitive than SDS 
PAGE and the western blot detected more than these two bands. These were of higher molecular 
weight and consistent with higher order VAMP2 oligomers (i.e. ≈54 kDa). The appropriate fractions 
were collected and concentrated before the protein was dialysed with storage buffer. This buffer 
contained no urea and had added detergent. The use of this buffer would improve the stability of 
VAMP2 whilst in storage at -80°C. After extensive dialysis the protein solution was concentrated 
further. It was seen that protein precipitated out of solution at relatively low concentrations. The 
highest concentration achieved was a 2 ml solution at 0.83 mg/ml (46.1 µM). 
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Figure 2.4. The concentrated protein solution from VAMP2 purification using urea was analysed by SDS PAGE 
and anti-VAMP2 western blot. This figure shows the result of these on the left and right of the figure 
respectively, with the molecular weight in kDa shown. Only two bands are visible on the SDS PAGE gel and are 
at approximately 18 and 36 kDa. The western blot shows these bands contain VAMP2 and are believed to be 
the VAMP2 monomer and VAMP2 dimer. The western blot shows additional bands at higher molecular weights 
consistent with higher order VAMP2 oligomers. 
2.1.2 THE SYNTAXIN 1A/SNAP-25 CO-EXPRESSION SYSTEM 
A co-expression construct was provided by Dr Schiavo, who commented that the expression level of 
both proteins was higher in this system than when separately expressed. He also saw that the t-
SNARE intermediary complex was easier to form from this system (Dr G. Schiavo; personal 
communication). The lack of membrane anchor in purified SNAP-25 solutions meant that SNAP-25 
could only added to in vitro assays in the presence of Syntaxin. Attempts to purify the t-SNARE 
proteins therefore began with the co-expression construct.  
The differences between un-induced and induced cell culture were clearly visible by SDS PAGE 
(Figure 2.5) with large additional protein bands seen in the induced culture at ≈31 kDa and 55 kDa. 
These were assigned as SNAP-25 and Syntaxin respectively which was confirmed by separate anti-
SNAP-25 and anti-Syntaxin western blots. 
Figure 2.5. This figure shows the SDS PAGE analysis of both un-
induced (Un) and induced (In) bacterial cultures containing the co-
expression vector. From comparison of the two samples the over 
expression of GST-Syntaxin (55 kDa) and His6-SNAP-25 (31 kDa) can 
be clearly seen. 
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The initial purification protocol exploited the N-terminal His6 tag of SNAP-25 and its affinity to 
Syntaxin. The cell lysate was incubated with K-elution buffer (as this was shown to be successful for 
VAMP2 purification) and then FPLC was performed with a HiTrap affinity column (HiTrap buffer 1a 
and b); this was followed by size exclusion (NaHEPES buffer). Analysis of the collected fractions by 
SDS PAGE showed SNAP-25 and Syntaxin to be present only in large aggregates as they eluted in the 
column void volume. A large number of additional protein bands were also seen on the gel. It is 
desirable to have a 1:1 ratio of the t-SNARE proteins as both the t-SNARE and SNARE complex have a 
1:1 ratio of these proteins in vivo. The results of this purification showed that the expression of 
SNAP-25 was far above that of Syntaxin (Figure 2.6). It was therefore necessary to modify the 
purification procedure. 
 
Figure 2.6. An SDS PAGE gel of the void volume fractions from size exclusion purification is shown. These 
fractions contain proteins of a molecular weight higher than the exclusion limit of the column used (1300 kDa). 
These proteins are therefore highly aggregated during purification. Proteins other than those of interest are 
detected on the gel and the fractions show that His6-SNAP-25 is in large excess of GST-Syntaxin, which is 
undesirable. 
Rather than a His6 tag, Syntaxin has an N-terminal GST tag. Following cell lysate incubation with K-
elution buffer, FPLC was therefore first performed using a GST affinity column (GSTrap buffer 1a and 
1b). Rather than the elution buffer (GSTrap buffer 1b) simply being GSTrap buffer 1a with the 
addition of reduced glutathione, an elution buffer was chosen which allowed the eluting protein 
solution to be loaded immediately onto a HiTrap affinity column. Thus, any excess SNAP-25 or 
Syntaxin would be removed through the combination of these two FPLC steps. The addition of the 
HiTrap FPLC step also removed free GST from the sample. SDS PAGE analysis of the final elution 
fractions showed only three visible protein bands; these ran to 31, 35 and 55 kDa. Western blot 
analysis confirmed the lower and upper band to be SNAP-25 and Syntaxin respectively. The middle 
band was not detected by either western blot and was therefore considered to be contaminating 
protein (Figure 2.7). 
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Figure 2.7. Figure A shows the SDS PAGE gel from the size exclusion purification step. Three protein bands can 
be seen at 31, 35 and 55 kDa. An anti-SNAP-25 western blot (B) and anti-Syxntaxin 1A western blot (C) identify 
the 31 kDa band as SNAP-25 and 55 kDa as GST-Syntaxin. However, neither blot shows these proteins to be 
present in the 35 kDa protein band. 
The initial attempt to remove the contaminating protein used size exclusion (NaHEPES buffer). The 
weights of SNAP-25 and the contaminant were close and also of relatively low molecular weight, this 
step was therefore performed using a Superdex 75 column. Analysis of the fractions revealed that 
despite its lower monomer molecular weight, SNAP-25 was eluted first from the column. This was 
followed by the contaminant and then Syntaxin. The gel showed that the separation of SNAP-25 and 
the contaminant was not sufficient and that SNAP-25, as expected from the elution profile, was 
present mainly as oligomers. Gel filtration was repeated under various conditions. A high salt buffer, 
high pH and low pH buffer were tried but the contaminant protein could not be removed. The 
overlapping elution profile of all three proteins and the stability of this profile, even under such 
harsh conditions, led to the conclusion that the contaminant must bind with high affinity to SNAP-25 
and/or Syntaxin. The SDS gel revealed the three proteins to be in an approximate 1:1:1 ratio. It is 
possible that the three proteins formed a SNARE-like complex structure.  
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The in vitro assay could not be used with such a large amount of a contaminating protein. It was 
therefore decided that the co-expression system would not produce acceptable protein solutions 
and focus moved to the purification of separately expressed t-SNARE proteins.  
2.1.3 PURIFICATION OF SNAP-25 
Like VAMP2, the expression vector (pQE-30) of the construct provided by Dr Schiavo inserted an N-
terminal His6 tag to the SNAP-25 sequence. The first purification protocol was based upon published 
work by Ernst(199) though guanidine was replaced by urea. This method lyses the cell pellets with a 
buffer containing the denaturant agent (breaking buffer 1). As with VAMP2, SNAP-25 is believed to 
be largely unfolded in the absence of binding proteins and SNAP-25 does not contain a folded 
transmembrane domain like VAMP2. It was therefore concluded that denaturation of SNAP-25 
during purification would not be detrimental. The denatured cell lysate was purified using FPLC with 
a HiTrap affinity column. In addition to the protocols described in section 2.4, a wash step was added 
before the use of HiTrap buffers 2a and 2b. In this step the column was washed with 10-column 
volumes of HiTrap wash buffer, which contained urea. A large number of protein bands were visible 
on the SDS PAGE gel of the FPLC fractions. Size exclusion, using NaHEPES buffer, was therefore 
added but revealed SNAP-25 to be highly aggregated, with elution in the column void volume.  
The Ernst protocol was repeated with modifications; 4M urea was added to the HiTrap buffers 
(renamed urea HiTrap 2a and b) and urea NaHEPES buffer was used. The purification was much 
cleaner and SDS PAGE analysis detected only two protein bands, at 25 and 30 kDa. Western blot 
analysis identified the 25 kDa but not the 30 kDa band as containing SNAP-25 (Figure 2.8). The 
western blot also detected a higher molecular weight band at 75 kDa, consistent with a SNAP-25 
trimer.  
 
 
 Figure 2.8. On the left is shown an SDS PAGE gel of size exclusion fractions where Ernst methodology with 
additional urea was used at each purification step. Two protein bands are 
kDa. The 25 kDa band was confirmed as SNAP
This blot also revealed higher order oligomers (weight consistent with a SNAP
on the SDS PAGE gel. The 30 kDa was not detected on the blot.
The best purification was achieved using the same buffers and protocols employed in the final 
purification of His6-VAMP2. The cell pellet was lysed in urea HiTrap 1a and then FPLC with HiTrap 
affinity column (urea HiTrap 1a and 1b) and size exclusion (urea NaHEPES buffer). The analysis of the 
fractions by SDS PAGE detected a double band at approximately 25 kDa, both of which were 
confirmed by western blot as SNAP
double band, with the lower one 
western blots, higher oligomers were detected including a SNAP
kDa respectively. The appropriate elution fractions were collected and concentrated. The solution 
was then dialysed with storage buffer and stored at 
1.5 ml was obtained with a concentration of 1.0
visible on this gel at 25 kDa and 30 
-25 monomer by anti-SNAP-25 western blot (shown on the right). 
-25 trimer) which were not visible 
 
-25 containing bands (Figure 2.9). SNAP-25 is known to produce a 
representing some C-terminal degradation(38)
-25 dimer and trimer at
-80°C. A protein solution of approximate volume 
9 mg/ml (43.6 µM). 
Figure 2.9. This figure shows the SDS PAGE gel (left) and 
corresponding anti-SNAP-25 western blot (right) with 
the molecular weights in kDa indicated. Only the SNAP
25 protein band is visible by SDS PAGE while the more 
sensitive western detects homo dimers and trimers at 50 
and 75 kDa respectively. 
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2.1.4 PURIFICATION OF SYNTAXIN 1A 
2.1.4.1 Full length Syntaxin 1A 
Full length Syntaxin 1A was expressed containing an N-terminal GST tag. In Ernst’s paper purification 
of GST-tagged proteins was achieved using denaturing agents. Unlike VAMP2 and SNAP-25, Syntaxin 
has a large folded region (the Habc domain) and it was therefore undesirable to denature Syntaxin 
due to concerns that it would not re-fold properly. The initial purification attempt instead used 
buffers and protocols based on the published method of Weber(38). This method uses detergent 
rather than denaturation, to reduce aggregation and improve purity. The cell pellet was first lysed in 
breaking buffer 2. This buffer differs slightly from the published buffer with no PMSF 
(Phenylmethylsulphonyl Fluoride) added and the substitution of 10 mM β-mercaptoethanol with 2 
mM DTT. FPLC was conducted using a GSTrap affinity column which had been pre-equilibrated with 
1% Triton X-100 wash buffer. The cell lysate was loaded onto the column and a 10-column volume 
wash step preformed with 1% Triton X-100 wash buffer before purification by GSTrap buffer 2a and 
2b. Appropriate fractions (as assessed by SDS PAGE) were collected and size exclusion performed in 
detergent NaHEPES buffer (like Weber, the detergent OβG was used). The analysis of the gel 
filtration profile showed that Syntaxin was eluted in the column void volume and as such indicated 
the formation of large aggregates. The purification was repeated with the substitution of the 
detergent OβG with DDM; however this gave the same result. 
GST is capable of forming homo-dimers and it was believed that this contributed to the formation of 
large protein aggregates. The expression vector pGEX-4T-2 contains a Thrombin cleavage site and so 
the cleavage of this tag was attempted (following the non-specific wash step of FPLC). SDS PAGE 
analysis of the eluted protein did not detect a protein band at the molecular weight of a Syntaxin 
monomer (33 kDa). Western blot analysis showed that only the bands at 55 and 66 kDa contained 
Syntaxin. This suggested that a large amount of the Syntaxin remained uncleaved (the 55 kDa band is 
GST-Syntaxin). An increase in the Thrombin incubation time caused non-specific cleavage of the 
protein. It is possible that the large aggregates formed prevented much of the Thrombin accessing 
the cleavage sites. The band at 66 kDa is consistent with a tag-free Syntaxin dimer. In vivo, the Habc 
domain of Syntaxin folds down to bind to the SNARE motif; in vitro it is possible that two Syntaxin 
molecules could interact in a head-tail manner to form a stable dimer. Chain formation due to 
aligned interaction between proteins could also been envisaged, leading to the formation of very 
large aggregates (Figure 2.10). Therefore even if full GST cleavage was successful it could result in a 
purified protein sample containing mainly SDS stable homo-dimers and large aggregates. A 
truncated version of Syntaxin 1A (∆N-Syx, 181-288) was therefore produced. 
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Figure 2.10. In vivo the Habc domain of Syntaxin (shown here in grey) folds down to form a complex with the 
SNARE motif (red) allowing Syntaxin to occupy two states; the open and closed conformations (shown on the 
left of this figure). In vitro regulatory proteins are not present and so multiple Syntaxin molecules can interact. 
Two Syntaxin molecules interacting in a head-tail fashion could form a homo dimer as the Habc domain of each 
binds to the SNARE motif of the other (centre right). Chain aggregates could also form if head-head interactions 
occurred. In this situation the Habc domain of protein one would bind to the SNARE motif of protein two, the Habc 
domain of protein two would then bind to the motif of a protein 3. This could repeat indefinitely, forming large 
aggregate structures. 
2.1.4.2 ∆N-Syntaxin 1A 
Due to the Habc domain of Syntaxin, it was not possible to use denaturation methods in the 
purification protocol. However, denaturation had proved to give high quality protein solutions for 
both SNAP-25 and VAMP2. As discussed in sections 1.2.3.1 and 1.5.4, in vivo Syntaxin forms a closed 
conformation as part of membrane fusion regulation. It has also been shown that removal of the Habc 
domain improves fusion rates in in vitro assays, due to the formation of the closed confirmation 
being prevented(159). Therefore, the removal of the Habc domain would potentially improve in vitro 
assays. As discussed in 2.1.4.1, this domain also contributed significantly to the highly aggregated 
nature of the purified protein; therefore, its removal could also improve the quality of the protein 
solution obtained. There were therefore several advantages associated with the production and use 
of ∆N-Syx when compared with wild type Syntaxin. As well as the potential reduction in aggregation 
just from its removal, the lack of the Habc domain would also allow purification to include denaturing 
agents as the remaining sequence is structurally similar to VAMP2.  
 ∆N-Syx was cloned into a new vector, pPROEX
page 176) which inserts an N-terminal His
weight of full length Syntaxin 1A is 33 kDa, while GST is a 26 kDa protein. A full length Syntaxin 
protein molecule is therefore almost doubled in weight by 
starting at the N-terminal regions of the SNARE proteins and the use of such a large tag at this 
terminus could impede future assays (a GST tag at the C
insertion). ∆N-Syx had the Habc domain removed and therefore contained the amino acid residues 
181-288 of full length Syntaxin. The sequence based predicted weight of 
kDa. It was thought ill-considered to use a protein tag (GST) so much larger than the protein 
interest, particularly when located at the N
vector was chosen to add a much smaller purification tag.
The cloning protocol is described in detail in section
synthetic oligonucleotides (primers) Synt.c
Syntaxin sequence only between amino acid residues 181
levels of the ∆N-Syx fragment when an annealing temperature of 54°C a
68°C were used. The PCR fragments and pPROEX
BamHI and HindIII followed by purification using standard kits. The His
was produced through ligation and w
colonies were selected. The DNA of these colonies was extracted, compared to pure pPROEX
vector and the DNA sequence checked for 
Figure 2.11. All three parts of this figure show agarose gels with base pair markers (M). Figure A shows the 
amplification of the ∆N-Syx fragment where the top ledger shows the negative control and temperature of 
each sample (°C). Figure B shows DNA extracted from
∆N-Syx pPROEX-HTb ligation product. These were compared to the empty vector (V). Figure C shows the 
digestion of the DNA from colonies 1
seen at approx. 350 bp corresponds to the PCR fragment weight, indicating successful fragment insertion.
-HTb (the vector map is supplied in the appendix, see 
6 tag rather than a GST tag. The sequence based predicted 
this tag. The SNARE complex forms 
-terminus instead would impede membrane 
∆N-Syx was therefore 
-terminal, as already discussed. For these reasons a 
 
 2.4. However briefly, the custom
-ter 5’ and Synt.c-ter 3’ were designed to read the 
-288. PCR amplification produced high 
nd extension temperature of 
-HTb vector were cut using the restriction enzymes 
6-∆N-Syx expression vector 
as then transformed into XL1-Blue cells from which single 
∆N-Syx insertion (Figure 2.11). 
 XL1-Blue colonies (1-6) which had been transformed with 
-3 and 5 using the restriction enzymes HindIII and BamHI. The f
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≈15 
of 
-made 
-HTb 
 
ragment 
 
 Once sequencing was confirmed, the DNA was transformed into Rosetta™ cells and expression trials 
conducted to optimise cell growth and prote
was that the epitope for the antibodies against Syntaxin is located in this domain. Western blot 
analysis of His6-∆N-Syx purification was therefore conducted using anti
using the method established for both His
HiTrap 1a and 1b followed by size exclusion using urea NaHEPES. SDS PAGE analysis detected a 
protein band at approximately 15 kDa which was also detected by 
2.12). As with His6-VAMP2 and His
and the solution dialysed into storage buffer. By this method a 1.5 ml solution containing 1.11 
mg/ml (74.0 µM) His6-∆N-Syx was obtained.
  
in expression. The one disadvantage of H
-His6. The protein was purified 
6-VAMP2 and His6-SNAP-25 i.e. FPLC purification using urea 
anti-His6 western blot (
6-SNAP-25, His6-∆N-Syx containing fractions were concentrated 
 
Figure 2.12. The SDS PAGE gel and anti
purified deltaN-Syx protein solution are shown on the left and 
right of this figure respectively. Only one protein band is 
visible by SDS PAGE at approx. 15 kDa. This band and another 
at 30 kDa were detected by western blot. These 
represent deltaN-Syx monomer and dimer.
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abc removal 
Figure 
-His western blot of 
bands 
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2.2 FLUORESCENT SNARE PROTEINS 
Fluorescent labelling of the SNARE proteins allowed protein insertion into a simple lipid model to be 
confirmed (see Chapter 3). The Alex Fluor® dyes (Invitrogen) were chosen for labelling. These dyes 
have high molar extinction coefficients and are small molecule dyes. A biochemical alternative would 
have been to use fluorescent protein tags such as GFP (Green Fluorescent Protein) and its 
modifications (Red FP, Cyan FP etc). However, these proteins are large (GFP is 26.9 kDa) and would 
therefore pose the same problems as GST (discussed in section 2.1.4). The small molecule nature of 
the Alexa dyes would not interfere with SNARE complex formation or membrane insertion. 
As the purified SNAP-25 protein was incapable of binding to membranes independently, it was 
decided that only VAMP2 and ∆N-Syx would be labelled. These two proteins were labelled with 
different Alexa Fluor® dyes so that the proteins could be distinguished. The labels could also act as 
FRET partners allowing future development of this project. In order to control the site of labelling, a 
maleimide form of the Alexa Fluor® dyes was chosen. This dye reacts with thiol groups and therefore 
reacts with the amino acid residue cysteine. Wild type Syntaxin 1A contains three cysteine residues; 
of these, one is found in the Hc helix (C145) and the other two (C171 and C172) are in the 
transmembrane region. VAMP2 only has one cysteine residue which is located in its transmembrane 
domain (C103). The cysteine residues within the membrane anchors are unavailable for labelling 
provided that the protein is in a membrane environment or in the presence of detergent. For 
Syntaxin, the use of the truncated form ∆N-Syx removed the remaining cysteine residue. It was 
therefore unnecessary to mutate the wild type cysteine residues.  
2.2.1.1 Cysteine Clones 
To provide available cysteine residues the proteins VAMP2 and ∆N-Syx were cloned to add cysteine 
residues to the C-terminal end. The C rather than N-terminal region was chosen so that, by FRET, 
monitoring of the formation of SNARE complexes would be possible in future studies. Custom-made 
synthetic oligonucleotides (primers) were designed so that the 3’ (reverse or antisense) primer 
contained the additional cysteine residues. The initial primers were designed to add two cysteine 
residues to the protein sequence. As with the production of ∆N-Syx, the vector pPROEX-HTb was 
used to provide each protein with an N-terminal His6 tag, for the use in purification.  
  
 ∆N-Syx-CysCys  
The primers Synt.c-ter 5’ and Synt.c
fragments. The amplification of the 
temperature gradient of 50-56°C (2 degree interval) was used with an extension temperature 
68°C (Figure 2.13). The 56°C PCR product was used for subsequent steps. 
Figure 2.13. In this figure the results of PCR amplification of the 
gel. A base pair marker (M) was loaded into the first lane followed by a negative control and each sample from 
the temperature gradient (50-56°C).The DNA was visualised by ultra violet light.
Once transformed into XL1-Blue 
restriction enzyme double digest (HindIII and BamHI) as well as DNA sequencing. Following sequence 
confirmation, His6-∆N-Syx-CysCys was transformed into Rosetta™ cells from which expression tria
were conducted followed by large scale expression and purification using the same protocol 
described for His6-∆N-Syx (section 
VAMP2-Cys 
The initial primers used were VAMP
temperature cycling protocol (such as changes to the annealing and extension temperatures), 
amplification of the PCR fragment was not detected by agarose gel. New syn
were therefore designed. VAMP-
residues would be added but the annealing backbone of the primer was increased. VAMP
was a modification such that it’s seque
residue added and VAMP-2-3’ 1Cys B was a combination of these modifications giving this primer 
only one cysteine residue but a longer annealing backbone. To accompany the 3’ primers with longer 
annealing backbones a new 5’ primer had to be designed which has been named VAMP
Details of primer sequences can be found in section 
-ter 3’ Cys were used for the production of 
∆N-Syx-CysCys fragment by this method was successful when a 
 
∆N-Syx-CysCys fragment is shown on agarose 
 
E. coli cells, the DNA was checked for fragment insertion by a 
2.1.4.2). 
-2-5’ and VAMP-2-3’ Cys. Despite many variations in the 
thetic oligonucleotides 
2-3’ Cys B was a modification of VAMP-2-3’ Cys so that two cysteine 
nce was that of VAMP-2-3’ Cys but with only one cysteine 
2.4.7.1.  
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∆N-Syx-CysCys PCR 
of 
 
ls 
-2-3’ 1Cys 
-2-5’ B. 
 Each possible combination of primers was trailed using the temperature gradient 48
58°C (again with 2 degree intervals). Only one combination showed PCR fragment amplification 
which used the primers VAMP-
therefore contain one, rather than two, additional cysteine residues. The 58°C PCR product was 
carried forward to subsequent cloning steps. Fragment insertion was confirmed by DNA sequencing 
and a double digest assay by the rest
confirmed, the DNA was transformed into Rosetta™ cells, the expression optimised and His
Cys protein purified in the same manner as His
Figure 2.14. In this figure the results of PCR amplification of the VAMP2
A base pair marker (M) was loaded into the first lane followed by a negative control and each sample from the 
temperature gradient (52-58°C).The DNA was visualised by ultra violet light.
2.2.1.2 Fluorescent Labelling 
The purified protein solutions of His
Fluor® 555 C2-maleimide (MW ≈1250 g/mol) and Alexa Fluor® 488 C
respectively. The protein solution was in storage buffer which already contained 1.5% sodium 
cholate and therefore dialysis or addition of detergent was unnecessary. Following the labelling 
protocol of Invitrogen, each protein was fluores
desalting column and extensive dialysis. Protein solutions were then assessed for the degree of 
labelling (Equation 2.1). 
 
Where Ax is the absorption of the dye at the absorption maximum wavelength and ε is the molar 
extinction coefficient of the dye.
  
2-5’ and VAMP-2-3’ 1Cys (Figure 2.14). The VAMP2 protein would 
riction enzymes HindIII and BamHI. Once sequencing was 
6-VAMP2. 
-Cys fragment is shown on agarose gel. 
 
6-∆N-Syx-CysCys and His6-VAMP2-Cys were labelled with Alexa 
5-maleimide 
cently labelled and excess dye removed using a 
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-54°C and 52-
6-VAMP2-
 
(MW 720.66 g/mol) 
Equation 2.1 
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Alex Fluor® dye λ at Ax, nm ε M
-1
 cm
-1 
Alexa Fluor® 488 C5-maleimide  493 72000 
Alexa Fluor® 555 C2-maleimide 556 158000 
Table 2.1 
From Equation 2.1 it was determined that a 0.5 ml sample of His6-VAMP2-488 at a concentration of 
0.55 mg/ml (30.6 µM) had been obtained with a protein: dye molar ratio of 1:1.2. For His6-∆N-Syx-
555, a 0.5 ml sample of 0.53 mg/ml (35.3 µM) concentration was obtained with a protein: dye molar 
ratio of 1:3. In both cases the ratio was slightly higher than expected (1:1 for His6-VAMP2-488 and 
1:2 for His6-∆N-Syx-555 would be expected, based on the number of cysteine residues) this is most 
likely due to incomplete removal of free dye. However, as discussed in 2.3, all free dye is removed in 
subsequent steps. 
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2.3 SMALL PROTEOLIPOSOMES 
Proteoliposomes were formed by mixing protein solution, detergent and lipid together followed by 
detergent extraction. The addition of lipid was such that the protein: lipid ratio was either 1:60 or 
1:300 prior to detergent extraction. The detergent: protein ratio used was 8:1. After the mixture was 
incubated at 4°C for 1 hour the detergent was extracted using a PD-10 desalting column packed with 
Sephadex G-50m matrix material. The absorption of each collected fraction was measured at 280 nm 
as well as the wavelength of maximum absorption if any fluorescent dye was incorporated (either 
fluorescent lipid probes or fluorescent protein). Elution profiles showed two peaks; the first peak 
showing elution of proteoliposomes in the void volume of the column and the second, elution of 
detergent, lipid monomers and free fluorescent dyes (Figure 2.15). The void volume fractions were 
collected and the proteoliposomes pelleted by ultra centrifugation. 
 
Figure 2.15. This figure shows the elution profile of two proteoliposome samples. Both samples are made from 
the lipid DOPC with one sample containing the fluorescent protein His6-∆N-Syx-555 and the other His6-VAMP2-
488. The protein: lipid molar ratio before detergent extraction was 1:300. Each fraction was analysed at 280 
nm and the wavelength for maximum absorption of the fluorescent label. For His6-VAMP2-488 this is at 493 nm 
and at 556 nm for His6-∆N-Syx-555. Proteoliposomes were eluted in the column void volume (3-5 ml). Free dye 
along with detergent and lipid monomers are eluted in the second, broad peak (6-13 ml). 
 2.3.1.1 Western Blot Analysis 
Proteoliposomes containing His6
western blot (Figure 2.16). The blots confirmed the presence
proteoliposome samples. As had been expected, due to its lack of membrane anchor, no SNAP
was detected when added independently to 
containing both His6-∆N-Syx and His
confirmed the presence of both proteins. It was therefore shown that SNAP
specifically associate with liposomes and that the protocol does not affect 
formation. 
Figure 2.16. Proteoliposomes formed from DOPC and SNARE protein were 
VAMP2 liposomes were analysed using anti
check for SNAP-25 incorporation, the SNARE proteins His
SNARE liposomes, these were analysed by anti
and though present, higher order oligomer bands are weaker
solutions. 
From this analysis, it can also been seen that
combination of high detergent concentration during proteoliposome formation and the membrane 
environment provided by lipids following detergent extraction seems to break down these oligomers 
so that the vast majority of the protein exists in its monomeric state. 
  
-VAMP2, His6-SNAP-25 or His6-∆N-Syx were formed and analysed by 
 of His6-VAMP2 or His
liposomes. Proteoliposomes were then produced 
6-SNAP-25. In this case separate anti-His6 and anti
∆N-Syx/SNAP
analysed by western blot. His
-VAMP2 (left) and His6-∆N-Syx liposomes by anti
6-SNAP-25 and His6-∆N-Syx were 
-SNAP-25 (right). All three western blots show protein insertion 
 than in the corresponding purified protein 
 higher order oligomer bands are weaker. The 
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6-∆N-Syx in 
-25 
-SNAP-25 blots 
-25 does not non-
-25 complex 
 
6-
-His (centre). To 
co-mixed to form t-
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2.3.1.2 HPLC Analysis 
It was important to establish the quantity of detergent still present in proteoliposomes as this would 
affect future in vitro assays. The pellets were therefore analysed by HPLC. The retention time of 
DOPC (≈14 min) and sodium cholate (5.3-6 min) was determined for the solvent conditions used. A 
calibration curve was produced for sodium cholate and a calibration curve for DOPC, produced 
under the same conditions, was provided by a current PhD student Duncan Casey (Figure 2.17). 
 
Figure 2.17. HPLC calibration curves were determined for the lipid DOPC and the detergent sodium cholate 
(NaChol) for the solvent regime to be used during analysis of proteoliposomes. The calibration curve for DOPC 
was obtained from D. Casey and is shown in red. The calibration curve for NaChol is shown in blue. 
Two samples of His6-VAMP2 DOPC proteoliposomes and two samples of t-SNARE (1:1 His6-∆N-Syx: 
His6-SNAP-25) DOPC proteoliposomes were analysed by HPLC (Figure 2.18). Within the background 
error, no detergent was detected. The amount of DOPC present was also established from the 
calibration curve. On the assumption that all the protein had inserted into liposomes and been 
eluted into the void volume during detergent extraction it was seen that the final protein: lipid ratio 
was 1:30 ±10 (regardless of whether a 1:60 or 1:300 protein: lipid ratio had been used). It was 
therefore necessary to add further lipid to proteoliposome samples prior to use in in vitro assays. 
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Figure 2.18. The HPLC profiles of two VAMP2 and two t-SNARE liposome samples are shown. The large peak at 
14.5 minutes shows the elution of DOPC from the column. The inset graph shows the region between 4 and 6 
minutes. The retention time of sodium cholate is 5.5 minutes; within background error no detergent is 
detected. The elution peaks seen between 2 and 4 minutes are due to residual storage buffer components. 
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2.4 MATERIALS AND METHODS 
2.4.1 SOLUTIONS AND BUFFERS 
2.4.1.1 Growth Media 
LB (Luria-Bertani) broth Purchased from Molecular Dimensions Limited (MDL) 
10 g/L Casein Hydrolysate (tryptone), 
5 g/L Yeast Extract, 
0.5 g/L NaCl 
 
Superior broth Purchased from MDL, developed by AthenaES 
proprietary medium formulation 
 
Power broth Purchased from MDL, developed by AthenaES 
proprietary medium formulation 
 
LB-Agar Purchased from MDL, developed by AthenaES 
proprietary medium formulation 
2.4.1.2 Antibiotics 
Ampicillin (Amp) 10% (w/v) in 50% EtOH (ethanol) 
Kanamycin (Kan) 3.5% (w/v) in d.H2O 
Chloramphenicol (Cam) 3.5% (w/v) in 95% EtOH  
2.4.1.3 Purification Buffers 
Dialysis Buffers 
Storage Buffer 
 
20 mM HEPES  
(4-(2-hydroxyethyl)-1-piperazineethanesulphonic Acid) pH 7.4,  
100 mM KCl,  
1.5% (w/v) sodium cholate  
Breaking and incubation Buffers 
K-elution buffer  
 
50 mM Tris (Tris(hydroxymethyl)aminomethane) pH 7.4,  
10 mM MgSO4,  
2 mM ATP 
 
Breaking buffer 1 50 mM Tris pH 8.2, 
4 M urea, 
10 mM imidazole 
 
Breaking buffer 2 50 mM Tris pH 8.0, 
300 mM KCl, 
10% (w/v) glycerol, 
2 mM DTT (Dithiothreitol) 
5% (v/v) Triton X-100 
4 EDTA-free protease inhibitor tablets 
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His6 Affinity Column Buffers 
HiTrap buffer 1a 25 mM HEPES pH 8.0,  
500 mM KCl,  
20 mM imidazole,  
5% (v/v) glycerol 
 
HiTrap buffer 1b HiTrap buffer 1a with 500 mM imidazole 
 
Urea HiTrap buffer 1a HiTrap buffer 1a + 4 M urea 
 
Urea HiTrap buffer 1b HiTrap buffer 1b + 4 M urea 
 
HiTrap wash buffer 50 mM Tris pH 8.2, 
4 M urea, 
20 mM imidazole 
 
HiTrap buffer 2a 20 mM Tris pH 7.7, 
300 mM NaCl, 
20 mM imidazole 
 
HiTrap buffer 2b HiTrap buffer 3-a with 250 mM imidazole 
 
Urea HiTrap buffer 2a HiTrap buffer 2a + 4 M urea 
 
Urea HiTrap buffer 2b HiTrap buffer 2b + 4 M urea 
 
GST (Glutathione S-Transferase) Affinity Column Buffers 
GSTrap buffer 1a PBS (Phosphate Buffered Saline) + 5% (v/v) glycerol 
 
GSTrap buffer 1b 50 mM Tris pH 8.0, 
10 mM reduced glutathione, 
5% (w/v) glycerol, 
0.05% Tween20 
 
1% Triton X-100 wash Breaking buffer 2 with 1% (v/v) Triton X-100 
 
GSTrap buffer 2a 50 mM Tris pH 8.0, 
100 mM KCl, 
10% (v/v) glycerol, 
0.8% (w/v) OβG (Octyl β-glucopyranoside) or DDM (n-
dodecyl β-D-maltoside) 
 
GSTrap buffer 2b GSTrap 2a + 10 mM reduced glutathione 
 
Binding buffer 20 mM sodium phosphate, pH 7.5 
0.15 mM NaCl 
 
High salt wash Binding buffer with 1 M NaCl 
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Size Exclusion Buffers 
NaHEPES buffer 20 mM HEPES pH 7.4,  
300 mM NaCl,  
5% (w/v) glycerol, 
mM DTT 
 
Urea NaHEPES buffer NaHEPES buffer + 4 M urea 
 
High salt NaHEPES buffer NaHEPES buffer 1, pH 9.0 
 
High pH NaHEPES buffer NaHEPES buffer 1 with 4M NaCl 
 
Low pH buffer 20 mM Sodium Citrate pH 4.0, 
300 mM NaCl, 
0.1 mM DTT, 
5% (w/v) glycerol 
 
Detergent NaHEPES NaHEPES buffer  + 0.8% (w/v) OβG or DDM 
Detection 
Tris-Acetate-EDTA (TAE)  
running buffer (50x) 
2 M Tris-acetate pH 8.3,  
0.05 M EDTA (Ethylenediaminetetraacetic Acid) 
 
DNA Agarose gel 1% (w/v) Agarose in TAE 
6.34 fM EtBr (Ethidium Bromide) 
 
DNA gel loading buffer 0.25% (w/v) bromophenol blue, 40% (w/v) sucrose 
 
SDS resolving gel 0.39 mM Tris pH 8.8,  
15% (v/v) acrylamide mix,  
0.1% (w/v)SDS,  
0.1% (w/v) APS (Ammonium Persulphate),  
0.04% (v/v) TEMED 
(NNN’N’Tetramethylethylenediamine) 
 
SDS stacking gel 0.065 mM Tris pH 6.8,  
4% (v/v) acrylamide mix,  
0.1% (w/v) SDS,  
0.1% (w/v) APS,  
0.04% (v/v) TEMED 
 
SDS loading buffer 200 mM Tris pH 8.8,  
8% (w/v) SDS,  
20% (v/v) glycerol,  
1 mM bromophenol blue,  
20 mM DTT 
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SDS gel running buffer (10x) 250 mM Tris,  
2 M glycine,  
0.4% (w/v) SDS 
 
Native gel 0.39 mM Tris pH 8.8,  
10% (v/v) acrylamide mix,  
0.1% (w/v) APS,  
0.04% (v/v) TEMED 
 
Native gel loading buffer 200 mM Tris pH 8.8,  
20% (v/v) glycerol,  
1% (w/v) bromophenol blue 
 
Native running buffer (10x) 250 mM Tris,  
2 M glycine 
 
Lysis buffer 10 mM Tris pH 8.0,  
0.1 M NaH2PO4,  
8 M urea 
 
PAGE Coomassie Blue  
stain solution 
30% (v/v) EtOH,  
10% (v/v) acetic acid,  
0.05% (w/v) Brilliant Blue R™ 
 
PAGE de-stain solution 30% (v/v) EtOH,  
10% (v/v) acetic acid 
 
Western Blot blocking solution 2.5% (w/v) skimmed milk powder  
(Sainsbury’s Basic) in dH2O 
 
CAPS transfer buffer (100x) 1 M CAPS (3-[cyclohexylamino]-1-propanesulphonic acid) 
pH 11.0 
 
PBS 10 mM NaH2PO4 pH 7.4,  
1.8 mM K2HPO4,  
140 mM NaCl,  
2.7 mM KCl 
 
PBST (PBS-Tween20) PBS + 0.05% (v/v) Tween20 
HPLC Solvents 
HPLC Solvent A 101/21/2/0.1 (w/w) 
n-hexane/isopropanol/acetic acid/triethyl amine 
 
HPLC Solvent B 155/17.5/2/0.1 (w/w) 
Isopropanol/water/acetic acid/triethyl amine 
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2.4.2 ANTIBODIES 
Antigen Antibody Description Source Application 
VAMP2 Anti-VAMP2 Mouse monoclonal clone 69.1 
Synaptic 
Systems (SYSY) 
1:10000 
SNAP-25 Anti-SNAP-25 Mouse monoclonal clone 71.1 SYSY 1:10000 
Syx 1A Anti-Syx 1A Mouse monoclonal clone 78.3 SYSY 1:10000 
His6 Anti-His6 Mouse monoclonal clone 4A12E4 Invitrogen 1:5000 
Mouse Ig Goat Anti-Mouse Ig Goat polyclonal DAKO 1:2000 
Table 2.2 
2.4.3 PROTEIN EXPRESSION 
The GST-Syntaxin 1A / His6-SNAP-25b co-expression system and His6-VAMP2 system were grown in 
Power media, the His6-SNAP-25b single expression system in LB with the addition of 1% glycerol and 
the GST-Syntaxin 1A system in Superior broth. 
2.4.3.1 Expression Vectors 
The vector maps and amino acid sequences of the proteins below can be found in the appendices. 
Construct UniProt Accession Vector Resistance Bacteria Source* 
His6-VAMP2 P63045 
pET-16b  
(Novagen) 
Amp Rosetta™ Dr G Schiavo 
His6-SNAP-25b P60881 
pQE-30  
(Qiagen) 
Amp Rosetta™ 
Dr G Schiavo 
(Prof JE Rothman) 
GST-Syx 1A† P32851 
pGEX-4T-2  
(GE Healthcare) 
Amp Rosetta™ 
Dr G Schiavo 
(Dr RH Scheller) 
GST-Syx 1A/ 
His6-SNAP-25b 
 pGEX KG/pET Amp/Kan Rosetta™ Dr G Schiavo 
His6-ΔN-Syx-1A 
(a.a 181-288) 
 
pPROEX-HTb  
(Invitrogen) 
Amp Rosetta™ - 
Table 2.3 
2.4.3.2 Production of Glycerol Stocks 
10 ml of LB (containing antibiotic solution at 1 µl/ml) overnight cultures were grown of each 
bacterial system provided by Dr Giampietro Schiavo (or later transformed Rosetta cells). 1 ml of 
overnight culture was pelleted by centrifuge in an eppendorf at 4000 rpm for 10 min at room 
temperature. The bacteria pellet was gently re-suspended in LB glycerol (10% glycerol (v/v)) and 
stored at -80°C for later use. 
                                                           
* The original source is shown in brackets. 
† Syntaxin 1A. 
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2.4.3.3 Isolation of Plasmid DNA 
The QIAprep MiniPrep kit and protocol were used to obtain small amounts of DNA from 5ml of LB 
Amp (or LB Amp/Kan) overnight cultures, according to the manufacturer’s instructions. DNA 
preparations were re-suspended in 50 μl ddH2O and then stored at -20°C. For larger quantities 
(predominantly for cloning), 100 ml cultures were grown and the QIAprep MidiPrep kit used. 
2.4.3.4 Transformation of E. coli 
50 µl electro-competent Rosetta™ (Novagen, Rosetta 2 (DE3), strain F- ompT hsdSB(rB
- mB
-) gal dcm 
(DE3) pRARE2 (CamR)) or XL1-Blue competent cells (Stratagene, strain recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F'proAB lacIqZ∆M15 Tn10 (Tetr)]) were thawed on ice. 2 ng of DNA was 
added and then the cells transferred to a pre-chilled 0.1cm gap cuvette. The cells were transformed 
using a BioRad Gene Pulsar (1.67 V, 25 μF, 200 Ω). Cells were then re-suspended in 200 μl LB and 
incubated with shaking at 37°C for one hour. 20 μl, 50 μl and 100 μl were then plated on LB agar 
(containing antibiotic solution (1 μl/ml)) and incubated at 37°C overnight. 
2.4.3.5 Protein Expression Trials 
5 ml of LB (with additional antibiotics 1 μl/ml) was inoculated using cells from glycerol stocks and 
then shaken overnight at 37°C. 20 ml of Broth with antibiotics (1 μl/ml) was inoculated with 2 ml of 
the overnight culture and grown at 37 or 32°C with shaking to an OD600 0.5-0.8. The culture was 
induced by addition of 1 mM IPTG (isopropyl-beta-D-thiogalactopyranoside) and incubation 
continued for four more hours. Cells were harvested by centrifugation at 4000 rpm for 10 min and 
stored at -80°C. Pellets were defrosted, re-suspended in 5 ml HiTrap buffer 1a and then lysed by 
ultrasound for 2 minutes (with 1 second pulses) at amplitude 15. 1 ml was pelleted by centrifuge at 
13000 rpm for 10 min. The supernatant was kept (soluble protein fraction) and the pellet re-
suspended in 1 ml lysis buffer (insoluble protein fraction). 
2.4.3.6 Large Scale Protein Expression 
His6-VAMP2, His6-SNAP-25b, GST-Syntaxin 1A and His6-∆N-Syntaxin 1A Systems 
150 ml of broth (with added antibiotics (1 μl/ml)) was inoculated using cells from glycerol stocks and 
then shaken overnight at 37°C. 6 x 1L of antibiotic broth were each inoculated with 25 ml of the 
overnight culture and grown at 37°C with shaking to an OD600 0.5-0.8. 1 mM IPTG was added to each 
litre and incubation continued for four more hours. Cells were harvested by centrifugation at 4000 
rpm for 10 min and the pellets stored at -80°C. 
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Co-expressed GST-Syntaxin 1A / His6-SNAP-25b System 
150 ml of broth (with added antibiotics (1 μl/ml)) was inoculated using cells from glycerol stocks and 
then shaken overnight at 37°C. 6 x 1L of antibiotic broth were inoculated with 25 ml of the overnight 
culture and grown at 37°C with shaking to an OD600 0.5-0.8. 1 mM IPTG was added to each litre and 
incubation continued for four more hours. Cells were harvested by centrifugation at 4000 rpm for 10 
min and the pellets stored at -80°C. 
2.4.4 PROTEIN PURIFICATION 
2.4.4.1 His6 Tag Purification 
Pellets of harvested cells were defrosted on ice and re-suspended in HiTrap buffer a, at 10 ml per 1L 
of culture grown. Sonication of the suspension on ice at amplitude 15 for 2 x 6 min (1 second pulses, 
suspension stirred vigorously in between time periods) lysed the cells. Cellular debris was removed 
by centrifugation at 18000 g for 30 min at 4°C. A HiTrap affinity column (5 ml, Amersham Bioscience) 
was used for purification of proteins with His6 tags (and those proteins that bind to His6 tagged 
proteins). The supernatant was loaded onto a Ni2+ charged HiTrap affinity column pre-equilibrated 
with HiTrap buffer a. Unbound protein was washed out with 10 column volumes of HiTrap buffer a 
and non-specific bound protein removed by a volume step of 8 column volumes of 10% HiTrap 
buffer b. A gradient from 10- 100% buffer b over 8 column volumes eluted the SNARE proteins. 4 ml 
fractions were collected over the buffer b gradient region. The purification was conducted at 4°C on 
a BioRad DuoFlow FPLC (Fast Protein Liquid Chromatography) system. 
2.4.4.2 GST Tag Purification 
A GSTrap affinity column (5 ml, Amersham Bioscience) was used for initial purification of proteins 
with GST tags (and those proteins that bind to GST tagged proteins). Pellets of harvested cells were 
defrosted on ice and re-suspended in breaking buffer or GSTrap buffer a (20 ml per 1L of culture 
grown; see section 2.1). Sonication on ice of the suspension at amplitude 15 for 2 x 6 min (1 second 
pulses, suspension stirred in between time periods) lysed the cells. Cellular debris was removed by 
centrifugation at 18000 g for 30 min at 4°C. 
The Supernatant was loaded overnight at 0.5 ml/min using a peristaltic pump onto a GSTrap affinity 
column (5 ml, Amersham Bioscience) pre-equilibrated with breaking buffer or GSTrap buffer a. The 
column was then mounted to a BioRad DuoFlow FPLC system where unbound protein was washed 
out with 10 column volumes of GSTrap buffer a. Non-specific bound protein was removed by a 
volume step of 8 column volumes of 10% GSTrap buffer b. A gradient from 10-100% buffer b over 8 
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column volumes eluted the GST tagged protein (and binding partners). 4 ml fractions were collected 
over the buffer b gradient region. The purification was conducted at 4°C. 
2.4.4.3 GST Cleavage 
The protocol described in section 2.4.4.2 was followed up to and including the non-specific wash 
step. Rather than a gradient step the column was then washed with 3 column volumes of GSTrap 
buffer a. 20 µl of 1 µg/μl Thrombin stock was added to 4.98ml PBS and loaded onto the GSTrap 
affinity column. The flow-through was discarded and the column incubated for 12 hours at room 
temperature. A benzamidine column (1 ml, GE Healthcare) pre-equilibrated with binding buffer was 
connected to the GSTrap affinity column. The columns were then washed with 4 column volumes of 
binding buffer and the flow through collected in 1 ml fractions. The columns were washed further 
with 4 column volumes of high salt wash and the flow through collected in 1 ml fractions. 
2.4.4.4 Size Exclusion 
Dilute protein preparations obtained from affinity column purification steps were concentrated in a 
centrifugal concentrator (20 ml iCON™, 9k MW cut off, Pierce) at 4000 rpm and 4°C. The 
concentrated fractions were assessed on SDS-PAGE gels to see if further purification was required. If 
required, proteins were purified further by size exclusion using a Superdex 200 column (Amersham 
Bioscience, void volume ≈38 ml, globular protein exclusion limit 1300 kDa). The column was 
equilibrated overnight with 1.5 column volumes of NaHEPES buffer. The concentrated protein 
solution was loaded into a static loop which had been washed with flow-through from the protein 
concentration step. The protein solution was loaded onto the column with additional NaHEPES (50% 
of loop volume). 100% NaHEPES over 1 column volume eluted the proteins. 4 ml fractions were 
collected over the entire run. This purification was run on a BioRad FPLC system at 4°C. 
2.4.4.5 Concentration of Dilute Protein Preparations 
Protein solutions were concentrated as described in section 2.4.4.4. The concentrated fractions were 
assessed on SDS-PAGE gels to see if further purification was required. 
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2.4.5 VISUALISATION OF PURIFIED PROTEIN 
2.4.5.1 Denaturing Polyacrylamide Gel Electrophoresis (SDS PAGE) 
These were used throughout, during both expression and purification steps. Gels were made from 5 
ml resolving gel topped with 1 ml stacking gel. Each protein sample was added to 5 μl SDS loading 
buffer and then denatured at 95°C for 5 minutes. Between 10 and 20 μl of each sample was then 
loaded onto the gel. 5 μl of Mark12™ Unstained Standard (Invitrogen) was also loaded into one lane. 
The gel was run at 180 V, 30 mA or 200 V, 50 mA for 1 hr 12 min for one and two gels respectively. 
Gels were stained with Coomassie stain then de-stained to visualise protein bands. 
2.4.5.2 Western Blot and Chemiluminescent Detection 
Proteins were separated by size using SDS-PAGE as described above but using 10 μl full range 
rainbow marker (GE Healthcare) rather than Mark12™ marker. Proteins were transferred to HyBond 
ECL (Enhanced Chemiluminescence) nitrocellulose membrane using a Hoefer SemiPhor protein 
transfer tank and the semi-dry procedure according to the manufacturer’s protocol. In brief this 
protocol is as follows: 
6 pieces of 3 mm chromatography paper (Anachem) and 1 piece of HyBond ECL nitrocellulose 
membrane (GE Healthcare) were cut to the size of the gel (usually 9.5 x 7 cm). The chromatography 
paper was soaked in 30 ml CAPS transfer buffer. The HyBond membrane was placed on top of the 
acrylamide gel and then sandwiched between triple layers of the CAPS soaked chromatography 
paper; this was placed in the transfer tank. The current needed was calculated from the dimensions 
of the acrylamide gel using a simple equation (amps = width (cm) x length (cm) x 0.8) and in most 
cases gave a current of 53 mA. With the power set to 100 W protein transfer proceeded for 1 hour.  
After transfer the nitrocellulose membrane was placed in a Petri dish with 50 ml block solution and 
rocked at room temperature for 60 min before being stored at 4°C overnight. The next day the 
membrane was left rocking at room temperature for at least 30 min before it was incubated (with 
rocking) with the primary antibody (1:10000 in 10 ml block solution) for 1-1½ hours, again at room 
temperature. The membrane was then washed with PBS, PBST and then PBS again for ten minutes 
each. Incubation (with rocking) with the secondary antibody (1:2000 in 10 ml block solution) then 
took place for 45 min. Again the membrane was washed with PBS, PBST and finally PBS.  
Protein bands were detected using an ECL Advance Western Blotting Detection Kit and Hyperfilm 
ECL (both from GE Healthcare) as recommended by the manufacturer. The membrane was exposed 
to the film for between 30 seconds and 1 hour. 
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2.4.6 QUANTIFICATION OF PROTEIN CONCENTRATION 
The Beer Lambert law (λ=εcl) was used to determine protein concentrations (c). The absorbance of 
the protein solution at 280 nm (λ) was found after dilution in 6 M guanidinium hydrochloride, 20 
mM phosphate buffer (pH 6.5); three readings were taken. Based on the known sequence of each of 
the proteins, plus any tags, the molecular weights and extinction coefficients (ε) were calculated 
using the ExPANSy ProtParam tool*.  
Protein Predicted Molecular Weight, Da Extinction Coefficient†, M-1cm-1 
His6-VAMP2 13513.6 13980 
His6-SNAP-25 24137.9 7210 
GST-Syntaxin 1A 58985.5 47440 
His6-∆N Syx 15633.0 10555 
Table 2.4 
2.4.7 CLONING 
2.4.7.1 Synthetic Oligonucleotides 
Synthetic oligonucleotides for PCR (Polymerase Chain Reaction) and mutagenesis were obtained 
from Eurofin MWG Operon (Ebersberg, Germany). 
Primer DNA Sequences 
Primer stock solutions of 1 µg/µl were made from the lyophilised primer by addition of ddH2O. The 
proteins ∆N-Syx, ∆N-Syx-CysCys, VAMP2 and VAMP2-Cys were all cloned in pPROEX-HTb. 
The restriction site for the enzyme BamHI was added to the 5’ fragments and the restriction site for 
the enzyme HindIII to the 3’ fragments. The predicted melting temperature (Tm) for the whole 
fragment and that of the annealing backbone (Tan) is also shown. Where cysteines have been 
introduced into the protein sequence, these are indicated in orange. 
Synt.c-ter 5’ 
5’- CGG GAT CCA TCA TCA TGG ACT CCA GC -3’    Tm 68°C, Tan 53.7°C 
Synt.c-ter 3’ 
5’- CCC AAG CTT CTA TCC AAA GAT GCC CC-3’    Tm 66.4°C, Tan 52.9°C 
Synt.c-ter 3’ Cys 
                                                           
* http://us.expasy.org/tools/protparam.html 
† At 280 nm assuming all cysteine residues to be half residues due to DTT use in purification steps. 
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5’- CCC AAG CTT CTA ACA GCA TCC AAA GAT GCC CCC G-3’  Tm 73.1°C, Tan 54.3°C 
VAMP-2-5’ 
5’- CGG GAT CCA TGT CGG CTA CCG CTG-3’    Tm 69.6°C, Tan 54.3°C 
VAMP-2-5’B 
5’- CGG GAT CCA TGT CGG CTA CCG CTG C-3’    Tm 71.2°C, Tan 57.0°C 
VAMP-2-3’ Cys 
5’- CCC AAG CTT TTA GCA GCA AGT GCT GAA GTA AAC GAT G-3’  Tm 70.6°C, Tan 52.4°C 
VAMP-2-3’ 1Cys 
5’- CCC AAG CTT TTA GCA AGT GCT GAA GTA AAC GAT G-3’  Tm 68.3°C, Tan 52.4°C 
VAMP-2-3’ 1CysB 
5’- CCC AAG CTT TTA GCA AGT GCT GAA GTA AAC GAT GAT G-3’  Tm 69.5°C, Tan 56.5°C 
VAMP-2-3’ CysB 
5’- CCC AAG CTT TTA GCA GCA AGT GCT GAA GTA AAC GAT GAT G-3’ Tm 71.5°C, Tan 56.5°C 
2.4.7.2 DNA Sequence Amplification 
PCR was used to amplify specific DNA sequences and in all cases a RoboCycler Gradient 40 
Temperature Cycler (Stratagene) was used. 
PCR samples (25 µl) 
 
17.5 µl dH2O 
2.5 µl PFU buffer (10 mM stock) 
200 µM dNTP (Deoxyribonucleotide Triphosphate) 
1 µl Forward (5’) primer (100 ng/µl) 
1 µl Reverse (3’) primer (100 ng/µl) 
1 µl DNA (5 ng/µl or water for negative control) 
1 µl 50% DMSO (Dimethyl Sulphoxide) 
0.5 µl PFU Turbo polymerase (2.5 units/µl stock) 
A negative control plus four samples underwent temperature cycling, where the following protocol 
was used: 
Temperature °C Time, sec Cycles 
95 30 1 
95 30 
10 Gradient 60 
68 30 
95 30 
20 65 60 
68 30 
68 300 1 
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The final temperature gradients that were used were 48-54°C (2 degree interval) for ∆N-Syx, 50-56°C 
for ∆N-Syx-CysCys and 52-58°C for VAMP2-Cys. The products were analysed by agarose gel and the 
highest temperature sample in each case (showing amplification) was then used. 
2.4.7.3 Agarose Gel Electrophoresis 
1% Agarose was dissolved in TAE buffer by heating in a microwave. When hand-hot the gel was 
poured into a mould and 50 ng/ml ethidium bromide solution added (to give ethidium bromide 
concentration of 6.34 fM). Once DNA sample was added, the gels were run in TAE buffer at 100 V 
and 70 mA. DNA was visualised under ultraviolet light by Gene Genius (Syngene). 
2.4.7.4 Restriction Digestion 
Vector DNA and PCR fragments were digested through the use of restriction enzymes. The primers 
were made to include the restriction sites of the enzymes BamHI and HindIII so that these could be 
used to digest PCR fragments. These enzymes were also used to cut the pPROEX-HTb vector. 
PCR fragment digestion 
 
10.3 µl dH2O 
2 µl 10x Enzyme buffer 
2 µl BSA (Bovine Serum Albumin; 500 µg/ml stock) 
0.7 µl HindIII (10 units/µl stock) 
0.5 µg PCR product 
The PCR fragments were digested overnight with the restriction enzyme HindIII by incubation at 
37°C. The enzyme was inactivated through heating (65°C for 20 minutes). The restriction enzyme 
BamHI was then added (7 units) and the sample incubated at 37°C for a further 2 hours. This enzyme 
was then inactivated through heating, as above, and the PCR fragment cleaned using a QIAprep PCR 
purification kit. 
Vector digestion 
 
2 µl 10x Enzyme buffer 
2 µl BSA (500 µg/ml stock) 
0.7 µl HindIII (10 units/µl stock) 
0.7 µl BamHI (10 units/µl stock) 
2 µg Vector 
Made to 20 µl with dH2O 
The vector was cut and cleaned in the same manner as PCR fragments with the exception that the 
enzymes were added together. Incubation at 37°C proceeded for two hours before enzyme 
inactivation by heating, followed by purification using the QIAprep PCR purification kit. 
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2.4.7.5 DNA Fragment Ligation 
To prevent self-ligation, the vector was first dephosphorylated. 
Dephosphorylation 
 
1 µl 10x Dephosphorylation buffer 
1 µl Shrimp Alkaline phosphatase (1 unit/µl stock) 
1 µg Vector 
7 µl dH2O 
The reaction mixture was incubated at 37°C for 10 minutes followed by deactivation at 65°C for 20 
minutes. Ligation of the PCR fragment and vector was achieved using a T4 ligase. 
Ligation 
 
100 ng Dephosphorylated vector 
Fragment (or water for negative control) 
1 µl 10x T4 Ligase buffer 
1 µl T4 Ligase (5 unit/µl) 
Made to 10 µl with dH2O 
Purified fragment solution was added so that the vector to fragment molar ratio was approximately 
1:3 (as assessed by agarose gel). This was then incubated at 16°C overnight. 
2.4.7.6 Fragment Insertion Verification 
XL1-Blue cells were transformed with ligation product (see transformation protocol, section 2.4.3.4) 
and grown on LB-Agar plates. Single colonies were chosen and grown in 5 ml LB broth. The DNA was 
extracted using a QIAprep MiniPrep kit. The DNA was analysed by agarose gel and compared to a 
sample of pure vector. Cultures from colonies containing DNA of the correct weight were then 
grown in 100 ml LB broth. DNA was extracted using a QIAprep MidiPrep kit and double digested 
using both the HindIII and BamHI restriction enzymes. The digestion products were checked, by 
agarose gel, for a fragment of correct weight. DNA sequence analysis was also used for further 
confirmation.  
2.4.8 FLUORESCENT LABELLING 
Alexa Fluor® 488 C5-maleimide and Alexa Fluor® 555 C2-maleimide were used to fluorescently label 
purified protein solutions of His6-VAMP2-Cys and His6-∆N-Syx-CysCys respectively (Invitrogen). The 
thiol-reactive probes protocol (provided by Invitrogen) was followed but is described briefly below. 
The following was conducted in the dark and using foiled covered vessels to minimise light exposure. 
500 µl of purified protein solution was stirred using a magnetic stirrer. A 10 mM solution of Alexa 
dye was made by dissolving the lyophilised dye product in DMSO. The dye solution was then added 
to the protein solution drop-wise to give a dye: protein molar ratio of between 10:1 and 20:1. The 
solution was incubated, with stirring, overnight at 4°C. 0.2 mg/ml reduced glutathione dissolved in 
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the storage buffer (the buffer of the protein solution) was then added, in excess of the dye. The 
solution was passed through a Sephadex G-25 packed PD-10 desalting column (GE Healthcare) 
followed by extensive dialysis to remove glutathione and excess dye.  
2.4.9 PREPARATION OF SEPHADEX G-25 AND G-50M COLUMNS 
Columns were prepared as instructed by the manufacturer (GE Healthcare). Sephadex G-25 or G-
50m matrix material (GE Healthcare) was soaked in ddH2O overnight at room temperature. The 
matrix was poured into PD-10 columns with the tip closed. The matrix was allowed to settle 
overnight at 4°C. Excess water was removed and the column washed through and packed with 10 
column volumes of water under gravity flow. When not in use, columns were stored upright in 20% 
ethanol at 4°C. 
2.4.10  FLUORESCENT PROTEOLIPOSOME FORMATION 
1.5 μmol lipid DOPC (Avanti Polar Lipids, USA) was suspended in storage buffer containing 10% (w/v) 
sodium cholate such that the lipid: detergent molar ratio was 1:8. In the dark, fluorescent protein 
(His6-VAMP2-488 or His6-∆N-Syx-555) was added to give a protein: lipid molar ratio of 1:300. The 
detergent was removed from the sample using a pre-packed, equilibrated Sephadex G-50m PD-10 
desalting column and storage buffer. 0.5-1 ml fractions were collected to a total of 15 ml. The 
absorption of each fraction was measured at 280 nm and the maximum absorption wavelength for 
the dye used (see Table 2.1). Fractions from the column void volume (which contain 
proteoliposomes) were collected. The proteoliposomes were concentrated by ultra centrifugation at 
200000 g for 90 min (Beckman Coulter, 1 ml tubes) followed by re-suspension in 10 µl storage 
buffer. The lipid concentration and protein: lipid ratio of the pellet were assessed by HPLC. 
2.4.11 HPLC ANALYSIS 
HPLC was used to analyse proteoliposome content. HPLC was conducted using a Waters 626 HPLC 
pump via a 150 x 4.6 mm nitrile column (Varian Inc, Yarnton, UK). Samples were dissolved in 1 ml 
absolute ethanol and analysed by evaporative light scattering with an ESA 301 detector (baseline 
noise +/- 0.4%, evaporation temperature 80°C, drift tube 45°C). The mobile phase ran from HPLC 
solvent A to HPLC solvent B over an 18 minute gradient at a flow rate of 1 ml/min. 5 ml HPLC solvent 
A was run after each sample to allow equilibration. 
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2.5 CHAPTER SUMMARY 
This chapter has described the purification methods used to obtain high quality protein solutions of 
all the proteins used in this project. Cloning work has been conducted to both improve purification 
and allow fluorescent labelling. Once purified, membrane incorporation of the SNARE proteins into 
simple membrane models was established. The particular fluorescent labels were specifically chosen 
for their ability to act as FRET partners allowing this project to be developed in the future. For 
example, the use of this property would allow the formation of the cis-SNARE complex to be 
monitored. 
From HPLC, it was seen that the final protein: lipid molar ratio was lower than expected (≈1:30) and 
that additional lipid was required for final proteoliposome samples to be used in in vitro assays. The 
insertion of SNARE proteins into GUVs (Giant Unilamellar Vesicles) made from these samples has 
been confirmed through the use of the fluorescent proteins produced in this chapter. This is 
discussed in Chapter 3. 
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Chapter 3.  
THE EFFECT OF SNARE PROTEINS ON LIPOSOME FORMATION 
In this chapter, data is presented that shows SNARE protein incorporation into giant unilamellar 
vesicles (section 3.3.2). This investigation used fluorescent SNARE proteins prepared by Alexa Fluor® 
dye labelling (discussed in Chapter 2). The microscopy images of GUVs show the homogeneous 
distribution of the proteins His6-VAMP2-488 and His6-∆NSyx-555 throughout the DOPC lipid bilayer 
(protein: lipid molar ratio 1:300). 
The affect of protein on liposomes has been investigated through analysis of the mean radius and 
size distribution of GUVs of both protein-free vesicles and proteoliposomes (section 3.3.3). The 
liposome compositions used varied in both the total protein: lipid molar ratio and the amount of 
protein able to membrane-associate. All liposome compositions were seen to contain two vesicle 
populations. For DOPC liposomes these populations were found to have a mean radius of 17.4 ± 2.58 
μm (40% total number of vesicles) and 10.1 ± 0.12 μm (60% total number of vesicles). The addition 
of small amounts of the transmembrane anchored protein VAMP2 (1:600 protein: lipid molar ratio) 
had no significant affect on either the mean radius or occupancy of these two populations (within 
experimental error). Further addition of VAMP2 (protein: lipid molar ratio 1:300) gave populations 
with mean radii of 9.60 ± 1.39 μm and 4.88 ± 0.05 μm with the latter distribution occupied by 92% of 
the total number of vesicles. The increase in membrane curvature in this case has been attributed to 
the hydrophobic mismatch between the VAMP2 transmembrane domain and the preferred 
thickness of the DOPC bilayer.  
It was also shown however, that protein could influence liposome formation even when there is no 
obvious means of direct membrane association. A t-SNARE liposome sample was prepared with a 
1:300 protein: lipid ratio containing a 1:1 ratio of the transmembrane anchored protein ∆N-Syntaxin 
and the anchorless protein SNAP-25. Despite this, a large population of proteoliposomes (47% total 
number of vesicles) occupied a distribution with a mean radius of 4.98 ± 0.03 μm. It is believed that 
this is due in part to the ability of SNAP-25 to influence membrane curvature even without a formal 
membrane anchor. As will be discussed in the subsequent chapter, the findings of chapter 4 suggest 
that protein aggregate structures may also have affected GUV formation in the t-SNARE sample. 
A detailed discussion of these results can be found in section 3.4. 
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3.1 INTRODUCTION 
3.1.1 VESICLES TYPES 
Vesicles are enclosed structures made from lipid bilayers and take various forms (Figure 3.1). Simple 
liposome models can be prepared by various techniques, where the method of choice depends on 
the type of vesicle required. Liposome type is usually separated by size and morphology. The size 
range definition varies from group to group(293) but generally small liposomes have a diameter ≤50 
nm, large liposomes between 100 nm and 1 µm and giant liposomes have a diameter ≥1 µm. 
Vesicles made of a single bilayer are also described as unilamellar; those made of a number of 
bilayers are multilamellar vesicles (for small numbers of bilayers they are sometimes referred to as 
oligolamellar vesicles i.e. bi-lamellar, tri-lamellar). During the formation of vesicles it is possible to 
trap other vesicles inside; these structures are referred to as multi-vesicular. 
 
Figure 3.1. Small vesicles have a diameter below 50 nm, large vesicles are typically between 100 nm and 1 µm 
in size and giant liposomes have diameters above 1 µm. Unilamellar vesicles contain only one bilayer. As such 
these vesicles can be classified as small, large or giant unilamellar vesicles (SUV, LUV or GUVs), defining both 
size and morphology. Liposomes can also be made from multiple bilayers and are called multilamellar or 
oligolamellar vesicles. Multivesicular structures are formed when vesicles become trapped inside larger 
vesicles. Figure taken from Jesorka(294). 
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3.1.2 ELECTROFORMATION MECHANISM 
GUVs are popular as in vitro models for cells, with the bilayer of the GUV considered to be a model 
for the plasma membrane. This is because the size of a GUV and cell (and therefore the global 
membrane curvature) is of the same order. Their size also means that they can be observed using 
optical microscopy.  
One of the most popular methods for producing GUVs is electroformation. A lipid film deposited 
onto an electrode is subjected to an ac electric field. While the precise mechanism is still not known, 
it is thought that liposome formation proceeds through three basic steps; 1) the separation of 
interacting bilayers, 2) induction of instability and 3) bilayer bending and closure(295). A lipid film 
deposited on a surface consists of stacked layers containing multiple bilayer domains and defects. 
Once a hydrating solution is added, the hydration force drives the solution through the layers 
(possibly through the defects) and the lipid film swells. This process is considered to be very fast with 
the inter-bilayer separation increasing from 0 to 10 Å in less than 10-4 seconds. Above this 
separation, the electrostatic repulsion between bilayers drives the inter-bilayer distance to increase. 
The application of an alternating current alters the electrostatic force, as well as van der Waals 
bilayer-substrate and bilayer-bilayer interactions, increasing the separation further to ≈0.1 µm. At 
defects, the hydrophobic regions of lipid molecules become exposed to water when the lipid film is 
hydrated. The defects therefore become areas of high energy and line tension occurs in the lipid 
layer; coupled with repulsive forces, bending instability results.  The application of an alternating 
electric field may also apply a mechanical stress. This is caused by the electrophoretic motion 
induced in the lipid molecules and solute. This causes bilayers to rupture, forming bilayer fragments 
of different sizes. The energetic cost of exposing the edges of these fragments to water (referred to 
from now on as the edge energy) is large and so (provided the energetic cost of bending the 
membrane is not larger) a fragment is driven to bend and form a closed structure. There are thought 
to be two main mechanisms by which closed structures are formed (Figure 3.2); these are bilayer 
fusion (where two bilayer fragments fuse to form one structure) and scission (where a vesicle bud 
seals at its neck in a manner akin to endocytosis). 
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Figure 3.2. Bilayer fusion, shown on the left, is one mechanism by which liposomes may form. Two fragments, 
formed by mechanical stress (induced by an electric field), eliminate edge energy (the energy associated with 
exposure of the hydrophobic regions of the edge lipid molecules to water) by fusing together to form a closed 
structure. In doing so, some of the external solution is trapped within the vesicle. Another possible mechanism 
is not dissimilar to endocytosis in vivo. An area of a bilayer bulges out due to osmotic effects, the combination 
of mechanical stress and tension at the neck region causes fission of this area, resulting in the formation of a 
vesicle (shown on the right). 
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3.1.3 FACTORS INFLUENCING GUV FORMATION 
As a result of electroformation, GUVs are metastable rather than thermodynamically stable 
structures. However, they are able to remain in these metastable states for many hours, even days. 
Many factors affect both the size and number of GUVs that are produced by the electroformation 
method. Some of these can be controlled including the electric field (type (ac or dc), voltage, 
frequency and function type (square wave, sinusoidal)) and buffer parameters (temperature, 
osmolarity and ionic strength). High salt concentration in the buffer for example, reduces both the 
size and number of vesicles formed and can inhibit formation completely(296). This is thought to be 
due to charge screening, which reduces the electrostatic repulsion between bilayers.  
Other factors include the thickness of the lipid film, which can be roughly controlled by using 
consistent lipid concentrations, volumes and deposition methods. The exact structure of the lipid 
film will however differ between experiments. Recently, research groups have used spin coating (a 
technique often used to produce supported lipid bilayers(297)) in an attempt to obtain more 
reproducible lipid films of uniform thickness(298). However, even with this development, the lipid-
lipid and lipid-substrate interactions will depend on the individual lipid properties resulting in 
differences between the lipid film composed of one lipid type and that of another.  
3.1.3.1 GUV Curvature Free Energy 
As would be expected, the need for a bilayer to bend and stretch during the formation of a liposome 
means that the properties of the bilayer itself (see section 1.3) are important variables. It has been 
shown for example that the addition of cholesterol to an egg lecithin sample inhibits liposome 
formation(296). It is possible to speculate that in this example, the addition of cholesterol prevents 
vesicle formation by increasing membrane rigidity(299, 300). In both the case of the fragment fusion 
mechanism and the endocytosis-like mechanism it can be seen that increasing the membrane 
rigidity increases the energy required to form GUVs. Addition of sufficient levels of cholesterol would 
make the energy required to form membrane buds unfeasible, inhibiting the endocytosis 
mechanism. Similarly, increasing the bending energy to be higher than the edge energy would inhibit 
the fragment fusion mechanism. It has also been shown that negatively charged lipid films can only 
form vesicles in the presence of an electric field (when deposited on the cathode). This may be 
explained by the ability of these lipids to form hydrogen bonds. In the absence of an electric field 
and upon hydration, a hydrogen-bonded bridge involving two negatively charge headgroups and one 
water molecule could form (Figure 3.3), increasing the energy required to separate bilayers. An 
electric field would disrupt the hydrogen-bond network, allowing vesicle formation to take place. 
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Figure 3.3. Strong bilayer-bilayer repulsion would be expected for bilayers made from a high composition of 
negatively charged lipids, due to electrostatic repulsive forces. The inability of these compositions to form 
liposomes without electric currents may be due to hydrogen bonding. A highly organised lattice of water 
molecules can form a hydrogen-bonded network with lipid headgroups; bridging bilayers. This would increase 
the energy required to separate the bilayers, which is required for vesicle formation. Application of an electric 
field would disrupt such hydrogen bonding and apply additional electrostatic force, allowing vesicle formation 
to occur. 
These examples reflect the importance of considering the lipid properties and therefore the 
curvature free energy of the system (introduced in section 1.3.2). Electroformation creates 
metastable liposomes that occupy local energy minima. While not the thermodynamic energy 
minimum of the system (which would have a relaxed mean curvature Hr), the local energy minimum 
can be considered to have a local relaxed curvature (Hr’). The curvature free energy of a surface can 
be expressed by Equation 1.5: 
   %&  '()(*  *$)  %&  '()(*  +) Equation 1.5 
As gc is the curvature free energy per unit area, the total curvature free energy (Gc) of a vesicle can 
be expressed as the summation of the individual energy contributions of the two monolayers: 
 3  455  466 Equation 3.1 
Where A is the surface area and the suffix i and o distinguish between the inner and outer 
monolayer. Assuming a vesicle is spherical with a radius R and bilayer thickness 2ℓ, Equation 3.1 can 
be re-expressed as: 
 3  .%'  '() 9(:  /) ;*$  (:  /)<
  (:  /) ;*$  (:  /)<
= Equation 3.2 
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From this, it can be seen that the free energy of the vesicle is quadratic with respect to the vesicle 
radius and that the minimal energy for each monolayer occurs when its radius (R ± ℓ) is equal to 
1/Hr. Therefore, as with this thermodynamic minimum, it can be expected that the local relaxed 
curvature,Hr’, of each vesicle grown will be reflected by its radius. 
3.1.3.2 Micelle and GUV Size Dispersion 
The aggregation of amphiphilic molecules into micelles is governed by the hydrophobic effect. Above 
the CMC (Critical Micelle Concentration) it becomes more energetically favourable for molecules to 
aggregate together rather than to exist as monomers. The chemical potential of an aggregate that 
contains N molecules>?  can be expressed in terms of the interfacial tension, γ, and the cross 
sectional area of the amphiphile headgroup, a, at the hydrophilic/hydrophobic interface: 
 >?  AB  AB (B  B) Equation 3.3 
Where B is the optimum cross sectional area and AB is equal to >CDE where <N> is the mean 
number of molecules. From Equation 3.3, the mole fraction of an N-mer aggregate, XN, can be 
written: 
 F?  ;FCDECDE<GHI?JK(L?)
MNOP  Equation 3.4 
Where Λ is equal to AB RCDE  and ST  T  CDE. Equation 3.4 shows that the size of 
aggregates is expected to follow a Gaussian distribution. If we consider GUV formation to be 
analogous to micelle formation it should be expected that the size dispersion of GUVs will also follow 
a Gaussian distribution. 
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3.2 MATERIALS AND METHODS 
3.2.1 SOLUTIONS AND BUFFERS 
 
Storage Buffer 20 mM HEPES pH 7.4,  
100 mM KCl,  
1.5% (w/v) sodium cholate 
 
Sucrose Solution 300 mM Sucrose 
ddH2O 
 
Glucose Solution 300 mM Glucose 
ddH2O 
3.2.2 FORMATION OF GIANT UNILAMELLAR VESICLES BY ELECTROFORMATION 
3.2.2.1 ITO Glass Preparation 
ITO (Indium Tin Oxide) coated (single-sided coat, 5-10 Ω) glass slides measuring 50 x 75 x 0.7 mm 
were purchased from Diamond Coatings, Halesowen, UK. Conductive tape (3M, UK) was added to 
the ITO coated side of each slide to allow connection to a function generator by means of crocodile 
clips. Two glass slides were cleaned thoroughly using several cleaning steps; first using detergent 
followed by ethanol, distilled water and finally chloroform. Glass slides were dried under vacuum for 
30 minutes. This procedure was followed prior to all experiments. 
3.2.2.2 Liposome Sample Preparation 
Analysis of proteoliposomes (see section 2.3) showed that pellets (following detergent extraction) 
contained protein and DOPC at an average molar ratio of 1:30. Before electroformation, liposome 
samples were made to a protein: lipid molar ratio of 1:53 and 1:267 by addition of further DOPC. 
Samples were then diluted with storage buffer to give a lipid concentration of 1mg/ml. Pure DOPC 
liposome samples were also prepared to a concentration of 1mg/ml by the same method. DOPC was 
purchased as a lyophilised powder from Avanti Polar Lipids, USA. 
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3.2.2.3 Electroformation 
To prepare GUVs, a thin lipid film was first deposited onto the glass surface to allow greater surface 
wetting by the aqueous samples. 0.5 µl DOPC (in chloroform at 0.5 mg/ml) was deposited onto the 
ITO side of one glass slide and dried under vacuum for 20 minutes. 2 µl of liposome sample was 
deposited on top of this dry lipid film and the slide dried for a further 10 minutes under vacuum. 
With the addition of the initial lipid film the total protein: lipid molar ratio was 1:60 or 1:300 for 
proteoliposome samples. 
An electroformation chamber was formed by sandwiching the dried lipid film between two ITO glass 
slides separated by a PDMS (Polydimethylsiloxane) spacer (Figure 3.4). The ITO coated sides of each 
slide formed the cell interior. Mini binder clips were used to make the cell water tight.  
 
Figure 3.4. This figure shows the electroformation chamber used to produce GUV samples. A lipid film 
surrounded by a PDMS spacer is sandwiched between two ITO coated glass slides and sealed with binder clips. 
Following addition of buffer, the chamber is connected to a function generator by attachment of crocodile clips 
to the conductive tape adhered to each glass slide. 
A needle was inserted through the PDMS into the cell chamber to allow air release. The cell chamber 
was then filled (using a syringe and needle) with 0.2 µm filtered sucrose solution until all air was 
removed. After the needles were removed the cell was placed onto a hotplate (pre-heated to 40°C) 
with the lipid film slide in contact with this heat source. The cell was connected to a function 
generator and a square wave ac current passed across the cell for a total of four hours.  
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The following procedure was used: 
10 Hz, 1.2 V for 3 hours 
4 Hz, 1.5 V for 30 min 
2 Hz, 1.5 V for 15 min 
1 Hz, 1.5 V for 15 min (voltage is the potential across the cell, as measured by voltmeter) 
The hotplate was then switched off and allowed to reach room temperature before the cell was 
removed. The cell was carefully disassembled and the sucrose GUV solution collected. The sample 
was stored at room temperature in a clean glass vial and diluted five-fold with 0.2 µm filtered iso-
osmotic glucose solution, just before use. GUV solutions were not kept for more than 24 hours. 
3.2.3 MICROSCOPY 
A 200 µl droplet of diluted GUV sample was deposited on a glass cover slide and the sample 
observed. The microscope used was developed by Dr. Xavier Mulet (former PhD student) with 
modifications made by Dr. Nicholas Brooks (current postdoctoral reseracher). Based upon an 
inverted Nikon TE2000-E microscope, it is fitted with a motorised stage. A CCD camera (Hamamatsu 
Photonics KK., Japan) allows image acquisition. Hoffman modulation optics with Plan Fluor optic 
lenses (x20 and x40 magnification) were used and an arc Xe lamp provides stable fluorescence 
illumination. A LabView (National Instruments) based program developed by Dr. Brooks controls 
functions such as the light source (type, illumination levels and exposure times) and a motorised 
filter wheel.  
3.2.4 GUV SIZE 
3.2.4.1 Image Analysis 
Several images at each position were taken at different focal depths so that each GUV could be 
analysed in full focus. Using the software Image J(301) each GUV (which is observed as a circle) was 
sized individually using the manual elliptical selection tool. Only GUVs in focus within a particular 
image were selected and each was labelled with an identification number to ensure it was only 
counted once. The measure application within Image J then gave the pixel area of the GUV (Figure 
3.5). In some cases a GUV would be pressed up to a neighbouring GUV, leading to deformation of 
the surface. In these circumstances the ellipse that best fit the GUV edge as a whole was used, 
usually leading to an over-estimation of the area. A micro-ruler was used during image acquisition to 
allow the pixel area determined by Image J to be converted into µm2.  
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Figure 3.5. The left of this figure shows a brightfield image obtained from a t-SNARE liposome sample (1:300 
protein: lipid and 1:1 SNAP-25: ∆N-Syx molar ratio). Each GUV (in focus) was manually selected with an 
elliptical selection tool and assigned a label. Where a vesicle was deformed (Vesicle 4 is an example), an ellipse 
which best fit the edge of the vesicle as a whole was chosen, leading to an over-estimation of the area. 
3.2.4.2 Error Analysis 
In order to establish the mean radius and size distribution, the vesicles were grouped into area 
classes of 50 µm2 size in the 0 to 13000 µm2 range. The population of each class was then 
determined. The error incurred by manual selection was calculated by the repeated selection of 
particular vesicles chosen from a randomly selected image (Table 3.1). 
Measurement Vesicle 1 Vesicle 2 Vesicle 3 
1 20880 9500 812 
2 20880 8992 812 
3 20612 9336 960 
4 20360 9336 908 
5 20612 9176 912 
6 20612 9336 960 
7 20880 9300 912 
8 20636 9336 1020 
9 20612 9176 860 
10 20636 9500 860 
Average 20672 9318.8 901.6 
Standard Deviation 164.698 165.783 67.177 
% Error 0.797 1.779 7.451 
Table 3.1 
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As expected, the percentage error of the pixel area increased as vesicle size decreased. An 
exponential decay curve was found to best fit the data and the equation of this curve was used to 
evaluate the error associated with each of the vesicle areas measured (Figure 3.6). Using this data, 
the smallest and largest area calculated for each vesicle was obtained and the population of each 
class recalculated, giving the population error. 
 
Figure 3.6. This figure shows how the percentage error of liposome area alters with vesicle size. An exponential 
decay curve was fit to the data and the equation of this curve used to assess the error of the area for each 
vesicle measured. 
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3.3 RESULTS 
3.3.1 GUV FORMATION 
The small proteoliposomes formed from detergent extraction (discussed in Chapter 2) were 
suspended in the protein storage buffer. This buffer contains the salt potassium chloride and 
therefore deposition of a lipid film would result in high concentrations of salt when the lipid solution 
was dried. It was first necessary to find an electroformation protocol which would allow GUV 
formation in these conditions. It was established that the addition of warm (40°C) sucrose solution 
at a relatively high concentration (300 mM) was sufficient for GUVs to form at a frequency of 10 Hz. 
It is likely that the use of warm sucrose solution dissolved and dispersed the salt within the lipid film, 
thereby reducing the salt concentration sufficiently to allow vesicle formation. The use of a high 
concentration of sucrose (and therefore also glucose) has the added advantage that it increases the 
contrast between vesicle and background under the microscope. However, GUV formation was only 
seen for the 1:300 protein: lipid preparations. Despite several different electroformation regimes 
being attempted, no GUVs were formed by the 1:60 protein: lipid preparation, suggesting protein 
influence on the lipid film (see section 3.4). As discussed in section 1.6, high protein densities are 
believed to create leaky vesicles. Therefore the lipid film of the 1:60 preparation may not have been 
stable enough to form GUVs during electroformation with the alternating current causing them to 
rupture. 
3.3.2 PROTEIN INSERTION INTO GUVS 
The insertion of the neuronal SNARE proteins into small proteoliposomes was established in Chapter 
2. However, during electroformation these proteoliposome preparations were dried to form a lipid 
film and subjected to electric fields. It was not clear whether, during electroformation, protein 
would incorporate into forming vesicles or whether it would remain adhered to the glass substrate. 
This was of particular concern when it was found that the 1:60 proteoliposomes were incapable of 
forming GUVs. It was possible that the 1:300 samples only grew due to the addition of large amounts 
of DOPC to proteoliposome pellets and that the GUVs produced did not in fact contain protein. 
Therefore, to check that this procedure would not affect protein insertion, 1:300 proteoliposome 
samples containing either the fluorescent SNARE protein His6-VAMP2-488 or His6-∆N-Syx-555 were 
produced and electroformation undertaken. 
  
 P a g e  99 
A FITC filter (Nikon, excitation 465-495 nm, emission 505 nm) was used for His6-VAMP2-488 samples 
and a Texas Red filter (Nikon, excitation 540-580 nm, emission 595 nm) for His6-∆N-Syx-555 samples. 
The fluorescent images obtained clearly show the incorporation of neuronal SNARE proteins into 
GUVs prepared by this method (Figure 3.7). The images also show the protein to be homogenously 
distributed within the lipid bilayer (within the resolution of the microscope). Bright spots and 
patches seen on the images correspond to additional membrane moieties attached to, or trapped 
within, the primary GUV. 
 
Figure 3.7. The top row of this figure shows the brightfield images of fluorescent SNARE GUVs grown by 
electroformation; the corresponding fluorescence images are shown underneath. Figures A and B show the 
incorporation and homogenous distribution of His6-VAMP2-488 into DOPC GUVs at a protein: lipid molar ratio 
of 1:300. Figures C and D, show the incorporation of His6-∆NSyx-555 (also at a ratio of 1:300). 
3.3.3 SNARE PROTEINS AFFECT GUV SIZE 
The size of GUVs, varying in composition, has been analysed. While many factors affect the size and 
number of liposomes obtained (see section 3.1.3), the experiment was conducted so that, within 
reasonable error, the composition (with respect to protein type and protein: lipid molar ratio) was 
the only variable. The electroformation chamber described in section 3.2.2.3 was used with a 
modified PDMS spacer. This spacer was created so that it contained four separate chambers, 
allowing four lipid films to be deposited and grown at the same time without cross contamination. 
This method allowed many variables such as the drying and growing times, temperature, frequency 
and voltage to be eliminated during data analysis. 
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Proteoliposome samples containing either His6-VAMP2 and DOPC or His6-SNAP-25, His6-∆N-Syx and 
DOPC were prepared with a total protein: lipid molar ratio of 1:300; for the latter (t-SNARE) 
proteoliposomes the molar ratio of SNAP-25: ∆N-Syx was 1:1. As the purified SNAP-25 does not have 
means to attach directly to membranes (it contains no lipid anchors or transmembrane domain), the 
t-SNARE sample contained only half as many membrane anchors as the VAMP2 sample. A 
proteoliposome sample of His6-VAMP2 and DOPC was therefore also prepared to a ratio of 1:600, 
allowing the influence of the transmembrane domains of VAMP2 and ∆N-Syx to be compared.  
On the assumption that each vesicle was spherical the radius of each vesicle was calculated and 
plotted against population frequency. As discussed in section 3.1.3.2, the size dispersion was 
expected to fit to a Gaussian distribution; this was therefore used in order to determine the mean 
size of each GUV sample (Figure 3.8, Figure 3.9, Figure 3.10 and Figure 3.11). In each case it was 
found that two Gaussian distributions best fit the data. 
 
Figure 3.8. The population distribution of DOPC liposomes is shown as a function of vesicle radius. A multiple-
peak Gaussian distribution has been fit to the data where the individual peaks are shown in green and the peak 
total is shown in black. From the distributions it can be considered that two vesicle populations exist, one with a 
mean size of 10 μm and the other with a mean size of 17 μm. 
 
 P a g e  101 
 
Figure 3.9. A graph showing the population distribution of t-SNARE DOPC liposomes as a function of vesicle 
radius is shown. The liposomes were made with a protein: lipid molar ratio of 1:300 and a SNAP-25: ∆N-Syx 
molar ratio of 1:1. A multiple-peak Gaussian distribution has been fit to the data where the individual peaks are 
shown in green and the peak total is shown in black. From the distributions it can be considered that two 
vesicle populations exist, one with a mean size of 11 μm and the other with a mean size of 5 μm. 
 
Figure 3.10. A graph showing the population distribution of VAMP2 DOPC liposomes as a function of vesicle 
radius is shown. The liposomes were made with a protein: lipid molar ratio of 1:300. A multiple-peak Gaussian 
distribution has been fit to the data where the individual peaks are shown in red and the peak total is shown in 
black. From the distributions it can be considered that two vesicle populations exist, one with a mean size of 10 
μm and the other with a mean size of 5 μm. 
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Figure 3.11. A graph showing the population distribution of VAMP2 DOPC liposomes as a function of vesicle 
radius is shown. The liposomes were made with a protein: lipid molar ratio of 1:600. A multiple-peak Gaussian 
distribution has been fit to the data where the individual peaks are shown in green and the peak total is shown 
in black. From the distributions it can be considered that two vesicle populations exist, one with a mean size of 
10 μm and the other with a mean size of 19 μm. 
Table 3.2 gives a summary of the mean size and standard deviation of each Gaussian distribution for 
the liposome compositions studied, based upon the multiple-peak Gaussian curve that was fit to 
each data set. For each composition it has been found that two vesicle populations existed. The 
relative occupancy of each population was calculated using the peak areas. 
Composition DOPC 
t-SNARE: DOPC 
1:300 
VAMP2: DOPC 
1:300 
VAMP2: DOPC 
1:600 
Sample Size 841 859 836 875 
Peak 1 Occupancy % 59.9 ± 11.2 52.6 ± 2.86 7.60 ± 3.55 69.4 ± 3.23 
Mean Radius (μm, 3sf) 10.1 ± 0.12 10.9 ± 0.40 9.60 ± 1.39 9.98 ± 0.05 
S.D (3sf) 3.28 ± 0.26 6.11 ± 0.27 2.83 ± 0.67 2.18 ± 0.07 
Peak 2 Occupancy % 40.1 ± 12.7 47.4 ± 1.90 92.4 ± 3.62 30.6 ± 4.86 
Mean Radius (μm, 3sf) 17.4 ± 2.58 4.98 ± 0.03 4.88 ± 0.05 18.7 ± 1.66 
S.D (3sf) 7.33 ± 1.23 1.55 ± 0.04 2.15 ± 0.03 8.71 ± 1.14 
Table 3.2 
A visual comparison is provided in Figure 3.12 where the Gaussian fit from each of the data sets has 
been combined graphically. The results show that the presence of protein in liposomes affects both 
the vesicle radius and the relative occupancy of the vesicle populations which exist. Compared to 
pure lipid vesicles, the addition of a membrane-anchored protein at a 1:600 ratio (VAMP2: DOPC) 
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seems to have had little affect. A comparison of the two vesicle populations within these samples 
shows that the mean size and occupancy of each be considered equal within error. Increasing the 
amount of VAMP2 protein to a ratio of 1:300 (VAMP2: DOPC) altered both the mean size and 
occupancy of the two Gaussian distributions. A population was still seen with a mean radius at 
approximately 10 μm but its occupancy was reduced to only 7.6% (compared to ≈60% for DOPC). 
However, the second distribution of the VAMP2 sample (which accounts for 92.4% of the vesicles) 
has a mean size of approximately 5 μm compared to the DOPC sample with a second distribution 
with a mean radius at ≈18 μm. This result shows a significant decrease in the liposome size overall as 
a result of VAMP2 addition at this protein: lipid ratio. Surprisingly, the t-SNARE liposomes also had a 
large population of vesicles with a mean radius of ≈5 μm, despite having only half the number of 
membrane-anchored proteins as the VAMP2 1:300 sample. The second population, as with all other 
compositions, is seen to have a mean radius of approximately 10 μm and has an occupancy level 
similar to that of the DOPC sample. A discussion of these results can be found in section 3.4. 
 
Figure 3.12. The Gaussian distribution fit to the data of each liposome population is shown. It can be seen that 
the size of the DOPC liposomes (blue) is comparable to the VAMP2 DOPC liposomes where the protein: lipid 
molar ratio is 1:600 (purple). The 1:300 VAMP2 DOPC liposome sample (green) is shown to have approximately 
half the mean radius of the 1:600 sample. Despite having the same number of membrane anchors, the t-SNARE 
DOPC liposome sample (red) also has a large population with a mean radius of approximately 5 μm, though a 
significant proportion still exhibit a mean radius comparable to that of the DOPC and 1:600 VAMP2 samples.  
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3.4 DISCUSSION 
The fluorescence imaging of GUVs containing either the fluorescent SNARE protein His6-VAMP2-488 
or His6-∆N-Syx-555 has established that the electroformation of GUVs formed from small 
proteoliposome preparations (created by detergent extraction) does lead to protein insertion into 
these simple lipid bilayer models.  
The use of a simultaneous electroformation technique has allowed data to be obtained where 
differences in the size of GUVs can be attributed to the presence of protein. As discussed in section 
3.1.3, it was expected that if the size dispersion was analogous to that of micelles the data would 
follow a Gaussian distribution. Fitting the data to such a distribution required the use of a multiple-
peak fitting method where two Gaussian peaks were used in each case. Employing this method gave 
variances higher than 93% in all cases. A comparison of the mean radii of the DOPC sample with 
either the VAMP2 or t-SNARE (∆N-Syx and SNAP-25) samples shows a decrease in the radius (i.e. an 
increase the local relaxed curvature Hr’) due to protein addition. For VAMP2 this can be explained by 
the effect of hydrophobic mismatch. 
When a transmembrane domain is inserted into a bilayer the lipid molecules are forced to stretch 
and compress in order to accommodate it. This occurs when the transmembrane region and the 
preferred lipid bilayer thickness differ. The larger the discrepancy, the greater the hydrophobic 
mismatch and the higher the stored energy of the bilayer becomes. The transmembrane region of 
VAMP2 has been modelled as α-helical(34). By definition(19), an α-helix is a right-handed helix with a 
pitch of 5.4 Å, each turn containing 3.6 amino acid residues (Figure 3.13A). The transmembrane 
domain sequence of VAMP2 is 20 amino acid residues long and is therefore calculated to be 30 Å 
long. Experimentally a pure DOPC bilayer has been found to be ≈35 Å thick(302). The anchor of VAMP2 
is therefore significantly shorter than the preferred thickness of a DOPC bilayer. As a result of this 
mismatch the lipid chains surrounding the anchor are required to compress, thinning the bilayer at 
the lipid-protein interface to prevent any exposure to water. However, a reduction in bilayer 
thickness can be achieved more favourably by bending the bilayer as the increase in energy can be 
evenly distributed throughout the system. The hydrophobic chains of lipid molecules on one leaflet 
are able to splay, reducing the thickness of that monolayer (Figure 3.13B) and the bilayer overall. It 
can therefore be seen that the addition of VAMP2 causes an increase in Hr’. It was not possible to 
grow GUVs that contained VAMP2 at a protein: lipid ratio of 1:60. The level of hydrophobic 
mismatch due to the presence of so much protein is likely to have prevented stable GUV formation. 
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This may provide an explanation for why vesicles containing this protein at high protein densities 
have historically been found to be leaky (section 1.6). 
 
Figure 3.13. Figure A on the left shows an α-helix which is a common secondary protein structure. This right-
handed helix contains 3.6 amino acid residues per turn and has a pitch of 5.4 Å (1.5 Å translation per residue). 
Figure B shows the consequences of hydrophobic mismatch. A hydrophobic insertion (such as a protein's 
membrane anchor) into a lipid bilayer forces the bilayer away from its preferred thickness if the anchor is too 
large or small (the latter is shown here). In order to thin the bilayer, at the lowest energetic cost, the bilayer 
bends allowing some lipids to splay. 
The hydrophobic mismatch between the VAMP2 transmembrane domain and lipid bilayer may only 
be a peculiarity of the chosen model system. The membranes of cells in vivo are highly complex, 
containing thousands of lipid species. A discrepancy between transmembrane length and bilayer 
thickness may therefore not exist in the biological context, though an influence of the local lipid 
composition would be expected. However, hydrophobic mismatch is thought to be relevant in vivo 
particularly where the transmembrane anchors are larger than the bilayer thickness(303). In these 
cases the domain tilts in order to accommodate itself in the membrane(304). So if it does occur, how 
could hydrophobic mismatch affect the membrane fusion process? 
During membrane fusion, VAMP2 is located on synaptic vesicles which are approximately 50 nm in 
diameter. These highly curved membrane bodies may have relatively thin bilayers and so the short 
anchor of VAMP2 may not have a mismatch in this environment. However, VAMP2 also resides at 
the trans-Golgi complex and plasma membrane at other stages of the fusion process. These 
membranes are flatter than synaptic vesicles and may also be thicker so that in these locations 
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VAMP2 would have a hydrophobic mismatch. In both of these membranes VAMP2 is recruited to 
vesicles as they bud. If hydrophobic mismatch does exist in these membranes, lipids surrounding the 
anchor would be more prone to bend and may partially determine the site of vesicle budding. 
Alternatively, when a membrane bud begins to form it would be energetically favourable for VAMP2 
to locate at these areas of higher curvature. The anchor may therefore have a role in the 
recruitment of VAMP2 into these buds. As discussed in section 1.4.3, hydrophobic mismatch may 
play an important role in increasing the membrane tension of the fusion site, for example the 
hemifusion diaphragm. Such tension is hypothesised to be essential for fusion pore formation and 
therefore the length of the VAMP2 anchor may be important for VAMP’s role in the fusion 
mechanism. 
Considering the 5 Å difference between the size of the VAMP2 transmembrane region and the 
preferred thickness of the DOPC bilayer, it is surprising that the addition of this protein at a ratio of 
1:600 had little or no affect. The result for the t-SNARE DOPC liposome sample is also unexpected. 
This liposome population contained protein at a total molar ratio of 1:300, but only half of this 
protein (∆N-Syx) has a membrane anchor. On this basis alone it would be expected that the data 
would be similar to that of the 1:600 VAMP2 liposome population. Another consideration is any 
hydrophobic mismatch between the ∆N-Syx transmembrane domain and the DOPC bilayer. The 
residue sequence of the ∆N-Syx membrane anchor is 23 amino acid residues long and like VAMP2, 
has been modelled as an α-helix(34); the transmembrane region of ∆N-Syx is therefore predicted to 
be 34.5 Å long. This anchor would be expected to have little mismatch with the lipid bilayer and 
therefore have less of an influence on Hr’ than VAMP2. However, the presence of the t-SNARE 
proteins has been seen to affect proteoliposome size significantly. 
As well as through transmembrane regions, Syntaxin 1A has been shown by EPR 
(Electroparamagnetic Resonance) to partially insert another part of its sequence (amino acid 
residues 261-265) into the membrane(92). This sequence is situated next to the transmembrane 
anchor (the linker region) and is thought to insert into one monolayer, eliminating any gap between 
vesicle and plasma membrane bilayers during SNARE-mediated fusion. A similar basic amino acid-
rich region has been identified in VAMP2 and is therefore also thought to partially insert into the 
membrane. As discussed in section 1.7.1 this would be expected to increase curvature by altering 
the area of the monolayer upon insertion of the linker. 
Despite lacking the ability to membrane associate in this study, the influence of the SNAP-25 protein 
needs to be considered. It is possible that SNAP-25, which has lipid anchors in vivo, also has short 
amino acid residue sequences that partially insert into the membrane. As discussed in section 
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1.2.3.2, the anchors of SNAP-25 take the form of four palmitoylated cysteine residues at sequence 
numbers 85, 88, 90 and 92 for homologue b. Using the Kyte-Doolittle hydropathy plot(305) ProtScale 
program from Expasy*, it can be seen that the amino acid residue sequence from 81-95 is the most 
hydrophobic region of the protein (Figure 3.14). The hydrophobicity of this region suggests that as 
well as the lipid anchors in this region, these amino acid residues partially insert into the bilayer. As 
discussed in the previous paragraph, this would increase the area of one monolayer and 
consequently the curvature of the bilayer. Unlike the VAMP2 1:300 sample, the t-SNARE sample can 
be seen to have two vesicle populations of similar occupancy. The inability of SNAP-25 to bind to 
membranes in this study may have led to vesicle forming with different protein densities. The 
population with a mean radius of ≈10 μm may reflect vesicles with little SNAP-25 present (making 
the composition similar to the VAMP2 1:600 sample) while the other (with a mean radius ≈5 μm) 
may contain much more SNAP-25 resulting in liposomes similar in size to the VAMP 1:300 sample. 
Alternatively, as will be discussed in chapter 4, the higher curvature may result from protein 
aggregate structures. These would restrict the growth of GUVs as additional energy would be 
required to break the aggregate to allow the vesicles to form. 
 
Figure 3.14. Produced using the Expasy ProtScale program, the Kyte-Doolittle hydrophobicity plot of the full 
wild-type SNAP-25 sequence (1-206) is shown. A window size of 7 has been used. Values above 1.6 are 
considered to be areas of hydrophobicity and such a region can be seen for the sequence at residues 81-95. This 
area contains the four cysteine residues (C85, C88, C90 and C92) which become palmitoylated post-
synthetically in vivo, forming lipid anchors. It is therefore expected that this protein region would be close to 
the lipid bilayer. As well as lipid anchors in vivo, the hydrophobicity of this area may indicate partial insertion of 
these residues into the proximal membrane leaflet. 
                                                           
* www.expasy.ch/tools/protscale.html 
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3.5 CHAPTER SUMMARY 
In this chapter it has been shown, through the use of fluorescently labelled protein, that the SNARE 
proteins can be incorporated and formed in giant unilamellar vesicles. The proteins were also seen 
to distribute evenly throughout the membrane surface.  
The sizes of liposomes, produced by electroformation, have been analysed and reveal that the 
incorporation of protein affects this property. Insertion of VAMP2 led to the formation of liposomes 
with a higher curvature relative to the pure lipid system. This has been attributed to hydrophobic 
mismatch between the transmembrane anchor and the preferred thickness of the model lipid 
bilayer used. VAMP2 may have evolved to have such a short anchor due to the high curvature of 
synaptic vesicles. In the flatter environment of the plasma membrane or Golgi complex this 
mismatch may partially determine sites of vesicle budding and/or aid the recruitment of VAMP to 
the buds. However, this phenomenon may only be a symptom of the choice of model lipid system 
and therefore further investigations using more complex lipid mixtures should be conducted. For the 
t-SNARE liposomes, changes in size are more difficult to explain. It is possible that the linker region 
of these proteins partially inserts into the bilayer, altering curvature properties. As will be discussed 
in chapter 4 the change may also be due to the formation of aggregate structures.  
In this chapter the influence of the SNARE proteins upon the curvature of bilayers has been 
investigated. During membrane fusion the bilayers must deform and therefore the ability of these 
proteins to manipulate the elastic properties of the membrane is also of interest. In order to 
quantitatively evaluate the changes in the membrane properties of GUVs as a result of SNARE 
protein insertion, an investigation using micropipette aspiration was undertaken. This technique and 
the data obtained by its use are discussed in Chapter 4. 
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Chapter 4.  
MICROPIPETTE ASPIRATION STUDIES OF MEMBRANE PROPERTIES 
In this chapter, a micropipette aspiration study of giant unilamellar vesicles is presented. This 
technique has been employed to provide quantitative data of the effect that SNARE protein 
incorporation has upon the membrane properties of these model membranes.  
A comparative study of DOPC and di-ether PC (ether-linked DOPC; 1,2-di-O-(9Z-octadecenyl)-sn-
glycero-3-phosphocholine) vesicles found that the DOPC vesicles had a bending rigidity (κ) of 13.4 ± 
2.00 kBT (3sf) and an area expansion modulus (+U) of 147 ± 22.3 mN/m (3sf). The literature values 
for a DOPC bilayer are 0.85 ± 0.1 x10-19 J (≈21 ± 2.5 kBT) and 265 ± 18 mN/m respectively
(306). While 
the bending rigidity found compares well, +U is significantly lower. This has been attributed to lipid 
degradation as a result of the formation of the vesicles using the electroformation method. Further 
interpretation of the data allowed vesicles with significant degradation to be excluded. The 
remaining DOPC vesicles had an area expansion modulus of 248 ± 9.77 mN/m, comparing favourably 
with the literature value. The bending rigidity of this group was found to be 14.9 ± 3.57 kBT (3sf). 
With the ester linkages replaced by ether groups, di-ether PC is not able to degrade in the same way. 
The overall bending rigidity of the di-ether PC vesicles was found to be 14.6 ± 4.68 kBT (3sf) with an 
area expansion modulus of 232 ± 25.5 mN/m (3sf). From this study it is concluded that where 
possible, a swelling method should be used to produce GUVS; in preference to electroformation.  
The effect of incorporating the SNARE protein VAMP2 was examined using a 1:300 protein: DOPC 
molar ratio. Micropipette aspiration revealed both moduli were decreased compared with pure 
DOPC vesicles with an area expansion modulus of 143 ± 7.06 mN/m (3sf) and a bending rigidity of 
5.32 ± 0.81 kBT (3sf). The hypothesis proposed in chapter 3, that VAMP2 causes bilayer thinning due 
to hydrophobic mismatch, is consistent with these findings. The insertion of the t-SNARE proteins 
SNAP-25 and Syntaxin 1A into DOPC GUVs (0.5: 0.5: 300 molar ratio) led to an increase in the area 
expansion modulus to 366 ± 37.1 mN/m (3sf). The overall bending rigidity was found to be 8.13 
±1.42 kBT (3sf). As with the DOPC study, the data required further interpretation due to the effects 
of electroformation. Removal of multilamellar vesicles and those containing degraded lipid products 
led to a selective population average of 493 ± 6.00 mN/m (3sf) for +U , with a bending rigidity of 8.30 
± 1.15 kBT. The increase in +U may reflect the ability of the t-SNARE proteins to interact with each 
other, forming an interconnected aggregate structure. 
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4.1 INTRODUCTION 
The mechanical properties of GUVs have been investigated for several decades, principally by shape 
fluctuation analysis(307-310) and micropipette aspiration(306, 311, 312). In this chapter, the latter technique 
has been employed to study the consequences of SNARE protein insertion on the membrane 
properties of a DOPC lipid bilayer. 
Data from Chapter 3 led to postulation that SNARE proteins affect lipid membranes by increasing the 
relaxed curvature. Micropipette aspiration has allowed in influence of these proteins on 
deformation energies to be assessed quantitatively. The two properties explored by the aspiration 
method are the bending rigidity, κ, and the area expansion modulus, +U (also referred to as the area 
compressibility modulus). The bending rigidity is a measure of the force required to bend the 
membrane while +U is the force required to stretch or compress the membrane. 
The following section introduces the theory of micropipette aspiration based upon work published 
by Henriksen in 2004(300) with the exception of the surface area equations, which were provided by 
Dr. Nicholas Brooks (personal communication) based upon a publication by Heinrich(313). 
4.1.1 PRESSURE AND SURFACE AREA 
 
Figure 4.1 It can be seen from this figure that though the membrane fragment fits into a frame area (Ap) of x*y, 
the undulations of the surface result in the actual surface area (A) being far greater. The optical resolution of a 
microscope is not sufficient to detect the undulation of the surface and therefore appears smooth. As a result, 
only Ap can be determined directly from microscopic images. Reproduced with the permission of HydeSoft 
Computing. 
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Under a microscope, the membrane surface of a vesicle looks smooth; however, below the optical 
resolution the membrane is undulated (Figure 4.1). There is therefore a discrepancy between the 
observable area of the vesicle, Ap (referred to as the frame area) and the actual microscopic surface 
area, A; with Ap< A. Micropipette aspiration uses external pressure to pull a vesicle into a pipette of a 
radius much smaller than the vesicle radius. In doing so the undulations are pulled out and the 
microscopic surface area becomes optically resolved. At higher pressures, the surface area increases 
as the membrane is stretched away from the equilibrium area per lipid molecule a0. By applying the 
following theory it is possible to determine the bending rigidity and area expansion modulus of the 
GUV membrane from the experimental data gathered during aspiration. 
4.1.1.1 Pressure 
 
Figure 4.2 In order to describe the pressure and shape of the whole system, it must be split into two 
subsystems. Subsystem 1 is the portion of vesicle that has entered the micropipette; which has a radius Rp. The 
amount of insertion is measured by the projection length; Lp. Subsystem 2 describes the spherical section of the 
vesicle (radius Rs) which has remained external to the pipette. Due to continuity, the internal pressure of the 
vesicle in each subsystem is equal (p1in=p
2
in), however, the external pressures differ and are denoted P
1
out and 
P2out. 
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An aspirated vesicle can be split into two subsystems (Figure 4.2). Subsystem 1 is the proportion of 
the vesicle membrane which has projected into the glass pipette upon exertion of pressure. 
Subsystem 2 represents the membrane portion that remains external to the pipette. The pressure 
difference between the outside and inside of the vesicle can be used to determine the force being 
applied. The total pressure difference, ∆p, is the summation of the pressure difference of each 
subsystem. As the continuous nature of the vesicle results in the internal pressure of each subsystem 
being equal; the pressure can be expressed as the difference between the outside pressures of the 
subsystems: 
 VW5  VW55X  VW56YZ  
 VW  VW  VW  W6YZ  W6YZ Equation 4.1 
Where [ indicates the subsystem. 
4.1.1.2 Surface Area 
A vesicle under zero pressure is assumed to be spherical with a radius R0. The volume of this vesicle 
is therefore: 
 \  ]^:^ Equation 4.2 
A vesicle under aspiration deforms as it enters the pipette. Two different shapes are used to 
calculate the deformation of the vesicle depending on how far it has been pulled into the pipette 
(Figure 4.3).  
 
Figure 4.3. When a vesicle begins to enter the micropipette the projection length Lp is less than the radius of the 
pipette Rp. In this situation the vesicle can be modelled as a sphere (external to the pipette) with a spherical 
projection cap. As the vesicle is pulled further into the pipette Lp becomes larger than Rp and the vesicle must be 
modelled as an external sphere with a hemi spherically capped cylinder projecting into the pipette. 
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When at a projection length, Lp, below the pipette radius, Rp, the vesicle can be modelled as a sphere 
(radius Rs) external to the pipette, with a spherical cap projection. The volume and surface area of 
this shape can be calculated from 
 \_`Ia`  ]^:b^  cde%f:e  de)g  
 4_`Ia`  .:b  de Equation 4.3 
As the vesicle projects further into the pipette the projection length becomes greater than the 
pipette radius. The membrane within the pipette must now be modelled as a cylinder with a 
hemispheric cap, while the membrane external to the pipette remains spherical. The volume and 
surface area in this case can be expressed as follows: 
 \_`Ja`  ]^:b^  :ede  ^:e^g  
 4_`Ja`  .:b  :ede  :e Equation 4.4 
As the external sphere projects into the pipette entrance this membrane area is counted twice. The 
final term of this equation provides a correction for this. 
The radius of the external sphere, Rs, cannot be accurately measured experimentally. However, the 
volume of the vesicle can be assumed to be constant and therefore it is possible to use the condition \  \_`Ia`  \_`Ja` to express Rs (and therefore the surface area) in terms of R0, Rp and Lp, which 
can be accurately obtained.  
 :b  :                                           under zero tension  
 :b  h:^  ijde^  kjde:ek       when Lp<Rp  
 :b  h:^  il:e^  klde:ek       when Lp>Rp Equation 4.5 
It should be noted that these measurements are obtained from microscopy and therefore these 
surface area calculations represent the frame area, Ap. 
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4.1.2 MEMBRANE DEFORMATION AND TENSION 
The deformation of a membrane following the application of pressure is assessed by the relative 
area change, α; 
 m  4e  4e5X4e5X  Equation 4.6 
Where 4e5X is the frame area at an initial (arbitrarily chosen) state and 4e is the frame area of the 
vesicle under the current aspiration pressure. By assuming that the volume of the vesicle is constant 
Equation 4.6 can be re-expressed: 
 mn  op:e:b5Xq
 Vd:e  r  ]^p:e:b5Xq
^ Vd:es
Mk  t A Equation 4.7 
 A    :ede5X  :e.%:b5X)  Equation 4.8 
Where Vd  de  de5X, γ is a geometric correction factor and :b5X is the spherical radius at 4e5X. 
Due to the optical resolution, the actual microscopic membrane surface area and the resolvable 
(frame) area are different. This is also true of membrane tension, giving rise to a surface tension, σ, 
and a frame tension, τ. The frame tension can be measured directly from micropipette aspiration 
using the following relationship; 
 
  VW:e ;  :e:b<
 
Equation 4.9 
4.1.3 PRESSURE REGIMES 
4.1.3.1 Flaccid Regime 
The flaccid or low pressure regime has a pressure range of 0-102 Pa (tension 0-10-1 mN/m) and in this 
regime the relative area change is due to the smoothing of membrane undulations. As a result, the 
difference between the true membrane surface area, A, and the frame area, Ap, decreases. At this 
pressure range, the total membrane surface area is considered to remain constant. Therefore: 
 m u vwx yz() Equation 4.10 
Where β is  &{| .  
Using this regime it is possible to evaluate w(the bending rigidity; assuming A is constant) by use of 
a linear fit of α vs. ln(τ).  
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4.1.3.2 Tense Regime 
Under a high pressure regime (103-104 Pa, tension 1-10 mN/m) the relative area change is governed 
by membrane stretching (an increase in the area per lipid molecule relative to the equilibrium value) 
and is therefore dependent on the area expansion modulus. As experiments measure 4e rather than A, this modulus also relates to 4e and is represented by +U(((( to provide distinction. 
 m u +U(((( Equation 4.11 
Using this relationship, +U(((( can be calculated from a linear fit of α vs. τ.  
4.1.3.3 Full Pressure Regime 
It is experimentally difficult to obtain data from the flaccid regime and though the formal cross-over 
region between the flaccid and tense regimes occurs in the 102-103 Pa pressure range, in reality, the 
relative area change of the flaccid regime does have a contribution from membrane stretching. 
Henriksen has combined the two regimes into a single equation allowing the full pressure range to 
be analysed. 
 m u m  vwx yz()  +U Equation 4.12 
The molecules of the membrane have an equilibrium area, a0; the equilibrium membrane area, A0, is 
therefore Na0 where N is the number of molecules in the membrane. In Equation 4.12, ν is the ratio 
of the initial frame area and the equilibrium membrane area (  4e5X 4 ). By including this term, 
the bending rigidity at A0 and +U (rather than +U(((() can be found. It should be noted that the tension 
in Equation 4.12 is the surface tension (σ) rather than the frame tension. 
Assuming that 4e5X  4 ,   ; this assumption also allows the frame tension to be identified with 
the surface tension (which cannot be determined experimentally). It is further assumed that A0 
remains constant throughout the experiment. 
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4.2 MATERIALS AND METHODS 
4.2.1 MAKING MICROPIPETTES 
Pipettes were prepared from thin walled borosilicate glass tubing (#1B100 (152mm length, 1mm 
outer diameter, 0.58mm internal diameter), World Precision Instruments, Stevenage, UK) using a 
Narishige PN 30 pipette puller. The main magnet was set to 48.0, sub magnet to 23.3 and the heater 
to 80.6 to produce fine, long tipped pipettes. Two pipettes can be formed from each glass tube. 
Following pulling, the tip of each pipette was cleaved and polished using a Narishige MF 900 
microforge. The forge consists of a platinum filament onto which a small soda-lime glass ball was 
melted and visualised under a x10 lens. The pipette was mounted into a pipette holder and its 
position controlled with micromanipulator dials. The filament heater was initially set to 40%. The 
filament was heated and the pipette tip bought into contact with the edge of the molten glass bead. 
Capillary action pulled soda-lime glass into the pipette and when the molten glass reached the 
required pipette diameter the heat was turned off. Retraction of both the filament and the glass 
bead as it cooled caused the pipette to snap, producing a straight end at the desired diameter. 
The pipette end was polished to ensure no sharp edges would burst vesicles during aspiration. The 
filament heater setting was increased to 70% and the pipette (in the holder) moved as far away from 
the filament as possible. With the heat turned on, the pipette was then bought slowly towards the 
filament until the pipette end just melts to become smooth, but not closed. 
The end region of the pipette must be long enough to allow sufficient aspiration of the vesicle and 
this region should be in the same focal plane. The pipette was therefore bent using the microforge. 
The angle of the pipette holder was changed to approximately 30% above the horizontal. The 
pipette was positioned so that the middle of the section to be bent was above the glass bead. The 
filament heater was set to 60% and, with the heat turned on; the pipette was bought slowly towards 
the filament, causing the pipette to bend. 
Before each experiment, a pipette was backfilled with 300mM glucose solution using a MicroFil 
syringe needle (World Precision Instruments, Stevenage, UK) and a high pressure syringe. Buffer was 
forced into the pipette until a droplet was formed at the pipette tip and then the needle was slowly 
extricated while continually adding buffer to prevent air bubbles. The pipette tip was then soaked in 
a 0.2 µM filtered BSA solution (1% w/v BSA in 300mM glucose) for 30 minutes to prevent vesicles 
adhering to the glass during aspiration. The pipette was washed thoroughly in 300mM glucose 
solution to remove excess BSA just prior to aspiration experiments. 
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4.2.2 ASPIRATION 
4.2.2.1 Microscope Set-Up 
The microscope used was based around an inverted Nikon TE2000-E microscope and modified by Dr. 
Xavier Mulet and Dr. Nicholas Brooks. As described in chapter 3, the microscope has a CCD camera 
for image acquisition and uses Hoffman modulation optics. A schematic of the microscope 
components can be seen in Figure 4.4. 
 
Figure 4.4 Provided by Dr Nicholas Brooks, a schematic of the microscope components used during 
micropipette aspiration studies is shown. 
 
  
 P a g e  118 
The pressure manometer, designed and built in-house, was connected to a micropipette holder 
(MPH4, World Precision Instruments). The holder was filled with water and any air bubbles 
excluded. With a water meniscus present on the holder and a buffer solution meniscus on the back 
opening of the micropipette, the pipette was inserted into the holder. The holder was tightened and 
checked to make sure there were no air bubbles before the holder was mounted onto a stage 
micromanipulator unit (three axis water hydraulic manipulators MHW-3, Narishige, Japan). This unit 
allowed the movement of the micropipette to be controlled in 3 directions through use of a joystick.  
4.2.2.2 Aspiration Procedure 
Setting Pressure 
The pressure manometer consists of two reservoirs on separate unislides; the reference reservoir, 
which is open to air and the aspiration reservoir, which is closed. Initially, two different pressures 
must be considered; the system pressure and the sample pressure. The system pressure results from 
the difference in height between the reference and aspiration reservoirs. The sample pressure 
results from the height difference between the two reservoirs and the microscope stage. A LabView 
based software program developed by Dr. Brooks was used to control the position of the reservoirs 
and to measure the system pressure.  
Before aspiration can begin, both the system and sample pressures must be set to zero. First, to 
ensure the system pressure was correctly calibrated, the pressure was set to zero using the LabView 
based program which set the two reservoirs to the same height. A manual dial on the manometer 
moves the level of both reservoirs in unison. Using this dial, the position of both reservoirs was 
altered so that they were positioned above the height of the microscope stage (resulting in positive 
sample pressure). The micropipette was moved to the surface of a glass cover slide, inside a 200 µl 
droplet of GUV sample (All lipids were purchased from Avanti Polar Lipids, USA and giant unilamellar 
vesicles were prepared as described in section 3.2.2.3.). The aspiration reservoir was opened to the 
reference reservoir and the dial of the demodulator adjusted so that the pressure read by the 
software (the system pressure) was zero. The aspiration reservoir was then closed to the reference 
reservoir and the software used to re-adjust the pressure to zero once again. This procedure was 
repeated three times to ensure the system pressure was measured as accurately as possible.  
The sample pressure was then set to zero. With the system pressure still set to zero, the height of 
the reservoirs was adjusted using the manual dial of the manometer. The micropipette was bought 
up to a vesicle with a diameter smaller than that of the pipette, allowing it to enter the pipette 
unhindered. The height of the reservoirs was adjusted until it was observed that the vesicle was 
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under neither positive nor negative pressure. As the experiment is extremely sensitive to pressure 
and is seen to fluctuate, a zero sample pressure is defined as the pressure at which a vesicle is seen 
to oscillate at the pipette mouth.  
With the system and sample pressure now equal, the aspiration pressure of the micropipette 
becomes the system pressure, as controlled by the LabView pressure program. At this point, it 
should be noted that the pressure reading is opposite to the pressure sign i.e. a positive reading 
indicates negative pressure and therefore a positive aspiration pressure will pull a vesicle into the 
micropipette. 
Vesicle Aspiration 
With the aspiration pressure set to zero, the sample was allowed to settle for 10 minutes so that the 
vesicles could sink to the cover slide surface (due to their internal content of 300 mM sucrose). A 
vesicle was then selected for aspiration based upon several criteria; the vesicle must: 
1) Fluctuate, indicating it may be unilamellar; 
2) Be at least twice the pipette diameter, in order for the vesicle to aspirate effectively; 
3) Be free of inclusions; 
4) Be free of membrane tethers. 
The pressure software allows the aspiration pressure to be altered as either a step or ramp function. 
When the step function was used, it was found that the pressure change occurred too quickly and 
that a vesicle under aspiration would rupture at relatively low pressures. The ramp function was also 
found to be unsuitable, on its own, as the vesicle was unable to equilibrate fast enough at higher 
pressures for ramp rates of 0.5 Pa/s or above. Therefore, accurate projection lengths could not be 
measured by this method. Slower ramp rates were attempted but caused pressure oscillations, 
causing the vesicle projection edge to oscillate substantially. This would destabilise the vesicle, 
either disrupting the projection edge or causing the vesicle to rupture. The ramp function was 
therefore used with equilibration steps added. 
First, an image of the chosen vesicle was taken with the CCD camera. At zero aspiration pressure, the 
pipette was then bought up to the vesicle and the aspiration pressure increased to 1 or 2 Pa so that 
the vesicle became ‘stuck’ in the pipette mouth. The vesicle was then left for 2 minutes to 
equilibrate and another image taken. Using a pressure ramp of 0.5 Pa/s the pressure was increased 
by 1 Pa. Following a one minute delay, to allow the vesicle to equilibrate, an image was taken and 
the pressure increased again using a pressure ramp. With one minute equilibration steps, images 
were taken at 1 Pa intervals in the 1-20 Pa pressure range. For pressures between 20 and 100 Pa, 
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images were taken every 5 Pa with the equilibration time increased to two minutes; over 100 Pa, an 
equilibration time of three minutes was used with images taken every 10 Pa. The experiment was 
continued until the vesicle ruptured.  
Upon rupture, the aspiration pressure was set to -50 Pa, to expel membrane fragments. Before 
another vesicle was selected, the aspiration pressure was set to zero and the sample pressure 
adjusted back to zero if necessary. Another vesicle was then aspirated as above. Due to potential 
complications arising from evaporation, no more than two vesicles were aspirated from a single 
droplet.  
4.2.3 DATA EXTRACTION 
A suite of programs has been developed by Dr Nicholas Brooks to extract the data on the vesicle 
area and tension from the microscope images taken during an aspiration experiment. These 
programs were all written using LabView 8.5 and Vision 8.5 (National Instruments). The image 
acquisition software of the microscope produces a text file containing both the image filename and 
the pressure at the time the image was recorded. Using the first of Dr. Brooks’ programs, the Tiff 
image files and the text file for a given vesicle were converted into one avi movie file.  
This movie file was then analysed using the second program; called BMM Integration. With this 
program, a horizontal and vertical region is selected from one movie frame, along with the pipette 
edge. Five aspects of an image are evaluated by this method (Figure 4.5). Integration of the vertical 
region of the image shows the position of the top and bottom of the external vesicle sphere, the 
pipette edge region accounts for pipette movement during the experiment and the horizontal 
integration tracks the back edge of the vesicle and the projecting vesicle edge. 
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Figure 4.5 The BMM Integration program developed by Dr Brooks uses the LabView and Vision 8.5 software to 
integrate each frame of the aspiration movie file. Three integration boxes are set to assess five features of each 
frame. The red box is set as the horizontal integration and is used to track the back edge of the vesicle (exterior 
to the pipette) and the projection edge (inside the pipette). The vertical integration in yellow, tracks the top and 
bottom edge of the external section of the vesicle. Finally, the pipette edge is tracked to allow for pipette 
movement during the experiment, the integration box is shown in green. 
The BMM Integration program integrates each frame of the movie based upon the integration 
region set in this initial frame. The program allows the peaks within the integration profile, which 
represent each of the edges, to be tracked from one frame to the next (Figure 4.6). The pixel 
position of the edges, along with the aspiration pressure, is extracted from each frame and used in 
the last program of the suite. 
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Figure 4.6 This figure shows a screen shot of the BMM Integration program developed by Dr Brooks using the 
LabView and Vision 8.5 software. In the top left corner is shown the horizontal integration of a movie frame. 
The frame number, aspiration pressure and movie file name are also shown in this corner. In the top right 
corner are the three integration profiles of this frame, from the set integration regions. From left to right, the 
horizontal integration showing the back and projecting edge of the vesicle (circled in red). The next integration 
profile shows the top and bottom edge of the vesicle, circled in yellow. Finally the pipette edge region is 
integrated, circled in green. Specific regions of these profiles can be analysed to find peak positions and these 
are shown in the five windows across the bottom of the program window. Again left to right these are the back 
edge of the external vesicle section, the pipette edge, the vesicle projection edge, the top and bottom of the 
external vesicle section. 
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In the final program (Show Data), the data is presented as a series of pixel vs. pressure plots, one for 
each of the five edges described above (Figure 4.7). One frame of the movie under analysis is chosen 
as a reference frame. This is usually the final frame of the movie (before vesicle rupture) as the 
projection length is at its greatest. Using LabView Vision, the visual position of the projecting edge in 
this frame is marked. The height and width of the external vesicle section in this frame is then 
entered into the program. Using the initial image of the vesicle, the radius of the vesicle under zero 
tension is entered to provide a value for 4e5X, and the magnification used during the experiment is 
entered to allow all of these measurements (which currently have pixel units) to be converted to 
microns. The relative positions of the edges are used and any variation in the pipette position is 
taken into account, allowing the projection length and vesicle size to be calculated more accurately. 
The frame area (4e) of the vesicle at each pressure is calculated by the program using Equations 4.3 
to 4.5, and the frame tension () using Equations 4.5 and 4.9. The program therefore outputs a 
frame tension (mN/m) vs. frame area (µm2) plot for the vesicle, over the whole aspiration 
experiment.  
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Figure 4.7 Using the BMM Integration program, the peak position of the projection, back, top, bottom and 
pipette edges were extracted for each movie frame. The screen shot here is of the Show Data program 
(developed by Dr. Brooks) which presents the position of each edge (in pixels) as a function of pressure (Pa). The 
program allows one frame of the movie to be selected and used as a reference frame. Once the magnification 
used is also entered, the program converts the aspiration data into a frame area (µm2) vs. frame tension 
(mN/m) plot. This final plot is exported to Microsoft Excel for final analysis. 
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4.2.4 DATA ANALYSIS 
Final data analysis was performed by exporting the frame area vs. frame tension data to Microsoft 
Excel. In order to evaluate the data, approximate values for both the bending rigidity and area 
expansion moduli were first found using the flaccid and tense regime equations described in section 
4.1.3. In the flaccid regime, using Equations 4.6 and 4.10, it can be seen that 4e varies as a function 
of dz(): 
 4e  4e5X 9 dz()vxw  = Equation 4.13 
Therefore, a linear fit of the first few data points of a dz() vs. 4e data plot gives an approximate 
value for the bending rigidity as the intersect of this line is 4e5X and the gradient is 4e5X vxw .  
For an initial value of the area expansion modulus, the tense pressure regime equation was used. 
From Equations 4.6 and 4.11, it can be seen that a linear fit to the high pressure data points of a τ vs. 
4e plot gives an axis intersection at 4e5X and a gradient of 4e5X +U  : 
 4e  4e5X  +U((((   Equation 4.14 
As already stated in section 4.1.3.3, taking 4e5X  4 allows the frame tension (τ) to be identified 
with the surface tension (σ). The values of the moduli obtained above were used to calculate a 
theoretical frame area for each tension value, based upon Equation 4.15 (which comes from 
substituting Equation 4.6 into Equation 4.12): 
 4e  4 9 dz()vxw  +U((((  = Equation 4.15 
The frame area data calculated from Equation 4.15 was plotted against the experimentally obtained 
data and the data sets compared using a nonlinear least square fit. Using the Solver application of 
Microsoft Excel, 4, κA0 and +U were varied to minimise the sum variance, producing a curve of best 
fit for the experimental data with known moduli values (Figure 4.8). 
 P a g e  126 
 
Figure 4.8 An example of the experimental data yielded from micropipette aspiration of a DOPC vesicle is 
shown in blue. The frame area vs. surface tension relationship was then calculated using Equation 4.15 and 
approximate values for the bending rigidity and area expansion moduli found. Using a nonlinear least square 
fit, the moduli and initial area values were altered to improve the fit of the calculated data curve to the 
experimental data. In this example it was found that the calculated curve best fit the experimental data (sum 
variance 699.3 (1 d.p)) when A0 was set at 5250.2 µm
2, Ka at 276.2 mN/m and κ to 3.5 kBT. 
  
 P a g e  127 
4.3 RESULTS AND DISCUSSION 
4.3.1 DOPC AND DI-ETHER PC MICROPIPETTE ASPIRATION STUDIES 
GUVs used for aspiration studies are most commonly formed using a swelling method as some 
researchers believe that electroformation causes defects in the vesicle bilayer, altering the 
membrane properties(314). The ester linkages of DOPC are susceptible to hydrolysis, degrading DOPC 
into 18:1 lysoPC (1-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine) and oleic acid. It is possible that 
the application of an electric field to a DOPC film increases the rate of degradation, resulting in the 
presence of significant amounts of the lysoPC and fatty acid in the GUV bilayer. This action is 
analogous to the role of the enzyme PLA2 in vivo. Computer simulations
(315) of the affects of PLA2 on 
the elastic moduli reveal that these moduli decrease in value with increasing enzyme activity. This 
would therefore suggest that if electroformation does cause lipid degradation, the moduli values 
found would be lower than the true value for a DOPC bilayer. However, despite numerous attempts, 
it has not been possible to form giant unilamellar vesicles containing SNARE protein by a swelling 
method. Despite the possible complications arising from lipid degradation, the aspiration studies 
discussed in this chapter have therefore been conducted on GUVs formed by electroformation. 
In order to assess the possible impact of the use of electroformation, a micropipette aspiration study 
of DOPC GUVs prepared by this method has been conducted. The membrane moduli values obtained 
can be compared to the published work of Rawicz and Evans who formed GUVs by a swelling 
method and found the elastic moduli values using micropipette aspiration(306). An aspiration study of 
di-ether PC vesicles (again prepared by electroformation) has also been conducted. Di-ether PC has a 
similar structure of DOPC but with the ester linkages replaced by ether links (Figure 4.9); it is 
therefore not able to hydrolyse easily at this position. There is no comparative data for the 
membrane properties of ether-linked DOPC; however, many studies have been performed on DPPC 
(1,2-dipalmitoyl-sn-glycero-3-phosphocholine) and its ether analogue DHPC (1,2-di-O-hexadecyl-sn-
glycero-3-phosphocholine). Comparisons of these two lipids show that the bilayers they form have 
the same membrane thickness, packing and lipid conformation (within experimental error) when in a 
fluid phase(316). This may suggest that the elastic moduli values of the two lipids are similar. However, 
the bending rigidity of DHPC has been found to be lower than that of DPPC at 0.42 ± 0.07 x10-19 J 
(≈10 kBT) and 0.67 ± 0.07 x10
-19 J (≈16 kBT) respectively
(317). 
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Figure 4.9 Di-ether PC is an ether-linked version of DOPC and the differences between the two structures is 
highlighted in red. The ester linkages of DOPC make it susceptible to hydrolysis, upon which it breaks down into 
18:1 lysoPC and oleic acid. Electroformation may increase the degradation of DOPC, altering the membrane 
properties compared to vesicles formed by a swelling method. Di-ether PC, with its ether link does not hydrolyse 
at this position easily and therefore should not degrade readily during electroformation. 
The bending rigidity (κ) and area expansion (+U) moduli values found by the aspiration of 24 vesicles 
composed of DOPC and prepared by electroformation are shown in Figure 4.10. To best present the 
data, the area expansion values are shown in ascending order with the bending rigidity of the 
corresponding vesicle shown directly below. The average moduli values from these vesicles were 
found to be 13.4 ± 2.00 kBT (3sf) for the bending rigidity modulus and 147 ± 22.3 mN/m (3sf) for the 
area expansion modulus (the error quoted in each case is the standard error). Rawicz and Evans(306) 
micropipette aspiration study found a bending rigidity of 0.85 ±0.10 x10-19 J (≈ 21.25 ±2.5 kBT) and 
area expansion modulus of 265 ± 18 mN/m for +U at 18°C.  
Focussing on the area expansion data (Figure 4.10A); it appears that the vesicles may belong to as 
many as four discrete groups with the +U values stepping up significantly from 19.7 to 46.8, 62.9 to 
116 and 119 to 194 mN/m. One of the criteria for choosing a vesicle is that it fluctuates, increasing 
the probability that the vesicles chosen are unilamellar. However, vesicles can still fluctuate if the 
number of bilayers is low and aspiration of these vesicles gives rise to moduli values which are 
multiples of the unilamellar values. If the grouping seen in this study represents results from 
multiple bilayer vesicles then the lowest value group would represent unilamellar vesicles. Visually, 
it would appear that this group contains five vesicles (21% of the total studies) and has an average 
area expansion modulus of 9.71 ± 3.57 mN/m (3sf). The highest value group contains 50% of the 
vesicles with a group average of 248 ± 9.77 mN/m (3sf). The difference in the average value of these 
two groups would suggest that the vesicles of the high value group contain approximately 25 
bilayers, a number making vesicle fluctuation unlikely. In addition, the bending rigidity data does not 
suggest the presence of multiple bilayers. As stated above, the literature value is 265 ± 18 mN/m 
and is therefore consistent with the latter group average. As already stated, hydrolysis of DOPC 
would be expected to lower the elastic moduli as is seen for the PLA2 enzyme. Therefore, these 
lower values are more likely to reflect DOPC degradation, due to the preparation method used. 
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Figure 4.10. The membrane properties of a DOPC bilayer were investigated by the micropipette aspiration of 24 
vesicles. Figure A shows the area expansion modulus of each vesicle, in ascending order. The red line shows the 
overall average value of this modulus; 147 ± 22.3 mN/m (3sf). The group indicated by ♦ represents vesicles 
without significant lipid degradation and has an average value of 248 ± 9.77 mN/m (3sf); shown by the green 
line. Figure B shows the bending rigidity of each vesicle (corrsponding to the area expansion modulus above) 
with the average value line (red) at 13.4 ±2.00 kBT (3sf). The average value based on only the ♦ group is 14.9 
±3.57 kBT (3sf). The error quoted is the standard error.  
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Micropipette aspiration of vesicles composed of di-ether PC gave an average bending rigidity 
modulus of 14.6 ± 4.68 kBT (3sf) and an area expansion modulus of 232 ± 25.5 mN/m (3sf; Figure 
4.11). Unlike the+U data of DOPC, the di-ether PC data shows no extremely low values of this 
modulus or obvious grouping. This would further suggest that some vesicles in the DOPC study had 
significant levels of lipid degradation. In order to assess the+U of DOPC bilayers, the vesicles with 
extremely low values should therefore be excluded. The largest data group for DOPC also represents 
the vesicles with the largest+U values. Here it is hypothesised that this group does not contain 
significant levels of lipid degradation. Given this hypothesis, the bending rigidity and+U values for 
DOPC should be taken from this group giving moduli values of 14.9 ± 3.57 kBT (3sf) and 248 ± 9.77 
mN/m (3sf) respectively. 
From the DOPC and di-ether PC aspiration studies, it is clear that using the electroformation method 
produces some GUVs with significantly lower +U. No considerable differences were seen for the 
value of the bending rigidity. This is unexpected as it too would be expected to be lower. A reduction 
in this value may be masked by the large experimental error associated with the bending rigidity 
data. It would be preferable to use a swelling method to form GUVs where possible. As already 
stated, GUVs containing SNARE proteins could not be produced using swelling. Electroformation has 
therefore been used for all the aspiration studies discussed in this chapter, allowing data to be 
directly compared. The influence of lipid degradation on the results however, is also discussed. 
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Figure 4.11. The membrane properties of a diether-PC bilayer were investigated by the micropipette aspiration 
of 8 vesicles. Figure A shows the area expansion modulus of these vesicles, in ascending order. The red line 
indicates the average value of this modulus; 232 ± 25.5 mN/m (3sf). Figure B shows the bending rigidity of each 
vesicle (corresponding to the area expansion modulus above) with an average value of 14.6 ± 4.68 kBT (3sf). 
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4.3.2 SNARE PROTEIN MICROPIPETTE ASPIRATION STUDIES 
To investigate the impact of inserting the v-SNARE protein VAMP2 into a membrane, a micropipette 
aspiration study of 19 DOPC vesicles containing VAMP2 (1:300 protein: lipid molar ratio) was 
conducted. A bending rigidity modulus of 5.32 ± 0.81 kBT (3sf) and an area expansion modulus of 143 
± 7.06 mN/m (3sf) were found (Figure 4.12). Unlike the +U data for DOPC, the data for VAMP2 does 
not appear to form discrete groups or contain low values (the +U values ranged from 88.1 to 206 
mN/m). This would suggest that the GUVs aspirated did not contain significant levels of degradation 
products.  
The aspiration of 33 vesicles composed of DOPC containing the t-SNARE proteins Syntaxin 1A and 
SNAP-25 (0.5: 0.5: 300 Syx 1A/SNAP-25/DOPC) found κ to be 8.13 ± 1.42 kBT (3sf) and +U to be 366 ± 
37.1 mN/m (3sf; Figure 4.13). Like the DOPC data, the presence of low values of +U suggests that 
some of the aspirated vesicles contained significant amounts of lipid degradation product. The 
highest values obtained for the +U were 733 and 799 mN/m (3sf) and the vesicles with these values 
also had the highest bending rigidity values (30.8 and 37.4 kBT respectively). As both elastic moduli 
values are significantly higher than the remaining data, these two vesicles may contain multiple 
(most likely two) bilayers and were therefore excluded from further analysis. The highest value 
group of the remaining data contains 18 vesicles (55% of the total studies). Like the DOPC study, this 
group is hypothesised to represent vesicles without significant lipid hydrolysis. Therefore, the 
average moduli values for this group are thought to provide values that better represent the effect 
of t-SNARE insertion on DOPC bilayers compared with the total averages. The +U average of this 
group was found to be 493 ± 6.00 mN/m (3sf) and κ to be 8.30 ± 1.15 kBT (3sf). 
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Figure 4.12 The membrane properties of a DOPC bilayer containing the SNARE protein VAMP2 (1:300 protein: 
lipid molar ratio) was investigated by the micropipette aspiration of 19 vesicles. Figure A shows the area 
expansion modulus of these vesicles, in ascending order. The red line indicates the average value of this 
modulus; 143 ± 7.06 mN/m (3sf). Figure B shows the bending rigidity of each vesicle (corresponding to the area 
expansion modulus above) leading to an average value of 5.32 ± 0.81 kBT (3sf). 
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Figure 4.13 The membrane properties of a DOPC bilayer containing the t-SNARE proteins Syntaxin 1A and 
SNAP-25 (1:1 protein molar ratio, 1:300 total protein: lipid ratio) was investigated by micropipette aspiration of 
33 vesicles. Figure A shows the area expansion modulus of each vesicle, in ascending order. The black line 
shows the overall average value of this modulus; 366 ± 37.1 mN/m (3sf). The group indicated by ♦ represents 
vesicles which are believed to be unilamellar with no significant levels of lipid degradation; the average value of 
this group is shown by the green line and is 493 ± 6.00 mN/m (3sf). Figure B shows the bending rigidity of each 
vesicle (corrsponding to the area expansion modulus above) with the average value line (black) at 8.13 ±1.42 
kBT (3sf). The average value based on only the ♦ group is 8.30 ± 1.15 kBT (3sf). 
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4.3.3 EFFECT OF SNARE PROTEIN INCORPORATION 
Table 4.1 shows the moduli values for each vesicle composition. In each case the average of all data 
obtained is given, however, for the DOPC and t-SNARE samples it is hypothesised that lipid 
degradation affected the study and therefore a group average value is also given, where the selected 
vesicle population is not believed to contain significant amounts of these degradation products. 
Composition 
Total Average Selective Population Average κ, kBT (1 d.p.)  mN/m (3sf) κ, kBT (1 d.p.)  mN/m (3sf) 
DOPC 13.4 ± 2.00 147 ± 22.3 14.9 ± 3.57 248 ± 9.77 
Di-ether PC 14.6 ± 4.68 232 ± 25.5 - - 
VAMP2: DOPC (1:300) 5.32 ± 0.81 143 ± 7.06 - - 
t-SNARE: DOPC (1:300) 8.13 ± 1.42 366 ± 37.1 8.30 ± 1.15 493 ± 6.00 
Table 4.1 
For model lipid systems in a fluid phase, the bending rigidities are expected to be of the order of 10 
kBT
(318), consistent with the data found in this study. Accurate calculation of the bending rigidity 
modulus requires small pressure changes at very low aspiration pressures. The micropipette 
aspiration equipment used, and the error on the aspiration pressure (± 1 Pa), makes this difficult to 
achieve and a large error is associated with the values found for this elastic modulus. While it cannot 
be stated conclusively, it is possible that the bending rigidities of membranes containing SNARE 
proteins are lower than that of the pure lipid bilayer (whether considering the total or selective 
average values). 
In section 1.4.1 membrane dimpling was discussed. As the SNARE complexes form and the 
membranes are brought closer together the SNARE proteins are forced to bend, applying a force to 
the membrane; causing it to dimple. This process is thought to be essential in lowering the inter-
membrane distance, allowing stalk formation to occur. A reduction in the bending rigidity due to the 
presence of SNARE proteins would decrease the energy needed to buckle the membranes. In 
addition, at other stages of the fusion process VAMP resides at the Golgi complex and plasma 
membrane. At both of these sites VAMP2 is incorporated into budding vesicles. Again, this requires a 
deformation of the bilayer and a reduction in the bending rigidity would lower the energy required. 
It would therefore be expected from these findings that VAMP2 would promote vesicle budding and 
that this protein and the t-SNARE proteins would promote fusion (at least to the hemifusion stage). 
It can be seen that the area expansion modulus value of liposomes containing VAMP2 is the same 
(within error) as the total average for the pure DOPC sample. While lipid degradation cannot be 
ruled out for the VAMP population, the data suggests that this was not present at significant levels in 
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the vesicles aspirated. The DOPC study did show lipid degradation and therefore comparing the 
VAMP2 data with the selective DOPC population data is more appropriate. It can be seen from this 
comparison that VAMP addition reduced the area expansion modulus. This indicates that the 
membrane becomes easier to stretch and like the change in the bending rigidity, would be expected 
to make membrane dimpling easier. It has been shown that the +U can be approximately related to 
the bending rigidity and the membrane thickness by the following expression(318): 
 +U    Equation 4.16 
Where  is the membrane thickness and  is a numerical constant (this is normally represented by α 
but has been changed to prevent confusion with its use in this chapter for relative area). The +U 
value of liposomes containing VAMP2 is approximately 58% that of the pure lipid vesicles. A rough 
calculation based upon Equation 4.16 shows that if the fall in +U was due only to the reduction of 
the bending rigidity then κ would have to fall to approximately 8.59 kBT, much higher than the 
experimental value found. However, in Chapter 3 it was hypothesised that the increase in the 
relaxed curvature of GUVs containing this protein was caused by thinning of the bilayer due to the 
hydrophobic mismatch of the protein transmembrane domain and lipid bilayer thickness. It was 
approximated in section 3.4 that the DOPC bilayer would have to reduce from 35 to 30 Å to 
accommodate the transmembrane region of a VAMP2 protein molecule. Assuming this to be true, it 
can be estimated that with a thickness of 30 Å, the bending rigidity of the bilayer would have to be 
6.31 kBT to result in the +U  found. This is only 0.18 kBT higher than the error range of the 
experimental value found and suggests that the hypothesis still stands.  
For the t-SNARE liposomes a comparison of the selective liposome population data with the selective 
population data for DOPC shows that the +U doubles due to presence of the proteins (the t-SNARE 
value is 199% the DOPC value). An increase is also clearly seen in a comparison of the total data 
averages.  Using the same approach as in the previous paragraph it can be seen that without a 
change in the bending rigidity, the bilayer would have to thin to ≈25 Å. Without each monolayer 
curving significantly to enable the headgroups to stay closely packed, the chain splay required to thin 
the bilayer by such a large amount would likely expose the hydrophobic regions to water. Unlike 
VAMP2, it is not expected that insertion of the Syntaxin 1A transmembrane domain will cause 
hydrophobic mismatch. Therefore, assuming no change in the membrane thickness, the bending 
rigidity would have to increase to ≈29.6 kBT to account for the increase in the area expansion 
modulus. This value lies significantly outside the error margin of the result shown in Table 4.1. From 
the results of this chapter it is suggested that t-SNARE insertion decreases the membrane bending 
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rigidity. It would appear that the relationship between the +U and the bending rigidity in this case 
does not match Equation 4.16. 
Another explanation for the results seen due to t-SNARE insertion is that these proteins interact to 
form interconnected protein complexes. The two SNARE motifs from SNAP-25 and the motif of 
Syntaxin 1A form a complex in vivo, along with a ‘place holder’ protein such as Tomosyn (see section 
1.5.5) which acts as an intermediate structure in the membrane fusion mechanism. The lack of 
chaperone proteins like Tomosyn in this in vitro experiment prevents precise control of t-SNARE 
complex formation. In vitro studies have shown that it is possible to form SNARE complexes 
composed of only Q-SNARE proteins (section 1.2.3.4) and it can be imagined that the t-SNARE 
proteins are able to interact in a variety of ways; as illustrated in Figure 4.14. As SNAP-25 has two 
SNARE motifs, it is possible that one SNAP-25 molecule participates in two separate complexes. This 
would result in a non-specific aggregated structure which could surround the lipid bilayer and alter 
the elastic moduli. It is possible that the high curvature found in chapter 3 is also due to this protein 
structure. The presence of such an aggregate during electroformation would be expected to increase 
the energy required to form vesicles from the lipid film, reducing the average size of the giant 
unilamellar vesicles over the time of the growing procedure. 
Unfortunately the presence of such aggregates may mean that the protein density is higher in the 
vesicles than the 1:300 ratio used in preparation. However, it is not thought that the density is vastly 
greater as electroformation was not possible when a 1:60 ratio was used in the VAMP2 studies of 
chapter 3. Also, high protein density is associated with leaky vesicles. These would be expected to 
rupture at lower aspiration pressures due to their instability but no differences were observed 
between the pressures at which these vesicle ruptured compared with that of the pure DOPC, di-
ether PC or VAMP2 containing vesicles. Equally the aggregation may result in lower protein: lipid 
ratios (as more protein would be left on the glass substrate during electroformation) but if this was 
the case then the true impact of the t-SNARE proteins on the elastic moduli must be even greater 
than that observed in this study. 
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Figure 4.14 The wild-type intermediary complex has a 1:1 stoichiometry of Syntaxin 1A and SNAP-25 with a 
placeholder protein such as Tomosyn providing the additional amphipathic helix required. Without regulatory 
proteins such as Tomosyn several t-SNARE complexes could form during in vitro experiments.  SNAP-25 (shown 
in green) contains two SNARE motifs and it can be imagined that one SNAP-25 molecule could participate in 
two separate complexes, thereby linking them. Depending on the t-SNARE protein ratio and the amount of 
cross-complex involvement by SNAP-25 it can be seen that complexes could form into lines or even an 
interconnected structure.  Ascending through the figure, the number of interconnected complexes increases 
and an interconnected aggregate structure can form while preserving the 1:1 SNAP-25: Syntaxin 1A ratio. All of 
these structures are anchored to the lipid bilayer by the transmembrane domain (yellow) of Syntaxin 1A (red). 
 P a g e  139 
The insertion of the t-SNARE proteins may not directly increase the rigidity of the membrane. If the 
aggregation structure is interconnected and covers the vesicle surface then the +U would increase as 
energy would be required to stretch and/or pull apart the proteins in addition to the energy 
requirements of stretching the lipid bilayer itself. The +U is therefore an indication of the strength of 
the protein aggregate. The aggregate formed by the t-SNARE proteins is linked together through the 
formation of Q-SNARE complexes and therefore it would be these complexes that need to be pulled 
apart during aspiration. The wild-type SNARE complex (VAMP2, SNAP-25 and Syntaxin 1A) is one of 
the strongest protein complexes known with a stabilisation energy of 35 kBT for the partially folded 
complex(85) but the Q-SNARE complex would not be expected to be as strong. Assuming the area 
expansion modulus of the lipid bilayer is equal to the pure lipid system this would give a +U value for 
the protein aggregate of 245 mN/m (DOPC 248, t-SNARE 493 mN/m). Making a further assumption 
that the protein: lipid ratio remains 1:300 ratio, as used during preparation, this would equate to a 
protein density of 1.89 x1020 proteins/m2. From these values, the energy required by break each Q-
SNARE complex would be 1.2 kBT. However, this assumes that it is necessary to break every Q-SNARE 
complex before the bilayer could stretch, which is unlikely; making the true energy required to break 
a Q-SNARE complex much higher. 
It has been hypothesised that SNARE complexes form a ring surrounding the membrane fusion site 
and therefore the strength and flexibility of this collar, as well as individual SNARE complexes is an 
important consideration. While in this study it is thought that SNAP-25 interlinks Q-SNARE 
complexes, it is unlikely that this occurs to form a ring of complexes in vivo. No such structures have 
ever been observed and there are no known proteins that could orchestrate the formation of such a 
structure. The complexity of the recycling mechanism by NSF/α-SNAP (see section 1.5.6) would also 
vastly increase. Some evidence suggests that the transmembrane domains of Syntaxin interact with 
each other, allowing the ringed structure to form. The strength of the aggregate in this study reflects 
the known stability of SNARE complexes in vivo. However, the bending rigidity found also suggests 
that the complexes are flexible as otherwise the rigidity in the presence of such an interconnected 
structure would be expected to be greater, not equal or lower than the rigidity of a pure lipid 
bilayer. A ringed structure would provide a scaffold that is therefore strong but flexible. 
As discussed throughout this thesis, membrane tension is seen as an essential requirement in the 
formation of fusion pores. Studies using theoretical modelling(113, 130), computer simulations(131) and 
experimental studies(129) have highlighted its importance in the fusion mechanism. In addition, 
studies have been conducted on the kinetics of phase transitions in bulk mesophases(319). Transitions 
between a fluid lamellar phase (a bulk mesophase in which bilayers are stacked) and a bicontinuous 
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cubic phase (interconnected sponge-like structures containing two distinct water channels) are 
thought to proceed via stalk-like structures, making such studies relevant to membrane fusion. It has 
been shown by such work that tension promotes the phase transition, suggesting that it drives the 
formation of these stalk-like intermediates. As well as tension, the computer simulations also 
hypothesise that membranes must be pulled sharply. Several researchers have proposed that the 
trans-SNARE complex provides a pulling force which induces fusion(114, 320, 321); though it is still unclear 
whether this is required for the hemifusion step, fusion pore step or both. 
If a ring of SNARE complexes does form around the fusion site then it would be conceived that a 
reduction in the bending rigidity would allow the membrane to dimple more easily. This would 
reduce the membrane separation. The interaction of the SNARE transmembrane domains in the 
formation of this ringed structure would also restrict lipid movement and such dimpling may 
therefore increase membrane tension. As discussed in the previous paragraph this would promote 
stalk formation. These affects may be sufficient to allow the bilayers to undergo hemifusion. During 
these processes, the SNARE complexes must be strong enough to overcome the repulsive forces 
associated with the close proximity of the membranes. 
A pulling force could be applied by a change in the conformation of the complexes. A recent AFM 
study(322) presented evidence that the formation of the trans-SNARE complex has two distinct energy 
barriers. The first, which they call the outer barrier, must be overcome for unbound SNARE proteins 
to form an intermediate complex structure (this may represent partial zipping). The second or inner 
barrier is much larger and governs the transition from this intermediate state to the fully formed 
trans-SNARE complex. As discussed above, a partially folded SNAREpin may be sufficient to induce 
hemifusion. The action potential of neurotransmission (see section 1.1.2) could then trigger a 
change from a partially folded to fully folded SNAREpin (overcoming the inner energy barrier due to 
interactions with regulatory proteins such as Synaptotagmin and Complexin; section 1.5.7 and 1.5.8). 
This could cause the hypothesised ring of complexes to pull on the membrane of the fusion site 
(possibly in the form of a hemifusion diaphragm) from all directions. As the membrane would 
already be under tension, this would lead to the formation of a fusion pore. For this to occur the 
complexes must be strong (to make membrane fusion favourable over complex disassembly) and 
flexible (so that minimal energy is required to change the complex conformation and allowing it to 
occur quickly, resulting in a sharp pull). These characteristics are suggested by the high +U but low 
bending rigidity values found for the t-SNARE liposome population. 
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4.4 CHAPTER SUMMARY 
In this chapter the effects of SNARE protein insertion on the membrane properties of a DOPC bilayer 
have been investigated by micropipette aspiration. It has been shown that GUVs produced by 
electroformation can have lower than expected moduli values and this has been attributed to the 
hydrolysis of the ester linkages of DOPC. Careful analysis of the vesicle data and the use of selective 
vesicle populations have allowed comparisons to be made between the membrane properties of 
pure DOPC vesicles and proteoliposomes. However, it is concluded that a swelling method for GUV 
formation should be used when possible in preference to electroformation. 
The insertion of VAMP2 has been shown to lower the energy of membrane dilation and a reduction 
in the bending energy is also indicated. The data is consistent with the hypothesis posed in Chapter 3 
that the lipid bilayer is forced to thin as a result of hydrophobic mismatch between the length of the 
transmembrane domain of VAMP2 and the width of the lipid bilayer. The lowering of the elastic 
moduli suggests that the energy required to deform lipid bilayers is decreased when VAMP2 is 
present and this may aid both membrane fusion and vesicle budding. 
As in Chapter 3, the interpretation of the data of the t-SNARE liposomes is more challenging. It is not 
thought that hydrophobic mismatch occurs in this case; however, like the insertion of VAMP2, a 
reduction in the bending rigidity may occur. The +U was found to be greater than that of the pure 
lipid vesicles and has been attributed to the presence of an interconnected protein aggregate. The 
higher energy required to stretch the bilayer is thought to be due to the need to break up this 
aggregate. The aggregate is thought to form interconnected Q-SNARE complexes and it is 
hypothesised that the strength and flexibility of the aggregate reflects the nature of wild-type SNARE 
complexes in vivo. It is suggested that these qualities allow a ring of SNARE complexes to put the 
membrane within the fusion site under tension and may induce hemifusion at this point. A 
conformational change in the SNARE complexes then applies a pulling force; inducing fusion pore 
formation. 
 
 P a g e  142 
Chapter 5.  
THE EFFECT OF MEMBRANE PROPERTIES ON LIPOSOME FUSION RATES 
This chapter presents two studies which investigate the affect of membrane composition on 
liposome fusion rates. A lipid fusion assay was employed in which two fluorescently labelled lipids 
which act as FRET (Förster (or Fluorescence) Resonance Energy Transfer) partners were used. These 
lipid probes were NBD-PE (1- oleoyl- 2- [12- [(7- Nitro- 2- 1,3- benzoxadiazol- 4-yl) amino] 
dodecanoyl]- sn- glycero- 3- phosphoethanolamine) and Rh-PE (1,2- dioleoyl- sn- glycero- 3- 
phosphoethanolamine- N- (lissamine rhodamine B sulphonyl) (ammonium salt)) and were 
incorporated into the membranes at 0.5 mol% each. A probe dilution technique was used whereby 
vesicles containing both probes were mixed with non-fluorescent vesicles and the reduction in 
acceptor emission was monitored. 
Two studies were conducted to examine composition affects. The first study investigated the change 
in fusion rates as a result of DOPE addition to DOPC membranes while the second studied the effect 
of cholesterol addition, also to DOPC membranes. The kinetic model proposed by Lee and Lentz(106) 
was used to interpret the data and contains three steps within the fusion process. It was found that 
it was not possible to determine the extent or rate of full-fusion events and a content mixing assay is 
required to provide additional information for this step. The initial, reversible step of non-fusion lipid 
transfer was found in both studies to be independent of membrane composition and to also 
contribute to less than 10% of the acceptor emission reduction. It was found that only the middle 
step which relates to hemifusion of the liposomes was dependent membrane composition.  
The addition of either DOPE or cholesterol resulted in an increase of the rate of hemifusion as well 
as the amount of hemifusion compared to non-fusion lipid transfer. For the DOPE study the rate of 
hemifusion rose continually with its addition. The rate of hemifusion for the cholesterol study were 
higher than those of DOPE but the rate reached a plateau with the addition of approximately 10 
mol%  cholesterol. The rate increases are thought to be due to changes in both the curvature free 
energy of the initial vesicles and the energy required to form the intermediate structures i.e. the 
stalk and hemifusion diaphragm. For DOPE, the spontaneous curvature is the dominating influence 
and thought to promote fusion by lowering the activation energy. For cholesterol, the spontaneous 
curvature also promotes fusion. However, at higher mol% the stiffening of the membrane by 
cholesterol hinders fusion by increasing the amount of energy required to form the intermediate 
structures. 
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5.1 INTRODUCTION 
Increasingly, the functions of membrane proteins are being explored using in vitro assays where the 
protein is placed in a lipid environment. However, it is now widely accepted that lipids provide more 
than just a structural framework for proteins to function, with lipid properties affecting protein 
characteristics such as binding affinity and conformation(70, 323, 324). This poses an interesting problem 
whereby the results of these assays are affected not only by the proteins but also the choice of 
lipids. Commonly, a natural lipid extract is used to provide an environment similar to that of the 
protein in vivo. However, the lipid composition of a particular membrane in vivo is dynamic and 
while perhaps better than using a synthetic mixture, the lipid composition may still skew the assay 
results compared to actual biological processes.  
The exact role of SNARE proteins in the fusion mechanism has been explored by several researchers 
using lipid mixing assays(38, 216, 325). These assays usually contain several controls in which protein-free 
and single protein containing membranes are compared to assays in which mixed membrane 
populations are used (i.e. v-SNARE liposomes mixed with t-SNARE liposomes). Typically the rate and 
extent of fusion are monitored, but the results found vary widely with some researchers observing 
only hemifusion and others recording full fusion events. These and other researchers(326) have also 
used liposomes to explore the effect of calcium introduction on fusion rates and again the results 
vary; often with contradiction. The variation seen may result partly because of differences in the 
lipid environment. 
The work presented in Chapter 3 and Chapter 4 found that SNARE proteins significantly alter 
membrane properties. The changes observed in fusion assays may in part be due to this and it is 
important to ascertain the proportion of the changes that are due to membrane energetics and the 
portion contributed by more active protein functions such as SNARE complex formation.  Clearly 
some of this information can be extracted from comparisons of single protein studies with the 
studies containing the full complement of proteins. But several questions arise when considering the 
lipid-protein relationship. Firstly, is it actually possible to decouple the effects of altered membrane 
properties from protein functions? Part of the protein’s function may be to alter lipid properties 
leading to the promotion of a particular event. Have proteins evolved so that they are designed for 
particular lipid environments (lowering the energy associated with its presence and providing some 
spatial selectivity) or does the lipid composition alter due to a protein’s design? In order to begin 
answering these questions for the SNARE proteins, the relationship between membrane properties 
and fusion rates must be explored and the studies presented in this chapter aim to investigate this. 
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5.1.1 LIPID MIXING ASSAYS 
FRET is a widely used technique in both the physical and life sciences. In FRET, energy is transferred 
from the excited state of one fluorophore (the donor) to another excited state fluorophore (the 
acceptor) without the appearance of a photon(327). Providing the spectral overlap integral J(λ) is 
sufficient, FRET can occur; but it is distance dependent (Figure 5.1).  
 
Figure 5.1 When the emission spectrum of one fluorophore overlaps with the excitation spectrum of another, 
FRET can occur (figure A). The spectral overlap integral J(λ) indicates the degree of spectral overlap and 
consequently the efficiency of FRET. When the spectra overlap, the energy of the donor fluorophore (in an 
excited state) can transfer to the excited state of the acceptor fluorophore. Relaxation of the acceptor to the 
ground state results in the release of a photon. A Jablonsky diagram of this process is shown in figure B. 
The rate of FRET, +P() is given by: 
 +P()   ;: <
c
 Equation 5.1 
The equation shows that the rate of FRET depends on the Förster distance (R0), the decay time of the 
donor in the absence of the acceptor, , and the distance between the FRET partners, . The 
Förster distance of a fluorophore is the distance at which the efficiency of energy transfer is 50%. As 
well as J(λ), the Förster distance depends on the quantum yield of the donor and the orientation of 
the fluorophore dipoles with respect to each other. R0 of a fluorophore is typically 10-100Å and 
therefore the donor and acceptor dyes must be at a distance below this for FRET to occur efficiently. 
The Förster distance is characteristic of the FRET pair being used and the decay time of each donor 
fluorophore is also specific. The FRET efficiency can be expressed as: 
     ( : )c Equation 5.2 
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During typical experiments, the only factor to change (and therefore altering the rate and efficiency 
of FRET) is the distance between the fluorophores. The power six dependence on the dye separation 
means that acceptor emission rapidly fades as it increases above R0 and makes the technique highly 
sensitive to distance variations. 
The lipid mixing fusion assay combines two populations of vesicles and monitors fusion through the 
use of FRET. There are two alternative methods; probe mixing and probe dilution(328). The former 
mixes vesicles containing the acceptor probe with vesicles containing the donor probe. As vesicle 
fusion occurs FRET is seen to increase. The second method is probe dilution and mixes labelled 
vesicles (which contain both fluorophores) with unlabelled vesicles. As these vesicles fuse, the 
percentage of lipid probe in a membrane decreases (increasing dye separation) causing a decrease in 
FRET efficiency (Figure 5.2). Thus, the fusion of vesicles can be monitored by measuring the decrease 
in emission from the acceptor molecule over time. Alternatively, the increase in donor emission can 
be monitored. The probe dilution method is preferable to probe mixing as it has been shown that 
probe mixing is sensitive to vesicle aggregation causing over reporting of fusion events(329). Probe 
dilution is affected by probe transfer across the solution but, providing that the fluorescent lipid 
probes used have sufficiently long hydrocarbon chains (above 16 carbons in length); this type of lipid 
transfer is negligible(328). 
 
Figure 5.2 Lipid mixing assays can be conducted using probe dilution or probe mixing. This figure shows probe 
dilution which, unlike probe mixing, is insensitive to vesicle aggregation. The FRET partners are inserted into 
one vesicle population and mixed with an unlabelled vesicle population. The labelled vesicles initially give rise 
to high acceptor emission (red). Fusion of vesicles from each population results in increased dye separation, 
leading to a reduction in FRET and therefore a fall in the accepter emission and an increase in donor emission 
(yellow). 
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5.1.2 CONTENT MIXING ASSAYS 
While lipid mixing fusion assays can be used to report fusion events, it is not always possible to 
distinguish adequately between hemi-fusion and full fusion events. In a hemi-fusion event the 
proximal leaflet of each liposome fuses together, for a probe dilution assay this causes increased dye 
separation and therefore a reduction in FRET. Full fusion, when the distal monolayers fuse, causes 
further probe dilution and the content of the vesicles mix. On a single vesicle pair basis it would be 
possible to distinguish between the two fusion events by monitoring a step-wise reduction in the 
FRET signal. However, fusion assays are most commonly global experiments which monitor 
thousands of vesicles at one time. In order to distinguish between these two fusion events it is 
usually necessary to also use a content mixing reporter either in a combined assay or as separate 
studies.  
There are two principal methods used for content mixing fusion assays(330) (Figure 5.3). The first uses 
two separate chemicals, each enclosed in a vesicle population. Upon full fusion of a vesicle from 
each population, the two chemicals mix, resulting in a change in the fluorescence. There are several 
examples of this assay type but the most rigorously examined (for reliability) are the use of Tb 
(terbium) with DPA (Dipicolinic Acid) or ANTS (Aminonaphthalenetrisulphonic Acid) with DPX (p-
xylylene bis(pyridinium) Bromide). In the first of these assays terbium weakly fluoresces but upon 
contact with DPA, it forms a chelate complex which has an intense fluorescence. The latter assay 
monitors the reduction in fluorescence as ANTS has an intense fluorescence but DPX acts as a 
quencher.  
The second method uses self quenching species. During preparation, fluorescent species must be 
protected from light at all times. One of the advantages of using this technique over those described 
in the previous paragraph, is that only one fluorescent vesicle population is made. The most 
commonly used chemicals for this assay are carboxyfluorescein based, such as calcein. According to 
the manufacturer (Invitrogen) the fluorescence of carboxyfluorescein and calcein is 95% self-
quenched above 100mM. Fusion of vesicles containing high concentrations of dye with dye-free 
liposomes causes a drop in concentration and therefore the fluorescence intensity increases. A 
disadvantage of this dye is that leakage into the bulk solution also causes an increase in the 
fluorescence intensity. It is possible to use Co2+ in the bulk solution to quench the dye but it is not 
always suitable to add it.  
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Figure 5.3 Content mixing fusion assays most commonly use one of three methods. The first, shown at the top 
of this figure is to mix terbium containing vesicles with those containing DPA. Upon fusion and content mixing, 
the fluorescence intensity increases. Alternatively, mixing ANTS and DPX vesicles causes a decrease in intensity 
due to quenching of the ANTS fluorescence by DPX. The final method, shown at the bottom of this figure, uses 
the self-quenching property of carboxyfluorescein. Encapsulated at high concentrations, the dye containing 
liposomes are mixed with vesicles containing only buffer. Upon fusion, the dye concentration falls below the 
self-quenching threshold and therefore the fluorescence intensity increases. 
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5.2 MATERIALS AND METHODS 
5.2.1 VESICLE PREPARATION 
All phospholipids and fluorescent lipid probes were purchased from Avanti Polar Lipids, USA. 
Cholesterol was purchased from Sigma Aldrich, UK.  
5.2.1.1 Unlabelled Vesicles 
 
Low Salt PBS (LS-PBS) 
 
2 mM KH2PO4 pH 7.4, 
50 mM NaCl, 
3 mM KCl, 
5 mM Na2HPO4 
DOPC was dissolved in chloroform at 10 mg/ml and DOPE or cholesterol at 1 mg/ml. The appropriate 
volumes of these lipid solutions were co-mixed in a 10 ml round bottom flask to give the required 
lipid composition. The chloroform was removed under a nitrogen stream and the lipid film dried in a 
vacuum desiccator for one hour. LS-PBS buffer was added to the film to give a total lipid 
concentration of 3 mM in 1 ml solvent. The flask was allowed to stand for one hour before being 
agitated with a vortex and allowed to stand for a further 30 minutes. Following this, the sample was 
freeze-thaw cycled five times using liquid nitrogen and a hair-dryer. The sample was then extruded 
using a mini-extruder (Avanti Polar Lipids inc., USA) 21 times through a 0.1 μm polycarbonate filter 
(Avanti Polar Lipids inc., USA) to produce 100 nm LUVs (Large Unilamellar Vesicles). 
5.2.1.2 Fluorescent Vesicles 
The fluorescent lipid probes NBD-PC (1-oleoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino] 
dodecanoyl]-sn-glycero-3-phosphocholine), NBD-PE and Rh-PE were purchased pre-dissolved in 
chloroform at 1 mg/ml. All steps were conducted in the dark and samples wrapped in foil where 
possible. Vesicles were made as described for unlabelled vesicles but replacing 1 mol% of the DOPC 
with 1 mol% total lipid probe.  
Rh-PE with either NBD-PE or NBD-PC can be used as FRET partners where NBD-PE (or PC) acts as the 
donor, ex 480 nm, and Rh-PE an acceptor, em 593 nm. The R0 for these FRET pairs is ˜50 Å
(328). The 
spectra of these dyes supplied by the manufacturer were taken in distilled water at 20°C; the spectra 
of each probe (Figure 5.4) was therefore analysed for the fusion assay conditions (i.e. at 37°C, in the 
form of LUVs containing 1 mol% probe in 99% DOPC LUVs and suspended in LS-PBS buffer). 
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Figure 5.4 The emission and excitation spectra of NBD-PC, NBD-PE and Rh-PE are shown. Sufficient overlap of 
the emission spectrum of the NBD probes with the excitation spectrum of Rh-PE indicates their ability to be 
used as FRET partners. From the spectra it was concluded that a wavelength of 480 nm would be used to excite 
the NBD probes and the emission of Rh-PE monitored at 593 nm. 
5.2.2 FLUORIMETER ASSAY 
Experiments were conducted using 10 mm light path, UV, 4 clear sided, 4.5 ml cuvettes (Kartell 
purchased from VWR, UK). A PerkinElmer luminescence spectrometer LS50B was used, heated to 
37°C using a water circulator. Excitation was set at 480 nm and emission at 593 nm (slit width 2.5 
mm). Background studies were conducted on a 0.33 mM fluorescent vesicle solution (330 μl 3 mM 
solution made up to 3 ml with LS-PBS). For fusion assays the sample also contained 0.67 mM 
unlabelled vesicle solution giving a 1 mM total lipid concentration. A ratio of 1 labelled to two 
unlabelled vesicles was used to increase the probability of labelled vesicles fusing with unlabelled 
ones. 
Individual vesicle populations were first placed in separate vials and equilibrated to the experiment 
temperature in the water circulator for 30 minutes. For the fusion assay, the populations were then 
mixed. Readings of the fluorescence were taken every 10 seconds for a minimum of 14 hours 
overnight. The experiment was calibrated by addition of 30 μl pre-warmed Triton X-100 (1% (v/v) 
solution). Following Triton X-100 addition the vial was vigorously shaken to lyse the vesicles, the 
cuvette was then placed back in the fluorimeter and the fluorescence intensity of the sample 
recorded for two minutes.  
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5.2.3 DATA ANALYSIS 
Triton X-100 causes the LUVs to break down and for the fluorescence intensity of the acceptor to fall 
to its lowest value. Using this final reading, each experimental run was converted from raw 
fluorescent units (RFU) to relative fluorescence, allowing for variations in concentrations and making 
the runs comparable (Figure 5.5). The RFU following Triton X-100 addition was set as 0% and the 
highest recorded RFU to 100%. For each liposome composition a background study was conducted 
where only fluorescent liposomes were present and therefore no change in FRET should have been 
observed. This allowed the effects of photo-bleaching to be accounted for over the time-scale of the 
experiments. 
 
Figure 5.5 The raw data recorded by the fluorimeter is shown. The data in black shows the background study 
and the red data is the corresponding fusion assay. In order to allow compare experiments the raw data is 
converted to relative fluorescence using a Triton X-100 calibration. This is achieved by setting the highest raw 
value to 100% and the average Triton X-100 value (circled in blue) to 0%. 
A nonlinear least square fit was used on the relative fluorescence plots for each composition; based 
upon the kinetic model proposed by Lee and Lentz in 1998(106). In this model the fusion of two 
vesicles is hypothesised to occur in three steps (Figure 5.6). First the vesicles form a transient 
structure which may represent the stalk intermediary structure (see section 1.4.2.2). This structure 
then develops into a hemifused structure where the proximal leaflets of each vesicle are fused but 
the distal leaflets remain discrete entities, preventing content mixing. A fusion pore opens when the 
distal leaflets fuse and the contents mix. In each of these steps lipid exchange occurs and therefore 
the emission of the acceptor fluorophore decreases in intensity. 
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Figure 5.6 Following close contact between two vesicles, the proximal leaflets can form a transient structure 
allowing lipid content exchange (I1). This structure may be similar to the stalk intermediary structure proposed 
in the fusion mechanism. The transient nature of this structure means it is a reversible step. In the second step 
the vesicles go from the stalk-like structure to a hemifused state (I2). The backwards step to the stalk structure 
is thought to be sufficiently slow that it can be neglected. The third and final step is full fusion by generation of 
a fusion pore (FP). It is assumed that this final stage has a Gaussian distribution due to the global nature of the 
experiment. The rate of this step therefore relates to the peak height of the distribution where σ is peak width. 
The figure has been modified from Lee(106). 
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In the Lee Lentz study, the vesicles were triggered to fuse by addition of the dehydrating agent PEG. 
Due to this trigger, they applied a constraint to the hemifusion step whereby 95% of the vesicles 
must have first undertaken the first, stalk forming step. A time delay term of 3/k1 was therefore 
imposed on this term. They further assumed that the final full fusion event followed a Gaussian 
distribution with a mean time of ,. The integration of this distribution gives the probability of fusion 
pore opening and the peak height gives the frequency. The rate constant for this step is considered 
to be the frequency and therefore is equal to   . The full equation for this kinetic model is 
given in Equation 5.3. 
     4HiZ  HM(ZHk i )   p  H(ZHZ,)MM 	 
q Equation 5.3 
Where y0 is the value of y at time zero, 'is the rate of formation of the transient stalk structure and ' is the rate of formation of the hemifusion structure. As stated above, the full fusion rate constant 
is determined from the peak height of the Gaussian distribution,   . 
The kinetic model was input into the graphing software program Origin 7.0 (OriginLab Corporation, 
Northampton, USA) with Equation 5.3 rewritten to expand the integral function. 
   4HiZ  4HM(ZH)  4fp    , H(ZHZ,)
M q  4. Equation 5.4 
As no trigger (like PEG induced dehydration) was used in this study, the 3/k1 constraint was altered 
to an arbitrary time delay τ. To improve iteration times the coefficient S replaced 2σ2. The coefficient 
y0 was replaced by A4 to also include the integration constant of the third term. The experimental 
data of each fusion assays was fitted to this function to find the rates and amplitudes (A1, A2 and 
A3) for each fusion step (Figure 5.7). 
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Figure 5.7 In this figure an example of a nonlinear least square fit to experimental data, based upon the kinetic 
model of Lee and Lentz is shown. This particular fusion assay consists of two vesicle populations; one composed 
of 90:10 DOPC: DOPE (at 0.67 mM concentration) and the other 90:9:0.5:0.5 DOPC: DOPE: NBD-PE: Rh-PE (0.33 
mM concentration). The ratios given are mol%. 
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5.3 RESULTS 
The affect of DOPE or cholesterol addition to DOPC bilayers on liposome fusion rates has been 
investigated. Fusion assays were performed on liposomes with various compositions and fit to the 
Lee Lentz fusion model (Equation 5.4). In all cases, the errors displayed are those resulting from the 
fit of the assay data to the kinetic model. Each data point contained within the graphs presented in 
this section (figures 5.8-5.13) represents an independent experiment. 
The third term of this model describes the full fusion step and the amplitude of this term (A3) was 
close to zero for all compositions (Figure 5.8). It was found to be several orders of magnitude smaller 
than the amplitude of the hemifusion (A2) or non-fusion lipid transfer (A1) term, suggesting full 
fusion accounts for only a small percentage of the FRET reduction monitored. The size of the third 
term amplitudes and the errors associated with them do not make it possible to determine the 
relationship between full fusion events and membrane composition. As content mixing assays 
monitor full fusion events specifically, the use of such an assay should provide this information. 
 
Figure 5.8 The amplitude of the full fusion rate step, A3, is shown as a function of the PE (black) or cholesterol 
(red) content. Liposomes were composed of DOPC, 0.5 mol% NBD-PE, 0.5 mol% Rh-PE and varying amounts of 
DOPE or cholesterol. For the PE study the contribution of the lipid probes is included in the x-axis. From the 
plots it can be seen that the amplitude is small in both cases and for all compositions. The error associated with 
each data point does not allow a relationship between composition and the amount of full fusion to be 
determined. 
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The time delay (τ) of the hemifusion step was found to be less than 360 seconds for each assay and 
the delay was not dependent on liposome composition in either study. Given the small time delay 
(the time scale of the experiment was 50400 seconds (14 hours)) and the error associated with it, 
this parameter can be considered to be zero. Along with the tiny contribution to FRET reduction by 
full fusion events, the Lee Lentz model effectively simplifies to a second order exponential curve 
(Equation 5.5). The remaining analysis will be discussed based on this premise. 
     4HiZ  4HMZ Equation 5.5 
The y0 term is theoretically the lowest relative fluorescence achievable by a given sample (Figure 
5.9). The data for the PE study clearly shows that this value decreases inversely with DOPE addition. 
In the cholesterol study it is less clear; it is possible that there is also a decrease but that the values 
quickly plateau. As well as cholesterol, the vesicles of this study also contain 1 mol% PE probe and 
therefore the comparison of the 1 mol% samples from each study allows the effect of just 
cholesterol addition to be assessed. It can be seen that the y0 value of the 1% cholesterol sample is 
considerably lower than the corresponding PE sample, suggesting that even at this low 
concentration cholesterol has a significant affect on the DOPC bilayer. The values of y0 obtained 
suggest that in both studies, the addition of these components promotes liposome fusion. 
 
Figure 5.9 The fusion of vesicles composed of x mol% DOPE or cholesterol (plus 1 mol% lipid probe with the 
remainder DOPC) was assessed by lipid mixing and the data fit to the Lee Lentz kinetic model(106). The y0 values, 
which represent the lowest theoretical fluorescence value, are shown as a function of PE (black) or cholesterol 
(red). A clear reduction in the value of y0 is observed for increasing PE content (where the PE contribution of the 
lipid probes is included). It is less clear for cholesterol addition but may show an initial reduction in y0 which 
reaches a plateau. These studies indicate that DOPE and cholesterol promote liposome fusion. 
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The first rate term of the Lee Lentz model takes account of non-fusion lipid transfer (referred to 
from now on as NFLT). The amplitude (A1) and rate (k1) of this step for both the PE and cholesterol 
study are shown in Figure 5.10 and Figure 5.11 respectively. The data suggests that the amount or 
rate of NFLT is not affected by the liposome composition. From these findings (and the very small 
contribution by full fusion events) it would therefore appear that the decrease in y0 values is 
predominantly due to the second term of the kinetic model; hemifusion. 
 
Figure 5.10 The amplitude of the rate step for non-fusion lipid transfer (A1) is shown as a function of PE (black) 
or cholesterol (red) content. Liposomes were composed of x mol% DOPE or cholesterol (plus 1 mol% lipid probe 
with the remainder DOPC). For the PE study the contribution of the lipid probes is included in the x-axis. From 
this data there appears to be no relationship between the amplitude of NFLT and the liposome composition. 
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Figure 5.11 The rate of non-fusion lipid transfer (k1) is shown as a function of PE (black) or cholesterol (red) 
content. Liposomes were composed of x mol% DOPE or cholesterol (plus 1 mol% lipid probe with the remainder 
DOPC). For the PE study the contribution of the lipid probes is included in the x-axis. From this data there 
appears to be no relationship between the rate of NFLT and the liposome composition. 
As stated above, it would appear from the findings relating to A1, k1, τ and A3 that the reduction in 
y0 can be attributed to the alteration of the second term of the kinetic model i.e. the effect of DOPE 
or cholesterol addition on the hemifusion stage of liposome fusion. From plotting the values found 
for the amplitude (A2, Figure 5.12) it can be seen that in both cases the amount of hemifusion 
occurring increases with the amount of DOPE or cholesterol. By comparing these values with those 
of NFLT it can be seen that the amount of hemifusion is an order of magnitude higher, suggesting 
that the majority of vesicles undergo this fusion event once the transient stalk-like structure 
associated with NFLT is formed. The results also indicate that while cholesterol has a greater affect 
than DOPE on this amplitude initially, the amplitude for cholesterol plateaus at higher 
concentrations unlike that of the DOPE study which continues to rise. This would suggest that above 
a certain level cholesterol is no longer able to promote hemifusion. 
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Figure 5.12 The amplitude of the hemifusion rate step (A2) is shown as a function of PE (black) or cholesterol 
(red) content. Liposomes were composed of x mol% DOPE or cholesterol (plus 1 mol% lipid probe with the 
remainder DOPC). For the PE study the contribution of the lipid probes is included in the x-axis. A comparison of 
these values with the amplitude of non-fusion lipid transfer indicates that the majority of vesicles, once in close 
enough proximity, undergo a fusion event rather than undergo the reversible NFLT step. A comparison between 
the two studies shows cholesterol to have a larger affect on the amplitude initially, which plateaus between 10 
and 15 mol%. The amplitude of hemifusion in the PE study continues to increase with its addition. 
The rate of hemifusion (k2, Figure 5.13) in both studies is also seen to increase, though once again 
the data for cholesterol suggests a plateau is reached above 10 mol%. The exact relationship 
between the DOPE content and the hemifusion rate is less clear as the data could be interpreted as 
either a linear or a curve such as an exponential association. It is therefore possible that the DOPE 
hemifusion rates also plateau. Additional data points would be required to assess this, but if the 
relationship is the same as that for the amplitude it would be expected to be linear. 
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Figure 5.13 The rate of hemifusion (k2) is shown as a function of either PE (black) or cholesterol (red) content. 
Liposomes were composed of x mol% DOPE or cholesterol (plus 1 mol% lipid probe with the remainder DOPC). 
For the PE study the contribution of the lipid probes is included in the x-axis. The addition of either DOPE or 
cholesterol results in an increase in the rate of hemifusion. The effect of DOPE addition is smaller than for 
cholesterol but the rate reaches a platues in the latter case. It is not clear whether this is also true for the DOPE 
study or if the rate continues to increase.  
The evidence gathered from lipid mixing probe dilution fusion assays suggests that the addition of 
either PE or cholesterol promotes at least the hemifusion stage of vesicle fusion. In order to assess 
the impact of their addition on full fusion a content mixing assay is required. Initial experiments have 
been conducted (using a self quenching content mixing assay) but are yet to be completed and are 
therefore not presented in this thesis.  
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5.4 DISCUSSION 
The Helfrich equation (Equation 1.3) is an expression of the curvature free energy of a membrane.  
   (    )  Equation 1.3 
As discussed in section 1.3.2, a symmetrical bilayer (like those of the liposomes in this study) has a 
relaxed curvature equal to zero. If we take two vesicles (spherical, radius = r) and fuse them together 
to form a single larger spherical vesicle, the final vesicle will have a radius of √2r (from the 
assumption that the surface area doubles). Assuming the composition of the initial vesicles to be 
equal, the elastic moduli of the initial and final states will be the same so that a change in the 
curvature free energy will be dependent only on the decrease of the principal curvatures c1 and c2 
(which are equal in a sphere). From this it can be seen that the decrease in curvature through fusion 
lowers the curvature free energy of the system, making it a favourable process.  
Another consideration is the stored curvature elastic stress. The bilayer relaxed curvature may be 
zero for a symmetric system but this is not true of the monolayers. The constraint on the 
monolayers to couple back to back results in a higher system energy compared to the relaxed 
curvature of the monolayers. If we apply Equation 1.3 to a flat monolayer surface then the free 
energy is equal to 2κ(m)c02 where κ(m) is the monolayer bending rigidity (κ(b) =2κ(m)) and c0 is the 
spontaneous curvature of the monolayer(331). From this it can be seen that bilayers with higher 
elastic moduli and spontaneous curvatures will have greater stored energy; these systems may be 
more driven to fuse in order to lower this stored energy. 
5.4.1.1 DOPE 
The bending rigidity of a DOPE bilayer at 0.94 x10-19 J(331, 332) is only 10% higher than that of a DOPC 
bilayer which has a bending rigidity of 0.85 x10-19 J(306). The spontaneous curvature however is 
significantly different with a value of -1/3 nm-1 for DOPE(333) and -1/8.7 nm-1 for DOPC(332, 334). 
Considering the free energy term for a flat monolayer (2κ(m)c02, previous paragraph), the addition of 
DOPE would increase the stored stress; predominantly due to the changes in the spontaneous 
curvature. The additional frustration of the monolayers would promote fusion as the system tries to 
lower its energy. 
PE has been shown by several researchers to promote fusion(121, 335-338) and the findings of this study 
(a continual rise in liposome fusion rates with its addition) are consistent with this. During fusion 
intermediate structures are formed such as the stalk and hemifusion diaphragm and the energy of 
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these states depends on the membrane properties. As discussed briefly in section 1.4.2.2, it is 
believed that membrane fusion occurs via the stalk and hemifusion structures. Type II lipids (such as 
DOPE) have a negative spontaneous curvature and the energy required for them to form these 
structures is lower than lipids of less negative or positive curvature. Calculations on the energy of 
the stalk structure when composed of DOPC or DOPE have shown that the difference in spontaneous 
curvature results in a change from 45 kBT for DOPC to -30 kBT for DOPE
(108). The fall in the energy of 
the stalk structure can be thought of as a lowering of the transition state energy; this would reduce 
the activation energy of the fusion ‘reaction’. The drop in stalk structure energy is known to allow 
DOPE to undergo spontaneous fusion(71). The structure of the hemifusion diaphragm is also 
favourable for type II lipids and the energy of this structure will fall as PE concentration increases. 
The combined effects of these energies changes would be a promotion of hemifusion (Figure 5.14). 
 
Figure 5.14 The figure shows a fusion reaction profile to illustrate the effects that DOPE addition has on a DOPC 
bilayer. The profile of pure DOPC liposomes is shown in blue with the consequence of increasing DOPE 
concentration shown in black (concentration increases from dashed to solid line). The free energy and stored 
curvature elastic stress of the membrane becomes raised and the energy required to form the stalk structure 
(transition state *) is reduced. This results in an overall decrease in the activation energy (Ea,1) and the 
promotion of hemifusion. The energy of the hemifusion diaphragm would be expected to remain approximately 
the same as the distal monolayers would show an energy increase and the proximal leaflets an energy 
decrease. For the full fusion event another energy barrier must be overcome (Ea,2). DOPE would be expected to 
hinder such a step due to increasing the energy of the second transition state (†). 
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The final stage (that of fusion pore formation) however, is thought to be inhibited  by type II lipids as 
the fusion pore is modelled to have positive curvature(71). The lower energy of the hemifusion 
diaphragm and the larger energy of the second transition state (the fusion pore) would raise the 
activation energy of the second step. Unfortunately, the data from the PE study which relates to this 
final step is too small to assess this theory. 
5.4.1.2 Cholesterol 
The spontaneous curvature of cholesterol(332) is between -1/2.9 and -1/2.3 nm-1 and would be 
expected to have a similar affect on fusion rates as DOPE. In 2006 Tenchov and Siegel(339) presented 
work examining the effects of cholesterol addition on bulk mesophases. Adding cholesterol to DOPC 
led to the formation of inverse bicontinuous cubic phases. As discussed briefly in chapter 4, 
phosphatidylcholine lipids such as DOPC form lamellar phases (stacked bilayers). The bicontinuous 
cubics are believed to form from these lamellar phases through the formation of stalk-like 
structures. Therefore, the ability of these systems to form the cubics is seen as an indication that the 
additional component can promote fusion. From this work, Siegel suggested that cholesterol is a 
fusogen. Haque(338) also found cholesterol to increase rates of fusion using liposome assays. While 
this was true with or without the presence of sphingomyelin he believed that without 
sphingomyelin, cholesterol made the vesicles leaky; increasing the rupture rather than fusion of 
vesicles. The lipid mixing study presented here indicates that cholesterol acts as a fusogen. If vesicles 
ruptured without a fusion event occurring it would be expected that the NFLT rates would also be 
affected by composition, which was not the case. It is not possible to assess conclusively whether 
the vesicles became leakier, as this would require a content mixing assay. If the vesicles do become 
leakier then it is suprising that a plateau in the hemifusion rates was reached at relatively low 
cholesterol concentration. It would be expected that increasing the cholesterol content would make 
them increasingly leaky, further increasing the rates observed.  
The hemifusion rates of cholesterol are higher compared with the DOPE sample of the same 
concentration. If we assume that these rates do indicate promotion of hemifusion then what causes 
cholesterol to be more fusogenic than DOPE? As already stated, the spontaneous curvature of these 
two components is similar and therefore the first consideration should be the affect that cholesterol 
has on the bending rigidity of the bilayer. The value for this modulus is not known for pure 
cholesterol but studies have shown that its addition to some phospholipid bilayers increases the 
bending rigidity(299, 332, 340-342). It would appear however that the consequences of cholesterol addition 
are not universal and that the saturation of the phospholipid is an important factor. The rigidity of 
bilayers composed of saturated lipids such as DMPC(342) (dimyristoyl phosphocholine) and DPPC(343, 
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344) (dipalmitoyl phosphocholine) were shown to increase upon cholesterol addition. This is also true 
of SOPC(345) (1-stearoyl, 2-oleoyl-sn-glycero-3-phosphocholine) and POPC(299) (1-palmitoyl, 2-oleoyl-
sn-glycero-3-phosphocholine) which contain one saturated and one monounsaturated hydrocarbon 
chain. However, the bending rigidity of a lipid bilayer where both hydrocarbon chains are 
unsaturated (such as DOPC) seems to be less affected(346). 
If we imagine for a moment that adding cholesterol does increase the bending rigidity of the 
liposomes then this membrane property (along with the change in spontaneous curvature of the 
monolayers) would increase the stored curvature elastic stress. This energy increase would drive the 
system to fuse and may initially lower the activation energy. However, increasing the bending 
rigidity would also mean that the energy required to deform/remodel the membrane would be 
greater, making the energy needed to form the intermediate structures higher. This would result in 
the activation energy rising as more cholesterol was added, inhibiting fusion. The plateau seen in the 
hemifusion rates of this study would be consistent with this theory.  
If the bending rigidity does not change significantly then what other affect could cholesterol have? 
Rawicz and Evans(347) have recently shown that cholesterol increases the area expansion modulus of 
a DOPC bilayer and an earlier study(343) showed this to occur for cholesterol addition to DPPC 
bilayers. This modulus is a measure of the energy required to stretch the membrane and as such 
shows how elastic the membrane is. Like the bending rigidity, an increase in this modulus raises the 
energy required to deform the membrane and the energy needed to form the stalk and hemifusion 
structures. So while the bending rigidity modulus may not be affected, it would appear that the 
membrane does become more rigid upon cholesterol addition and therefore the arguments of the 
previous paragraph stand. It can be predicted from this theory that further cholesterol addition 
would result in a reduction in the hemifusion rates. 
The addition of cholesterol to a DOPC bilayer also increases the orientational order and bilayer 
thickness(346). This indicates that the presence of cholesterol restricts the movement of the DOPC 
hydrocarbon chains, causing them to stretch. Both of these events would increase the stored 
curvature elastic stress of the bilayer. As previously discussed, this would increase the drive for 
fusion to occur and raise the initial state energy; lowering the activation energy at first. At higher 
concentrations the increase in the transition state energy would work to increase the activation 
energy, slowing hemifusion rates and causing the plateau in hemifusion rates observed. Like DOPE, it 
is predicted that cholesterol would inhibit the final fusion step, that of fusion pore formation. This 
would result from the higher energy required to deform the membrane, increasing the second 
transition state energy (Figure 5.15). 
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Figure 5.15 The figure shows a fusion reaction profile to illustrate the effects that cholesterol addition has on a 
DOPC bilayer. The profile of pure DOPC liposomes is shown in blue with the consequences of increasing 
cholesterol concentration shown in red (concentration increases from dashed to solid line). The free energy and 
stored curvature elastic stress of the membrane becomes raised due to cholesterol increasing the order and 
thickness of the bilayer, as well as the monolayer spontaneous curvature; driving fusion forward. To begin with, 
the rise in the initial state energy reduces the activation energy (Ea,1), increasing the rate of hemifusion. As the 
concentration of cholesterol increases, the energy required to form the transition state (*, stalk structure) rises; 
inhibiting hemifusion. For the full fusion event another energy barrier must be overcome (Ea,2). Cholesterol 
would be expected to hinder this step due to an increase in energy required to deform the membrane. This 
stiffening and the influence of the negative spontaneous curvature would increase the energy of the second 
transition state (†). 
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5.5 SUMMARY 
In this chapter, lipid mixing assays have been used to investigate the affect of membrane properties 
on the fusion rates of liposomes. Fluorescent lipid probes that act as FRET partners were used and 
the reduction in acceptor emission monitored. It was not possible assess the impact on full fusion 
using these assays and therefore the studies should be extended to include content mixing assays. 
The rate of non-fusion lipid transfer was seen in both the DOPE and cholesterol study to be 
independent of bilayer composition and accounted for less than 10% of the reduction in acceptor 
emission monitored. The addition of DOPE to DOPC membranes has been shown to increase the rate 
of hemifusion and is thought to result from a lowering of the activation energy, predominantly due 
to the more negative spontaneous curvature. The addition of cholesterol to the bilayers has also 
been shown to promote fusion with an increase in hemifusion rates shown. However, the rate 
quickly reached a plateau (at approximately 10 mol% cholesterol) and this has been attributed to 
cholesterol stiffening the membrane, increasing the energy of formation for the intermediate 
structures. This raises the activation energy of the fusion process, hindering fusion at higher 
cholesterol content. 
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5.6 IMPLICATIONS FOR SNARE-MEDIATED MEMBRANE FUSION 
Both lipid and content mixing assays have been performed with bilayers containing SNARE 
proteins(38, 216, 218, 221, 224, 348-350) and show that these proteins increase the rate of fusion (either 
hemifusion or full fusion). The increase in the fusion rate has been attributed to the formation of the 
SNARE complex but how this (and the protein insertion itself) might influence membrane properties 
to promote such an event has rarely been considered. A study by Lui in 2008(102) investigated the 
effect of adding DOPE to SNARE proteoliposomes. In this study v-SNARE vesicles were prepared 
containing 0-60 mol% DOPE (plus 15 mol% DOPS, 1mol% fluorescent lipid and the remainder made 
up with POPC) and their fusion with t-SNARE planar bilayers containing 0 or 20 mol% DOPE (plus 15 
mol% DOPS and the remainder POPC) monitored. The study showed that PE inhibited full fusion and 
promoted hemifusion but as has been seen from the results of this chapter (and other studies), the 
promotion of hemifusion by DOPE is true whether proteins are present or not. However, the findings 
do add to the evidence that SNARE-mediated fusion follows the same fusion mechanism as protein-
free systems, albeit from an in vitro assay. Unfortunately, a protein-free assay was not performed by 
Lui to allow a direct comparison of the results. It would be interesting to know if the change in fusion 
rates he observed could not be explained by PE addition alone. Some proteins change conformation 
in different lipid environments(324) and so an additional contribution may come from changes in the 
structure of the SNARE proteins (most likely in the transmembrane and linker regions).  
Considering the effect of protein insertion itself, the liposome studies of Chapter 3 showed that 
VAMP2 or t-SNARE incorporation increased the relaxed curvature of the bilayer and the aspiration 
studies in Chapter 4 showed that their insertion potentially reduces the bending rigidity (for VAMP2 
a reduction in the area expansion modulus was also found). In view of the findings of this chapter, 
the modification of the membrane properties due to SNARE protein insertion is expected to 
promote fusion. The increase in curvature will work to raise fusion rates by increasing the free 
energy and stored curvature elastic energy of the initial state. This competes directly with the effect 
of changing the bending rigidity which will initially reduce both of these energies. However, at higher 
protein concentrations the reduction in the bending rigidity will make it easier to deform/remodel 
membranes and therefore the activation energy will be lowered. This can be considered to be the 
opposite effect to that seen by cholesterol addition. In vivo, it has been hypothesised that several 
SNARE complexes form a ring around the fusion site and therefore the local concentration of SNARE 
proteins would be high. 
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By applying the theory of the previous paragraph to membrane fusion in vivo, it can be seen that the 
SNARE proteins may assist the merger of two bilayers in several ways (Figure 5.16). As discussed in 
section 3.4, the higher relaxed curvature in the presence of VAMP2 may aid vesicle budding as well 
as VAMP2 recruitment to synaptic vesicles. In the fusion mechanism itself, this higher curvature may 
promote the dimpling of both the synaptic vesicle bilayer and plasma membrane; reducing the inter-
membrane distance. The lower bending rigidity (and area expansion modulus in the case of VAMP2) 
would decrease the energy required to form such dimples. In section 4.3.3 the necessity of 
membrane tension was discussed, where both kinetic studies of bulk mesophases and computer 
simulations suggested tension promotes stalk formation. As well as decreasing the membrane 
separation, dimpling of the bilayers by the SNARE proteins would be expected to increase the 
membrane tension. It is therefore hypothesised that the manipulation of the bilayers by SNARE 
proteins should be sufficient to induce the proximal leaflets of the membranes to merge, forming 
the hemifusion diaphragm.  
The computer simulations investigating the need for membrane tension(131) also found tension was 
necessary for a full fusion rather than hemifusion event to occur. The strength and flexibility of a t-
SNARE protein aggregate structure (Chapter 4) is believed to reflect these qualities in native SNARE 
complexes. Following hemifusion the SNARE complexes would influence the hemifusion diaphragm. 
As with dimpling, the complexes may exert a torque force on the diaphragm and along with the 
transmembrane domains around the rim, may further increase the tension. If the trans-complexes 
folded further this would also increase the tension. As the complexes then fully fold into the trans 
state, they would pull on the hemifusion diaphragm causing it to rupture and forming a fusion pore. 
This conformational change could be triggered by the action potential of the neuron (causing 
changes in regulatory proteins). 
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5.7 CONCLUSIONS 
Membrane fusion in vivo is a highly regulated process utilising a myriad components. Despite the 
SNAREs being identified as fusion proteins 16 years ago, the intricacies of the fusion mechanism 
mean that there is still much to be discovered about how they truly function. The properties of the 
lipid bilayer itself have been shown to be important for the competency and efficiency of fusion and 
links between proteins (such as Synaptotagmin) and certain lipids have been made. It is only now 
however, that the influence of the SNARE proteins on lipid bilayer properties has been explored.  
Studies showing increases in fusion rates due to the presence of SNARE proteins have attributed this 
to the formation of the SNARE complex (see section 5.6). However, fusion via a stalk structure is the 
most favoured model; suggesting that fusion does not involve proteins directly. As discussed 
throughout this thesis, speculations have been made using theoretical modelling and computer 
simulations of how SNARE proteins might influence lipid bilayers; but little experimental evidence 
has been produced. This project has used in vitro assays to investigate this aspect of SNARE protein 
function. The SNARE complex certainly brings membranes into close proximity, but this is unlikely to 
be sufficient for full fusion events to occur(351). The SNARE proteins have not been found to bind 
directly to lipids but the results of this project show that they nonetheless influence the properties 
of bilayers; suggesting their role goes beyond simply bringing (and holding) membranes together.  
The neuronal SNARE proteins have been purified and incorporated into model membrane systems. 
In Chapter 3, the SNARE proteins were shown to increase the relaxed curvature of the lipid bilayer. 
The micropipette aspiration studies of Chapter 4 suggested the bending rigidity of membranes was 
reduced upon SNARE protein insertion and changes in the area expansion modulus were also found. 
In Chapter 5, the addition of DOPE to DOPC bilayers was shown to promote hemifusion; consistent 
with previously published works (for references see section 5.4.1.1). Cholesterol addition was also 
shown to promote fusion but raising the concentration inhibited hemifusion due to increasing 
membrane stiffness. Combining the findings of all these studies it is hypothesised that the SNARE 
proteins promote the fusion process, achieving this through bringing membranes into close 
proximity and altering the membrane properties; driving the fusion process forward, reducing the 
energy required to form intermediate structures and increasing membrane tension. 
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5.8 FUTURE WORK 
The changes in the membrane properties of a DOPC bilayer due to the insertion of VAMP2 has been 
attributed to a hydrophobic mismatch between the preferred bilayer thickness and the length of the 
transmembrane domain of the protein. While these changes are expected to promote fusion, it is 
important to establish if these changes are a universal effect of VAMP2 incorporation or whether it 
is only due to the choice of lipid for the model. For this reason it would be prudent to expand the 
studies of chapters 3 and 4 to include vesicles composed of a more complex mixture of lipids. 
Studies have shown the lipid content of synaptic vesicles to be 36-40 mol% PC, 23-32 mol% PE, 12 
mol% PS, 5 mol% PI and 10-40 mol% cholesterol(325, 352). The remainder is made up primarily of 
sphingomyelin and ceramide. The most commonly used composition in the literature(325) is 
PC/PE/PS/cholesterol at 48:20:12:20 and therefore the most logical composition to study initially. 
The dependence of fusion rates on membrane properties was studied in chapter 5. No information 
could be gained from the lipid mixing assays on the final, full fusion step. As mentioned in the 
discussion of that chapter, the use of content mixing assays (in addition to the lipid mixing assays) 
would provide useful information, improving the interpretation of the data. Also related to the 
studies of chapter 5, the effects of PE addition to PC are fairly well understood but the effect of 
cholesterol addition appears to depend on the type of phospholipid bilayer to which it is added. It 
has been found that cholesterol has a greater affect on raising the bending rigidity of bilayers 
composed of saturated phospholipids compared to bilayers of unsaturated lipids such as DOPC. The 
membrane properties of the compositions used in the studies of chapter 5 should therefore be 
explored quantitatively; perhaps using micropipette aspiration. This data would provide additional 
information on how fusion rates are affected by membrane properties. Benefits would also be 
gained by evaluating fusion rates of more complex mixtures. 
Studies of fusion rates of vesicles containing SNARE protein have shown that the rates obtained 
depend on the vesicle composition and it is known that the conformation of some proteins is 
affected by the lipid environment. The transmembrane domains of the SNARE proteins appear to be 
instrumental for the function of these proteins in the fusion mechanism. It would be interesting to 
establish whether the structure of these domains is also composition dependent and what 
membrane properties this corresponds to.  
For the in vitro assays performed in which t-SNARE proteins were inserted, it was suggested that the 
results were affected by the formation of large, interconnected protein aggregates. Conducting 
micropipette aspiration studies using just the transmembrane domain of Syntaxin would provide 
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greater clarity to results from this study. In addition, expressing SNAP-25 in a mammalian cell line 
would allow purified protein to be produced containing the palmitoyl lipid anchors. Repeating the 
studies of chapters 3 and 4 with membrane-associated SNAP-25 would provide further insights. 
The role of the SNARE proteins in the membrane fusion mechanism is fairly well established, but 
many questions remain as to how this is achieved. This project has investigated how these proteins 
may alter the local lipid environment to aid the fusion process. As illustrated above however, there is 
much scope for the project to be developed further. It is hoped that the work of this thesis highlights 
the importance of the interplay between proteins and lipids and that it (along with the raft of 
literature previously published) will encourage researchers not to consider either of these elements 
in isolation. 
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APPENDICES 
Vector Maps 
PET-16B 
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PQE-30 
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PGEX-4T-2 
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PGEX KG 
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PPROEX-HTB 
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Protein Sequences 
SYNTAXIN 1A SEQUENCES 
Full Length, Wild-Type Syntaxin 1A (Rattus norvegicus) 
Amino Acid Sequence 
1 MKDRTQELRT AKDSDDDDDV TVTVDRDRFM DEFFEQVEEI RGFIDKIAEN VEEVKRKHSA 
61 ILASPNPDEK TKEELEELMS DIKKTANKVR SKLKSIEQSI EQEEGLNRSS ADLRIRKTQH 
121 STLSRKFVEV MSEYNATQSD YRERCKGRIQ RQLEITGRTT TSEELEDMLE SGNPAIFASG 
181 IIMDSSISKQ ALSEIETRHS EIIKLENSIR ELHDMFMDMA MLVESQGEMI DRIEYNVEHA 
241 VDYVERAVSD TKKAVKYQSK ARRKKIMIII CCVILGIIIA STIGGIFG  
DNA Sequence 
1 atgaaggacc gaacccagga gctccgcacg gccaaggaca gcgatgacga cgatgatgtc 
61 actgtcactg tggaccgaga ccgcttcatg gatgagttct ttgaacaggt ggaagagatc 
121 cggggcttta ttgacaagat tgctgaaaac gtggaggagg tgaagaggaa acacagcgcc 
181 atcctggcct ccccgaaccc cgatgagaag accaaggagg aactggagga gctcatgtcg 
241 gacattaaga agacagcgaa caaagttcgc tccaagctaa agagcatcga gcagagcatc 
301 gagcaggagg aaggtctgaa ccgctcgtcg gcggacctga ggatccggaa gacgcagcat 
361 tccacgctgt cccgaaagtt tgtggaggtc atgtccgagt acaacgccac tcagtcagac 
421 taccgagaac gctgcaaagg gcgcatccag aggcagctgg agatcactgg ccggaccacg 
481 accagtgagg agttggaaga catgctggag agtgggaatc ccgccatctt tgcctctggg 
541 atcatcatgg actccagcat ctcgaagcag gccctcagtg agatcgagac caggcacagt 
601 gagatcatca agttggagaa cagcatccgg gagctacacg atatgttcat ggacatggcc 
661 atgctggtgg agagccaggg ggagatgatt gacaggatcg agtacaatgt ggaacacgct 
721 gtggactacg tggagagggc cgtgtctgac accaagaagg ccgtcaagta ccagagcaag 
781 gcacgcagga agaagatcat gatcatcatt tgctgtgtga ttctgggcat catcatcgcc 
841 tccaccatcg ggggcatctt tggatag    
ΔN-Syntaxin 1A 
Amino Acid Sequence: 181-288 of full length Syntaxin 1A; DNA Sequence: 541-867 of full length Syntaxin 1A 
ΔN-Syntaxin 1A Cysteine Mutant 
Amino Acid Sequence (residues 1-108 correspond to residues 181-288 of the full length Syntaxin 1A sequence) 
1 IIMDSSISKQ ALSEIETRHS EIIKLENSIR ELHDMFMDMA MLVESQGEMI DRIEYNVEHA 
61 VDYVERAVSD TKKAVKYQSK ARRKKIMIII CCVILGIIIA STIGGIFGCC  
DNA Sequence 
1 atcatcatgg actccagcat ctcgaagcag gccctcagtg agatcgagac caggcacagt 
61 gagatcatca agttggagaa cagcatccgg gagctacacg atatgttcat ggacatggcc 
121 atgctggtgg agagccaggg ggagatgatt gacaggatcg agtacaatgt ggaacacgct 
181 gtggactacg tggagagggc cgtgtctgac accaagaagg ccgtcaagta ccagagcaag 
241 gcacgcagga agaagatcat gatcatcatt tgctgtgtga ttctgggcat catcatcgcc 
301 tccaccatcg ggggcatctt tggatgctgt tag   
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SNAP-25B SEQUENCE 
Full Length, Wild-Type SNAP-25b (Rattus norvegicus) 
1 MAEDADMRNE LEEMQRRADQ LADESLESTR RMLQLVEESK DAGIRTLVML DEQGEQLERI 
61 EEGMDQINKD MKEAEKNLTD LGKFCGLCVC PCNKLKSSDA YKKAWGNNQD GVVASQPARV 
121 VDEREQMAIS GGFIRRVTND ARENEMDENL EQVSGIIGNL RHMALDMGNE IDTQNRQIDR 
181 IMEKADSNKT RIDEANQRAT KMLGSG    
VAMP2 SEQUENCES 
Full Length, Wild-Type VAMP2 (Rattus norvegicus) 
Amino Acid Sequence 
1 MSATAATVPP AAPAGEGGPP APPPNLTSNR RLQQTQAQVD EVVDIMRVNV DKVLERDQKL 
61 SELDDRADAL QAGASQFETS AAKLKRKYWW KNLKMMIILG VICAIILIII IVYFST 
DNA Sequence 
1 atgtcggcta ccgctgccac cgtcccgcct gccgccccgg ccggcgaggg tggcccccct 
61 gcacctcctc caaatcttac cagtaacagg agactgcagc agacccaggc ccaggtggat 
121 gaggtggtgg acatcatgag ggtgaatgtg gacaaggtcc tggagcggga ccagaagcta 
181 tcggaactgg atgatcgcgc agatgccctc caggcagggg cctcccagtt tgaaacaagt 
241 gcagccaagc tcaagcgcaa atactggtgg aaaaacctca agatgatgat catcttggga 
301 gtgatttgcg ccatcatcct catcatcatc atcgtttact tcagcactta a 
VAMP2 Cysteine Mutant 
Amino Acid Sequence 
1 MSATAATVPP AAPAGEGGPP APPPNLTSNR RLQQTQAQVD EVVDIMRVNV DKVLERDQKL 
61 SELDDRADAL QAGASQFETS AAKLKRKYWW KNLKMMIILG VICAIILIII IVYFSTC 
DNA Sequence 
1 atgtcggcta ccgctgccac cgtcccgcct gccgccccgg ccggcgaggg tggcccccct 
61 gcacctcctc caaatcttac cagtaacagg agactgcagc agacccaggc ccaggtggat 
121 gaggtggtgg acatcatgag ggtgaatgtg gacaaggtcc tggagcggga ccagaagcta 
181 tcggaactgg atgatcgcgc agatgccctc caggcagggg cctcccagtt tgaaacaagt 
241 gcagccaagc tcaagcgcaa atactggtgg aaaaacctca agatgatgat catcttggga 
301 gtgatttgcg ccatcatcct catcatcatc atcgtttact tcagcacttg ctaa 
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